[go: up one dir, main page]

MX353234B - Variantes de polipeptidos con función efectora alterada. - Google Patents

Variantes de polipeptidos con función efectora alterada.

Info

Publication number
MX353234B
MX353234B MXPA04011973A MXPA2004011973A MX353234B MX 353234 B MX353234 B MX 353234B MX PA04011973 A MXPA04011973 A MX PA04011973A MX PA2004011973 A MXPA2004011973 A MX PA2004011973A MX 353234 B MX353234 B MX 353234B
Authority
MX
Mexico
Prior art keywords
effector function
altered effector
polypeptide variants
region
present
Prior art date
Application number
MXPA04011973A
Other languages
English (en)
Inventor
G Presta Leonard
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX353234B publication Critical patent/MX353234B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a polipéptidos que comprenden una región variante Fc. Más particularmente, la presente invención se refiere a polipéptidos que contienen una región Fc que han alterado su función efectora como consecuencia de una o más modificaciones de aminoácidos en la región Fc de los mismos.
MXPA04011973A 1999-01-15 2000-01-14 Variantes de polipeptidos con función efectora alterada. MX353234B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11602399P 1999-01-15 1999-01-15
PCT/US2000/000973 WO2000042072A2 (en) 1999-01-15 2000-01-14 Polypeptide variants with altered effector function

Publications (1)

Publication Number Publication Date
MX353234B true MX353234B (es) 2018-01-08

Family

ID=22364785

Family Applications (2)

Application Number Title Priority Date Filing Date
MXPA04011973A MX353234B (es) 1999-01-15 2000-01-14 Variantes de polipeptidos con función efectora alterada.
MXPA01007170A MXPA01007170A (es) 1999-01-15 2000-01-14 Variantes de polipeptidos con funcion efectora alterada.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MXPA01007170A MXPA01007170A (es) 1999-01-15 2000-01-14 Variantes de polipeptidos con funcion efectora alterada.

Country Status (16)

Country Link
US (4) US7371826B2 (es)
EP (4) EP2386574A3 (es)
JP (4) JP2003512019A (es)
KR (5) KR101155191B1 (es)
CN (2) CN1237076C (es)
AU (2) AU778683B2 (es)
BR (1) BR0008758A (es)
CA (1) CA2359067C (es)
ES (1) ES2694002T3 (es)
HU (2) HUP0104865A3 (es)
IL (5) IL144056A0 (es)
MX (2) MX353234B (es)
NZ (1) NZ539776A (es)
PL (3) PL209786B1 (es)
WO (1) WO2000042072A2 (es)
ZA (1) ZA200105484B (es)

Families Citing this family (1828)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
MX353234B (es) 1999-01-15 2018-01-08 Genentech Inc Variantes de polipeptidos con función efectora alterada.
EP1176981B1 (en) 1999-05-07 2005-11-30 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002250293B2 (en) * 2001-03-09 2007-10-11 Arnason, Barry G. Mr Polymeric immunoglobulin fusion proteins that target low-affinity FCGammaReceptors
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
CA2463879C (en) * 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20040002587A1 (en) * 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
AU2003232456B2 (en) 2002-05-30 2009-06-04 Macrogenics, Inc. CD16A binding proteins and use for the treatment of immune disorders
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
ATE541857T1 (de) 2002-09-27 2012-02-15 Xencor Inc Optimierte fc-varianten und herstellungsverfahren dafür
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DK1562972T3 (da) 2002-10-15 2010-12-06 Facet Biotech Corp Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
RS20100366A (sr) 2002-12-16 2011-04-30 Genentech, Inc. Varijante imunoglobulina i njihova upotreba
AU2011265460B2 (en) * 2003-01-09 2014-07-17 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7960512B2 (en) * 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7355008B2 (en) * 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1596804A4 (en) 2003-01-13 2008-02-06 Macrogenics Inc SOLUBLE FCyR FUSION PROTEINS AND METHODS OF USE
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
KR101092171B1 (ko) 2003-04-09 2011-12-13 제넨테크, 인크. Ｔｎｆ-알파 저해제에 대해 부적절한 반응을 하는환자에서의 자가면역 질환의 치료법
JP4685764B2 (ja) * 2003-04-10 2011-05-18 アボット バイオセラピューティクス コーポレイション 変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
KR100973564B1 (ko) * 2003-05-02 2010-08-03 젠코어 인코포레이티드 최적화된 Ｆｃ 변이체 및 그의 제조 방법
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
AU2004256042A1 (en) 2003-06-05 2005-01-20 Genentech, Inc. BlyS antagonists and uses thereof
EP2292264A3 (en) 2003-07-24 2012-12-19 Innate Pharma Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
EP2502935B1 (en) 2003-08-22 2017-03-29 Biogen MA Inc. Improved antibodies having altered effector function and methods for making the same
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
JP2007531707A (ja) 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
GB0324368D0 (en) * 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
HUE042914T2 (hu) 2003-11-05 2019-07-29 Roche Glycart Ag CD20 antitestek fokozott fc receptorkötõ affinitással és effektorfunkcióval
EP2385069A3 (en) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
WO2005063815A2 (en) * 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
US20080193441A1 (en) * 2003-11-18 2008-08-14 Iconic Therapeutics, Inc. Homogeneous Preparations of Chimeric Protein
WO2005056759A2 (en) 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
BRPI0417429A (pt) 2003-12-10 2007-04-03 Medarex Inc anticorpo monoclonal isolado ou uma porção de ligação de antìgeno deste, composição, imunoconjugado, molécula biespecìfica, vetor de expressão, célula hospedeira, camundongo transgênico, hibridoma, e, métodos de inibir uma resposta inflamatória ou autoimune, de tratar uma doença inflamatória ou autoimune, de tratar uma infecção viral ou bacteriana e de preparar um anticorpo anti-ip-10
IN2009KN02655A (es) 2003-12-10 2015-10-23 Medarex Inc
WO2005070963A1 (en) 2004-01-12 2005-08-04 Applied Molecular Evolution, Inc Fc region variants
DE602005018325D1 (de) 2004-02-19 2010-01-28 Genentech Inc Antikörper mit korrigierten cdr
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
EP2374817B1 (en) * 2004-04-13 2017-09-06 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
JP2007536932A (ja) 2004-05-10 2007-12-20 マクロジェニクス，インコーポレーテッド ヒト化ＦｃγＲＩＩＢ特異的抗体とその利用法
KR100545720B1 (ko) * 2004-05-31 2006-01-24 메덱스젠 주식회사 당화된 면역글로불린 및 이를 포함하는 면역접합체
BRPI0510915A (pt) 2004-06-04 2007-11-13 Genentech Inc método para o tratamento da esclerose múltipla e artigo manufaturado
RU2412202C2 (ru) 2004-06-21 2011-02-20 Медарекс, Инк. Антитела рецептора 1 интерферона альфа и их применение
MX2007000404A (es) * 2004-07-12 2008-03-04 Macrogenics Inc Identificacion de ingenieria de anticuerpos con regiones de fc variante y metodos para usar las mismas.
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
DK2471813T3 (en) * 2004-07-15 2015-03-02 Xencor Inc Optimized Fc variants
JP5102028B2 (ja) 2004-07-26 2012-12-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗ｃｄ１５４抗体
PL2213683T3 (pl) 2004-08-04 2013-10-31 Mentrik Biotech Llc WARIANTY REGIONÓW Fc
EP1778726A4 (en) * 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
US20060067930A1 (en) * 2004-08-19 2006-03-30 Genentech, Inc. Polypeptide variants with altered effector function
CN101087807A (zh) 2004-10-05 2007-12-12 健泰科生物技术公司 治疗血管炎的方法
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1810035A4 (en) * 2004-11-10 2010-03-17 Macrogenics Inc GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
DK1817340T3 (da) 2004-11-12 2012-08-13 Xencor Inc Fc-varianter med ændret binding til fcrn
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
EP1838735A2 (en) * 2004-12-31 2007-10-03 Genentech, Inc. Polypeptides that bind br3 and uses thereof
PL1846030T3 (pl) 2005-01-21 2019-05-31 Genentech Inc Ustalone dawkowanie przeciwciał her
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
US20060263357A1 (en) 2005-05-05 2006-11-23 Tedder Thomas F Anti-CD19 antibody therapy for autoimmune disease
PL1853718T3 (pl) 2005-02-15 2016-01-29 Univ Duke Przeciwciała anty-CD19 i zastosowania w onkologii
EP3195879A1 (en) 2005-02-23 2017-07-26 Genentech, Inc. Extending time to disease progression or survival in cancer patients
IL296666A (en) 2005-03-23 2022-11-01 Genmab As Antibodies against 38cd for the treatment of multiple myeloma
WO2006105062A2 (en) * 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
CA2602663A1 (en) * 2005-03-31 2006-10-05 Xencor, Inc. Fc variants with optimized properties
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2707152T3 (es) 2005-04-15 2019-04-02 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
JO3058B1 (ar) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
MX2007013978A (es) 2005-05-09 2008-02-22 Ono Pharmaceutical Co Anticuerpos monoclonales humanos a muerte programada 1 (pd-1) y metodos para tratamiento de cancer utilizando anticuerpos anti-pd-1 solos o en combinacion con otros inmunoterapeuticos.
AU2006251647A1 (en) 2005-05-20 2006-11-30 Genentech, Inc. Pretreatment of a biological sample from an autoimmune disease subject
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
TR201902033T4 (tr) 2005-06-30 2019-03-21 Janssen Biotech Inc Anti-IL-23 antikorları, bileşimleri, yöntemleri ve kullanımları.
CN105330741B (zh) 2005-07-01 2023-01-31 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
WO2007009469A2 (en) * 2005-07-21 2007-01-25 Genmab A/S Potency assays for antibody drug substance binding to an fc receptor
UA97469C2 (uk) 2005-07-25 2012-02-27 Емерджент Продакт Дівелопмент Сіетл, Елелсі Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну
CN101267836A (zh) 2005-07-25 2008-09-17 特鲁比昂药品公司 单剂量cd20特异性结合分子的用途
PL1919503T3 (pl) 2005-08-10 2015-04-30 Macrogenics Inc Identyfikacja i inżynieria przeciwciał ze zmiennymi regionami FC oraz sposoby ich stosowania
TWI478940B (zh) 2005-08-26 2015-04-01 Roche Glycart Ag 具有經改變細胞傳訊活性之改質抗原結合分子
CA2624189A1 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
AU2006302254B2 (en) 2005-10-06 2011-05-26 Xencor, Inc. Optimized anti-CD30 antibodies
KR20080049113A (ko) 2005-10-21 2008-06-03 노파르티스 아게 Ｉｌ-13에 대항한 인간 항체 및 치료적 용도
NZ594285A (en) 2005-11-04 2013-02-22 Genentech Inc USE OF COMPLEMENT PATHWAY INHIBITOR ANTIBODY AGAINST C5a TO TREAT OCULAR DISEASES
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
CA2627981A1 (en) 2005-11-07 2007-05-18 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
EP2623516B1 (en) 2005-12-02 2015-07-15 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
AU2006338198B2 (en) 2005-12-02 2012-04-26 Genentech, Inc. Binding polypeptides and uses thereof
EA017491B1 (ru) 2005-12-08 2012-12-28 Медарекс, Инк. Человеческие моноклональные антитела к фукозил-gm1 и способы применения антифукозил-gm1 антител
AU2006326937B2 (en) 2005-12-20 2012-01-19 Cephalon Australia Pty Ltd Anti-inflammatory dAb
US7935344B2 (en) 2005-12-29 2011-05-03 Centocor Ortho Biotech Inc. Human anti-IL-23 antibodies, compositions, methods and uses
EP1973950B1 (en) 2006-01-05 2014-09-17 Genentech, Inc. Anti-ephb4 antibodies and methods using the same
AR059096A1 (es) 2006-01-20 2008-03-12 Genentech Inc Anticuerpos anti- efrina -b2 y metodos que usan estos
CN103232540A (zh) 2006-02-01 2013-08-07 赛法隆澳大利亚控股有限公司 结构域抗体构建体
EP1999148B8 (en) 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
AR059851A1 (es) 2006-03-16 2008-04-30 Genentech Inc Anticuerpos de la egfl7 y metodos de uso
US20090220504A1 (en) 2006-03-21 2009-09-03 Anan Chuntharapai Combinatorial therapy
DK3056568T3 (da) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
EP2011870A4 (en) * 2006-04-14 2010-09-15 Medical & Biol Lab Co Ltd MUTANT POLYPEPTIDE WITH EFFECTOR FUNCTION
BRPI0711249A2 (pt) 2006-05-30 2012-03-13 Genentech, Inc. Anticorpos, polinucleotídeos, vetores, células hospedeira, métodos para fabricar um anticorpo, para detectar a presença de cd2 em uma amostra biológica, para tratar uma disfunção proliferativa de células b, para inibir proliferaçõa de células b, para tratar câncer, para fabricar um composto conjugado anti-corpo-droga. imunoconjugados,composições farmacêuticas, formulações farmacêuticas, conjugado anticorpo-droga, compostos conjugados anti-corpo-droga, teste para detectar células b e artigo de fabricação
KR20090027227A (ko) 2006-06-06 2009-03-16 제넨테크, 인크. 항-ｄｌｌ4 항체 및 이의 사용 방법
MX363905B (es) 2006-06-12 2019-04-08 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
WO2008002933A2 (en) 2006-06-26 2008-01-03 Macrogenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
JP5764290B2 (ja) 2006-06-26 2015-08-19 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体およびその使用法
PL2046833T3 (pl) 2006-07-14 2014-01-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
JP2009543579A (ja) 2006-07-19 2009-12-10 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗炎症反応のための標的としてのＷＳＸ−１／ｐ２８
ME01786B (me) 2006-08-14 2014-09-20 Xencor Inc Optimizovana antitela usmerena na cd19
MX2009002418A (es) 2006-09-05 2009-04-23 Medarex Inc Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
WO2008031056A2 (en) 2006-09-08 2008-03-13 Medimmune, Llc Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP2845912A1 (en) 2006-09-12 2015-03-11 Genentech, Inc. Methods and compositions for the diagnosis and treatment of lung cancer using KIT gene as genetic marker
US20100297103A1 (en) 2006-09-14 2010-11-25 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
AU2007299843B2 (en) 2006-09-18 2012-03-08 Xencor, Inc Optimized antibodies that target HM1.24
HUE033630T2 (en) 2006-10-02 2017-12-28 Squibb & Sons Llc CXCR4 binding human antibodies and their use
TWI414531B (zh) * 2006-10-12 2013-11-11 Genentech Inc 淋巴毒素α之抗體
WO2008048545A2 (en) * 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof
US7754213B2 (en) 2006-10-19 2010-07-13 Merck & Co., Inc. High affinity antibody antagonists of interleukin-13 receptor alpha 1
EP2068922B1 (en) 2006-10-19 2012-06-27 CSL Limited Anti-il-13r alpha 1 antibodies and their uses thereof
ES2636089T3 (es) 2006-10-27 2017-10-05 Genentech, Inc. Anticuerpos e inmunoconjugados y usos para los mismos
US8618248B2 (en) 2006-10-31 2013-12-31 President And Fellows Of Harvard College Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
CL2007003161A1 (es) 2006-11-02 2008-05-30 Genentech Inc Anticuerpos anti-factor d; acidos nucleicos que los codifican; vector y linea celular que los comprenden; metodo de produccion; composicion farmaceutica que comprende a los anticuerpos; y su uso para tratar trastornos mediados por el complemento como
CA2669921A1 (en) 2006-11-15 2008-06-26 Medarex, Inc. Human monoclonal antibodies to btla and methods of use
US8067179B2 (en) 2006-11-30 2011-11-29 Research Development Foundation Immunoglobulin libraries
JP5398538B2 (ja) 2006-12-01 2014-01-29 メダレックス・リミテッド・ライアビリティ・カンパニー Ｃｄ２２に結合するヒト抗体およびその使用
US20080127996A1 (en) * 2006-12-04 2008-06-05 Weinhold Dennis G Method and apparatus to remediate an acid and/or liquid spill
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
EP2097534A4 (en) 2006-12-14 2010-05-12 Medarex Inc HUMAN ANTIBODIES BINDING TO CD70 AND USES THEREOF
EP3095455A1 (en) 2006-12-19 2016-11-23 Genentech, Inc. Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
ES2538990T3 (es) 2007-01-24 2015-06-25 Kyowa Hakko Kirin Co., Ltd. Composición de anticuerpo genéticamente recombinante que tiene una actividad efectora mejorada
EP2107115A1 (en) 2007-01-24 2009-10-07 Kyowa Hakko Kirin Co., Ltd. Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
WO2008100805A2 (en) 2007-02-09 2008-08-21 Genentech, Inc. Anti-robo4 antibodies and uses therefor
WO2008109440A2 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her dimerisation inhibitor based on low her3 expression
PT3199180T (pt) 2007-03-08 2022-04-01 Univ Monash Anticorpos epha3 para o tratamento de tumores sólidos
BRPI0809042B1 (pt) 2007-03-22 2021-08-31 Biogen Ma Inc. Proteína de ligação a cd154 isolada, seu uso, e composição
WO2008118324A2 (en) 2007-03-26 2008-10-02 Macrogenics, Inc. Composition and method of treating cancer with an anti-uroplakin ib antibody
TWI570135B (zh) 2007-04-27 2017-02-11 建南德克公司 高效、穩定且非免疫抑制之抗－ｃｄ４抗體
WO2008137475A2 (en) 2007-05-01 2008-11-13 Research Development Foundation Immunoglobulin fc libraries
KR20100017514A (ko) 2007-05-07 2010-02-16 메디뮨 엘엘씨 항 ｉｃｏｓ 항체, 및 종양, 이식 및 자가면역성 질환 치료에서의 이의 용도
WO2008141197A1 (en) * 2007-05-10 2008-11-20 Sea Lane Biotechnologies, Llc Chain reaction creating oligomers from repeat units of binding molecules
EP2173381B1 (en) 2007-05-14 2013-10-02 NovImmune SA Fc receptor-binding polypeptides with modified effector functions
EP3392273A1 (en) 2007-05-30 2018-10-24 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
EP2666787B1 (en) * 2007-05-31 2022-02-09 Genmab A/S STABLE IgG4 ANTIBODIES
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
EP2592156B1 (en) 2007-06-08 2016-04-20 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
WO2008156622A1 (en) * 2007-06-12 2008-12-24 Ac Immune S.A. Humanized antibodies to amyloid beta
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
PL2158221T3 (pl) 2007-06-21 2019-02-28 Macrogenics, Inc. Kowalencyjne diaciała i ich zastosowania
US20100254992A1 (en) * 2007-06-29 2010-10-07 Anuk Das Anti-mcp-1 antibodies, compositions, methods and uses
EP2188302B1 (en) 2007-07-09 2017-11-01 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
US20110091992A1 (en) * 2007-07-10 2011-04-21 Medimmune, Llc CRYSTALS AND STRUCTURE OF HUMAN IgG Fc VARIANT
CN111499748A (zh) 2007-07-16 2020-08-07 健泰科生物技术公司 抗cd79b抗体和免疫偶联物及使用方法
NZ583318A (en) 2007-07-16 2012-07-27 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugates and methods of use
WO2009018386A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
ES2719728T3 (es) 2007-09-04 2019-07-12 Compugen Ltd Polipéptidos y polinucleótidos, y usos de los mismos como una diana farmacológica para producir fármacos y agentes biológicos
KR102467302B1 (ko) 2007-09-26 2022-11-14 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
US20100297012A1 (en) * 2007-10-05 2010-11-25 Andrea Pfeifer Humanized antibody
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
PL2233149T3 (pl) 2007-10-16 2016-08-31 Zymogenetics Inc Kombinacja przezbłonowego aktywatora i ligandu cyklofiliny (taci) oraz przeciwciała anty-cd20 do leczenia chorób autoimmunologicznych
US20120047586A9 (en) 2007-10-24 2012-02-23 Otsuka Chemical Co., Ltd Polypeptide having enhanced effector function
ES2663077T3 (es) 2007-11-02 2018-04-11 Novartis Ag Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (lrp6)
AU2008323770B2 (en) 2007-11-07 2014-08-07 Genentech, Inc. Compositions and methods for treatment of microbial disorders
WO2015164330A1 (en) 2014-04-21 2015-10-29 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
PT2222706E (pt) 2007-12-14 2014-07-28 Novo Nordisk As Anticorpos contra nkg2d humano e utilizações dos mesmos
US8795667B2 (en) 2007-12-19 2014-08-05 Macrogenics, Inc. Compositions for the prevention and treatment of smallpox
AU2008339576B2 (en) 2007-12-21 2014-05-22 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Ralpha)
EP2235059B1 (en) 2007-12-26 2015-02-18 Xencor, Inc. Fc variants with altered binding to fcrn
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
AU2009205995B2 (en) 2008-01-18 2014-04-03 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
ES2587392T3 (es) 2008-01-31 2016-10-24 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
EP2650017A3 (en) 2008-02-05 2014-01-22 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses
MX2010008578A (es) 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
JP6161233B2 (ja) * 2008-03-31 2017-07-12 ジェネンテック， インコーポレイテッド 喘息の治療及び診断のための組成物及び方法
CN102046655B (zh) 2008-04-02 2016-09-14 宏观基因有限公司 Bcr-复合体-特异性抗体和其使用方法
CN107236044B (zh) 2008-04-02 2021-07-02 宏观基因有限公司 HER2/neu-特异性抗体和其使用方法
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
AU2009241589B2 (en) * 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
US9109026B2 (en) 2008-06-03 2015-08-18 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
EP2282770B1 (en) 2008-06-04 2018-03-07 MacroGenics, Inc. Antibodies with altered binding to fcrn and methods of using same
TW201012475A (en) 2008-07-08 2010-04-01 Abbott Lab Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
AR077718A1 (es) * 2008-07-15 2011-09-21 Genentech Inc Metodos para tratar enfermedades autoinmunes usando anticuerpos anti cd4. formulacion farmaceutica
SI2328616T1 (sl) 2008-08-05 2015-08-31 Novartis Ag Sestavki in postopki za protitelesa proti komplementnemu proteinu C5
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
JP5778577B2 (ja) 2008-09-19 2015-09-16 メディミューン，エルエルシー Ｄｌｌ４に対する抗体およびその使用
US20100098730A1 (en) * 2008-10-14 2010-04-22 Lowman Henry B Immunoglobulin variants and uses thereof
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
US20110293605A1 (en) 2008-11-12 2011-12-01 Hasige Sathish Antibody formulation
SI2361085T2 (sl) 2008-11-22 2018-11-30 F. Hoffmann-La Roche Ag Uporaba protitelesa proti vegf v kombinaciji s kemoterapijo za zdravljenje raka dojk
AU2009325878B2 (en) 2008-12-08 2014-01-16 Compugen Ltd. TMEM154 polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
WO2010068722A1 (en) 2008-12-12 2010-06-17 Medimmune, Llc Crystals and structure of a human igg fc variant with enhanced fcrn binding
AU2009335798B2 (en) 2008-12-19 2014-11-27 Macrogenics, Inc. Covalent diabodies and uses thereof
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
CA2748158A1 (en) 2008-12-23 2010-07-01 Astrazeneca Ab Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
CN102341411A (zh) 2008-12-31 2012-02-01 比奥根艾迪克Ma公司 抗-淋巴细胞毒素抗体
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
EA201190132A1 (ru) 2009-02-23 2013-01-30 Гленмарк Фармасьютикалс С.А. Гуманизированные антитела, связывающиеся с cd19, и их применение
KR101769160B1 (ko) 2009-03-05 2017-08-17 옥스포드 바이오테라퓨틱스 리미티드 Ｃａｄｍ１에 특이적인 완전 인간 항체
NZ594950A (en) 2009-03-06 2013-06-28 Kalobios Pharmaceuticals Inc Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
WO2010105290A1 (en) 2009-03-16 2010-09-23 Cephalon Australia Pty Ltd Humanised antibodies with anti-tumour activity
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
AR075896A1 (es) 2009-03-20 2011-05-04 Genentech Inc Anticuerpos anti-her (factor de crecimiento epidermico)
EP2411024A4 (en) * 2009-03-24 2013-02-27 Bayer Healthcare Llc Variants of factor viii and associated methods of use
HRP20150965T1 (hr) 2009-03-25 2015-11-06 Genentech, Inc. Anti-fgr3 protutijela i metode koje ih koriste
MY173526A (en) 2009-03-25 2020-01-31 Genentech Inc Novel anti-?5?1 antibodies and uses thereof
ES2363358B1 (es) 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2417156B1 (en) 2009-04-07 2015-02-11 Roche Glycart AG Trivalent, bispecific antibodies
EP3009454A3 (en) 2009-04-20 2016-10-19 Oxford Bio Therapeutics Limited Antibodies specific to cadherin-17
WO2010124113A1 (en) 2009-04-23 2010-10-28 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
MX2011011352A (es) 2009-04-27 2011-11-18 Novartis Ag Composiciones y metodos para aumentar el crecimiento muscular.
CN102414223A (zh) 2009-04-27 2012-04-11 诺瓦提斯公司 对IL12受体β亚基特异的治疗性抗体的组合物和方法
MX2011011670A (es) * 2009-05-01 2011-11-18 Abbott Lab Inmunoglobulinas de dominio variable dual y usos de las mismas.
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
EP3431501A1 (en) 2009-06-18 2019-01-23 Pfizer Inc Anti notch-1 antibodies
US20120213705A1 (en) 2009-06-22 2012-08-23 Medimmune, Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
WO2011008517A2 (en) * 2009-06-30 2011-01-20 Research Development Foundation Immunoglobulin fc polypeptides
JP6095367B2 (ja) 2009-07-13 2017-03-15 ジェネンテック， インコーポレイテッド 癌治療のための診断方法および組成物
TW201106972A (en) 2009-07-27 2011-03-01 Genentech Inc Combination treatments
JP2013500993A (ja) 2009-07-31 2013-01-10 ジェネンテック， インコーポレイテッド Ｂｖ８アンタゴニスト又はｇ−ｃｓｆアンタゴニストを用いた腫瘍転移の阻害
CN102762593B (zh) 2009-07-31 2015-05-20 梅达雷克斯有限责任公司 抗btla的完全人抗体
MX355650B (es) 2009-08-11 2018-04-26 Genentech Inc Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
WO2011020049A1 (en) 2009-08-14 2011-02-17 Genentech, Inc. Biological markers for monitoring patient response to vegf antagonists
WO2011022264A1 (en) 2009-08-15 2011-02-24 Genentech, Inc. Anti-angiogenesis therapy for the treatment of previously treated breast cancer
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
GB0914691D0 (en) * 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
EP3222287A1 (en) 2009-08-24 2017-09-27 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2772715C (en) 2009-09-02 2019-03-26 Genentech, Inc. Mutant smoothened and methods of using the same
EP3211094A3 (en) 2009-09-03 2017-11-01 F. Hoffmann-La Roche AG Methods for treating, diagnosing, and monitoring rheumatoid arthritis
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
US20110064670A1 (en) 2009-09-11 2011-03-17 Genentech, Inc. Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
MX2012002909A (es) 2009-09-17 2012-04-19 Hoffmann La Roche Metodos y composiciones para su uso en diagnostico de pacientes con cancer.
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
AU2010303415B2 (en) 2009-10-07 2015-02-19 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
US20120231004A1 (en) 2009-10-13 2012-09-13 Oxford Biotherapeutic Ltd. Antibodies
PT2488554T (pt) 2009-10-14 2019-09-13 Humanigen Inc Anticorpos para epha3
BR112012008833A2 (pt) * 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
MX2012004647A (es) 2009-10-22 2012-06-19 Genentech Inc Anticuerpos antihepsina y metodos para su uso.
ES2788457T3 (es) 2009-10-23 2020-10-21 Millennium Pharm Inc Moléculas de anticuerpo anti-GCC y composiciones y métodos relacionados
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
SG10201912571XA (en) 2009-11-02 2020-02-27 Univ Washington Therapeutic nuclease compositions and methods
US8637019B2 (en) 2009-11-04 2014-01-28 Merck Sharp & Dohme Corp. Engineered anti-TSLP antibody
CA2780143A1 (en) 2009-11-05 2011-05-12 Genentech, Inc. Methods and composition for secretion of heterologous polypeptides
US8932588B2 (en) 2009-11-05 2015-01-13 Teva Pharmaceuticals Australia Pty. Ltd. Treatment of cancer involving mutated KRAS or BRAF genes
WO2011060015A1 (en) 2009-11-11 2011-05-19 Genentech, Inc. Methods and compositions for detecting target proteins
RS60033B1 (sr) 2009-11-24 2020-04-30 Medimmune Ltd Ciljano vezujući agensi usmereni na b7-h1
PT2506871T (pt) * 2009-11-30 2016-11-07 Janssen Biotech Inc Mutantes de fc de anticorpos com funções efetoras inutilizadas
EP2507265B1 (en) 2009-12-01 2016-05-11 Compugen Ltd. Antibody specific for heparanase splice variant T5 and its use.
IN2012DN05169A (es) 2009-12-02 2015-10-23 Acceleron Pharma Inc
WO2011071577A1 (en) 2009-12-11 2011-06-16 Genentech, Inc. Anti-vegf-c antibodies and methods using same
CA2785139A1 (en) 2009-12-22 2011-06-30 Novartis Ag Tetravalent cd47-antibody constant region fusion protein for use in therapy
AU2010336485B2 (en) 2009-12-23 2015-03-26 Genentech, Inc. Anti-Bv8 antibodies and uses thereof
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
MX341687B (es) 2010-02-10 2016-08-30 Immunogen Inc "anticuerpos cd20 y su utilización".
BR112012019902A2 (pt) 2010-02-10 2019-09-24 Novartis Ag "método e compostos para o crescimento muscular"
CA2784211C (en) 2010-02-18 2019-12-24 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
EP3590966B1 (en) 2010-02-23 2025-03-05 Sanofi Anti-alpha2 integrin antibodies and their uses
RU2012140447A (ru) 2010-02-23 2014-03-27 Дженентек, Инк. Антиангиогенная терапия для лечения рака яичника
US9260529B2 (en) 2010-02-24 2016-02-16 The University Of Washington Through Its Center For Commercialization Molecules that bind CD180, compositions and methods of use
EP2543727B1 (en) 2010-03-02 2016-08-31 Kyowa Hakko Kirin Co., Ltd. Modified antibody composition
LT2542256T (lt) 2010-03-04 2019-10-25 Macrogenics Inc Su b7-h3 reaguojantys antikūnai, jų imunologiškai aktyvūs fragmentai ir jų naudojimas
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
BR112012022044A2 (pt) 2010-03-24 2020-08-25 Genentech Inc ''anticorpo,imunoconjugado,formulação farmacêutica,uso do anticorpo,método de tratamento,anticorpo biespecifico isolado e célula hospedeira''.
KR101882523B1 (ko) 2010-03-26 2018-07-26 트러스티스 오브 다트마우스 칼리지 Ｖｉｓｔａ 조절 ｔ 세포 매개 단백질, ｖｉｓｔａ 결합제 및 그것의 용도
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
CN102971340A (zh) 2010-03-29 2013-03-13 酵活有限公司 具有增强的或抑制的效应子功能的抗体
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
EP2371860A1 (en) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
SG185415A1 (en) 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
WO2011138392A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
US9187552B2 (en) 2010-05-27 2015-11-17 Merck Sharp & Dohme Corp. Method for preparing antibodies having improved properties
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
WO2011153243A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
SG185430A1 (en) 2010-06-03 2012-12-28 Genentech Inc Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
CA2794731C (en) 2010-06-18 2019-03-19 Genentech, Inc. Anti-axl antibodies and methods of use
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
US20130189268A1 (en) 2010-06-22 2013-07-25 Precision Biologics, Inc. Colon and pancreas cancer specific antigens and antibodies
WO2011161189A1 (en) 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use
TW201217527A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
CN103097418A (zh) 2010-07-09 2013-05-08 霍夫曼-拉罗奇有限公司 抗神经毡蛋白抗体及使用方法
CA2804246A1 (en) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
CN104634971A (zh) 2010-07-19 2015-05-20 霍夫曼-拉罗奇有限公司 鉴定响应抗癌疗法的可能性升高的患者的方法
WO2012010582A1 (en) 2010-07-21 2012-01-26 Roche Glycart Ag Anti-cxcr5 antibodies and methods of use
RU2598711C2 (ru) 2010-07-22 2016-09-27 Те Риджентс Оф Те Юниверсити Оф Калифорния Антитело к противоопухолевому антигену и способы применения
EP2596026B1 (en) 2010-07-23 2020-04-08 Trustees of Boston University Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
KR102080704B1 (ko) 2010-07-29 2020-02-24 세센 바이오, 아이엔씨. 키메라 il-1 수용체 유형 i 항진제 및 길항제들
CA2806909C (en) 2010-07-30 2019-12-17 Ac Immune S.A. Safe and functional humanized antibodies
ES2667100T3 (es) 2010-08-02 2018-05-09 Macrogenics, Inc. Diacuerpos covalentes y sus usos
NZ607480A (en) 2010-08-03 2014-10-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2012018771A1 (en) 2010-08-03 2012-02-09 Genentech, Inc. Chronic lymphocytic leukemia (cll) biomarkers
BR112013002532A2 (pt) 2010-08-05 2016-05-31 Hoffmann La Roche proteína de fusão de citocina anti-viral do anticorpo anti-mhc
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
NZ703653A (en) 2010-08-13 2016-09-30 Roche Glycart Ag Anti-fap antibodies and methods of use
EP2603526A1 (en) 2010-08-13 2013-06-19 Medimmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
MX2013001336A (es) 2010-08-13 2013-03-08 Roche Glycart Ag Anticuerpos ani-tenascina c a2 y metodos de utilizacion.
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
MY162825A (en) 2010-08-20 2017-07-31 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
TW201215405A (en) 2010-08-25 2012-04-16 Hoffmann La Roche Antibodies against IL-18R1 and uses thereof
PH12013500337A1 (en) 2010-08-26 2017-08-23 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
US20130224191A1 (en) 2010-08-27 2013-08-29 Robert A. Stull Notum protein modulators and methods of use
TWI560199B (en) 2010-08-31 2016-12-01 Sanofi Sa Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
RU2013114360A (ru) 2010-08-31 2014-10-10 Дженентек, Инк. Биомаркеры и способы лечения
CN106620693A (zh) 2010-09-03 2017-05-10 艾伯维施特姆森特克斯有限责任公司 新型调节剂及使用方法
US9150655B2 (en) 2010-09-03 2015-10-06 Academia Sinica Anti-C-met antibody and methods of use thereof
WO2012032080A1 (en) 2010-09-07 2012-03-15 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Stabilised human fc
US8999335B2 (en) 2010-09-17 2015-04-07 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
US9068014B2 (en) 2010-09-23 2015-06-30 Precision Biologics, Inc. Colon and pancreas cancer peptidomimetics
HUE031956T2 (en) 2010-09-27 2017-08-28 Morphosys Ag Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and NHL
WO2012045703A1 (en) 2010-10-05 2012-04-12 Novartis Ag Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
AU2011312205B2 (en) 2010-10-05 2015-08-13 Curis, Inc. Mutant smoothened and methods of using the same
BR112013009083B1 (pt) 2010-10-13 2021-08-10 Janssen Biotech, Inc. Anticorpos humanos para oncostatina m, seu processo de fabricação, fragmento de ligação a antígeno, composição farmacêutica, polinucleotídeo isolado, célula hospedeira recombinante estavelmente transformada ou transfectada
US20130259878A1 (en) * 2010-10-20 2013-10-03 Oxford Biotherapeutics Ltd Antibodies
MX352929B (es) 2010-11-05 2017-12-13 Zymeworks Inc DISEÑO DE ANTICUERPOS HETERODIMÉRICOS ESTABLES CON MUTACIONES EN EL DOMINIO Fc.
KR20220070586A (ko) 2010-11-08 2022-05-31 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
CA2815840A1 (en) 2010-11-10 2012-05-18 Genentech, Inc. Methods and compositions for neural disease immunotherapy
LT2643352T (lt) 2010-11-23 2018-08-10 Glaxo Group Limited Antigeną onkostatiną m (osm) surišantys baltymai
DK2643018T3 (da) 2010-11-23 2021-01-18 Vitaeris Inc Anti-il-6-antistoffer til behandling af oral mucositis
EP2643351A1 (en) 2010-11-24 2013-10-02 Glaxo Group Limited Multispecific antigen binding proteins targeting hgf
TWI761912B (zh) 2010-11-30 2022-04-21 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
WO2012075037A1 (en) 2010-11-30 2012-06-07 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
FI3434767T3 (fi) 2010-11-30 2026-02-12 Chugai Seiyaku Kk Sytotoksisuutta aiheuttava terapeuttinen aine
AU2011338425A1 (en) 2010-12-08 2013-05-02 Stemcentrx, Inc. Novel modulators and methods of use
SG191039A1 (en) 2010-12-15 2013-08-30 Wyeth Llc Anti-notch1 antibodies
TWI708944B (zh) 2010-12-16 2020-11-01 美商建南德克公司 關於th2抑制作用之診斷及治療
AU2011349443B2 (en) 2010-12-20 2015-12-24 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
PH12013501339A1 (en) 2010-12-22 2013-08-28 Genentech Inc Anti-pcsk9 antibodies and methods of use
NZ612379A (en) * 2010-12-23 2014-10-31 Janssen Biotech Inc Active protease-resistant antibody fc mutants
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
CN102128937B (zh) * 2010-12-31 2014-05-28 江苏华冠生物技术股份有限公司 用于脱敏治疗效果评价的过敏原特异性IgG4抗体检测试剂盒的制备方法
KR20140016262A (ko) 2011-01-14 2014-02-07 레드우드 바이오사이언스 인코포레이티드 알데하이드-태깅된 면역글로불린 폴리펩타이드 및 이의 사용 방법
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
US8952132B2 (en) 2011-02-07 2015-02-10 Research Development Foundation Engineered immunoglobulin FC polypeptides
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
WO2012132067A1 (ja) 2011-03-30 2012-10-04 中外製薬株式会社 抗原結合分子の血漿中滞留性と免疫原性を改変する方法
SG192945A1 (en) 2011-02-25 2013-09-30 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc antibody
RU2013141078A (ru) 2011-02-28 2015-04-10 Ф. Хоффманн-Ля Рош Аг Одновалентные антигенсвязывающие белки
JP6271254B2 (ja) 2011-02-28 2018-01-31 ジェネンテック， インコーポレイテッド Ｂ細胞アンタゴニストに対する生物学的マーカー及び応答を予測するための方法
MX341921B (es) 2011-02-28 2016-09-07 Hoffmann La Roche Proteinas de union a antigeno.
TR201815420T4 (tr) * 2011-03-29 2018-11-21 Roche Glycart Ag Antikor fc varyantları.
AU2012233313C1 (en) 2011-03-30 2017-08-03 Chugai Seiyaku Kabushiki Kaisha Method for altering plasma retention and immunogenicity of antigen-binding molecule
CN113999307A (zh) 2011-03-30 2022-02-01 中外制药株式会社 改变抗原结合分子的血浆中滞留性和免疫原性的方法
AU2012236304C1 (en) 2011-03-31 2017-01-05 Genentech, Inc. Methods of administering beta7 integrin antagonists
BR112013024717A2 (pt) 2011-04-07 2017-08-08 Genentech Inc anticorpo isolado, ácido nucleico isolado, célula hospedeira, imunoconjugado, formulação farmacêutica, método de tratar um indivíduo que tem câncer e método de inibir proliferação celular em um indivíduo
US9469676B2 (en) 2011-04-13 2016-10-18 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
NZ713461A (en) 2011-04-15 2017-02-24 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
WO2012145493A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
WO2012145746A1 (en) 2011-04-21 2012-10-26 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for the treatment of neuromyelitis optica
GB201107170D0 (en) 2011-04-28 2011-06-15 Clark Michael Binding molecules with biased recognition
PH12013502441B1 (en) 2011-04-29 2019-02-08 Univ Washington Therapeutic nuclease compositions and methods
WO2012146630A1 (en) 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof
KR101992502B1 (ko) 2011-05-12 2019-06-24 제넨테크, 인크. 프레임워크 시그너처 펩티드를 사용하여 동물 샘플에서 치료 항체를 검출하기 위한 다중 반응 모니터링 lc-ms/ms 방법
WO2012156309A1 (en) 2011-05-13 2012-11-22 Millegen Antibodies against her3
PH12013502294A1 (en) 2011-05-16 2014-01-27 Genentech Inc Fgfr1 agonists and methods of use
MY173899A (en) 2011-05-21 2020-02-26 Macrogenics Inc Cd3-binding molecules capable of binding to human and non-human cd3
JP6145088B2 (ja) 2011-05-21 2017-06-07 マクロジェニクス，インコーポレーテッド 脱免疫化血清結合ドメイン及び血清半減期を延長するためのその使用
CN103857699B (zh) 2011-05-24 2016-08-31 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
CN103582650A (zh) 2011-05-25 2014-02-12 默沙东公司 用于制备具有改善性质的含Fc多肽的方法
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
WO2012170969A2 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
EP2721067B1 (en) 2011-06-15 2019-07-31 F.Hoffmann-La Roche Ag Anti-human epo receptor antibodies and methods of use
CN103635490A (zh) 2011-06-16 2014-03-12 诺瓦提斯公司 用作治疗剂的可溶性蛋白
CA2839508A1 (en) 2011-06-22 2012-12-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-axl antibodies and uses thereof
US9409988B2 (en) 2011-06-22 2016-08-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-Axl antibodies and uses thereof
AR086982A1 (es) 2011-06-22 2014-02-05 Hoffmann La Roche Eliminacion de celulas diana por parte de celulas t citotoxicas especificas de virus utilizando complejos que comprenden mhc de clase i
EP2537864B1 (en) * 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
SMT201700447T1 (it) 2011-06-28 2017-11-15 Oxford Biotherapeutics Ltd Anticorpi nei confronti della adp-ribosil ciclasi 2
US20130004484A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
US9890218B2 (en) 2011-06-30 2018-02-13 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
WO2013001517A1 (en) 2011-06-30 2013-01-03 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
DK2726099T3 (en) 2011-07-01 2018-11-05 Novartis Ag Method of treating metabolic disorders
UA117901C2 (uk) * 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
CA3158257A1 (en) 2011-07-11 2013-01-17 Ichnos Sciences SA Antibodies that bind to ox40 and their uses
US9238689B2 (en) 2011-07-15 2016-01-19 Morpho Sys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
US20130022551A1 (en) 2011-07-22 2013-01-24 Trustees Of Boston University DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
CA2842099A1 (en) 2011-07-27 2013-01-31 Glaxo Group Limited Antigen binding constructs
AU2012296613B2 (en) 2011-08-15 2016-05-12 Amplimmune, Inc. Anti-B7-H4 antibodies and their uses
KR20140068877A (ko) 2011-08-17 2014-06-09 제넨테크, 인크. 불응성 종양에서의 혈관신생의 억제
CN103890007A (zh) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 神经调节蛋白抗体及其用途
MX2014002053A (es) 2011-08-23 2014-04-25 Roche Glycart Ag Anticuerpos anti -mcsp y metodos de uso.
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
BR112014005720A2 (pt) 2011-09-15 2017-12-12 Genentech Inc método de seleção e/ou identificação de um antagonista de usp1, antagonista de uaf1 e/ou um antagonista de id que promove uma alteração no destino celular do dito método
AR087918A1 (es) 2011-09-19 2014-04-23 Genentech Inc Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
CN107098967A (zh) 2011-09-30 2017-08-29 达纳-法伯癌症研究所股份有限公司 治疗肽
TW201945034A (zh) 2011-09-30 2019-12-01 日商中外製藥股份有限公司 包含依離子濃度之條件對抗原之結合活性會改變之抗原結合分域、及於pH中性之條件下對FcRn有結合活性之FcRn結合分域、且誘導對標的抗原的免疫反應之抗原結合分子
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
CN110639014A (zh) 2011-09-30 2020-01-03 中外制药株式会社 促进抗原消除的抗原结合分子
US20150299313A1 (en) 2011-10-05 2015-10-22 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting clearance from plasma of antigen comprising suger chain receptor-binding domain
BR112014008212A2 (pt) 2011-10-05 2017-06-13 Genentech Inc método para tratar uma condição hepática, método de indução por diferenciação hepática e método de redução de proliferação anormal do ducto biliar
KR102102862B1 (ko) 2011-10-14 2020-04-22 제넨테크, 인크. 항-HtrA1 항체 및 사용 방법
EP2766033B1 (en) 2011-10-14 2019-11-20 Novartis AG Antibodies and methods for wnt pathway-related diseases
US9358250B2 (en) 2011-10-15 2016-06-07 Genentech, Inc. Methods of using SCD1 antagonists
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
EP3559049B1 (en) 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
AU2012328980A1 (en) 2011-10-28 2014-04-24 Genentech, Inc. Therapeutic combinations and methods of treating melanoma
JP6371059B2 (ja) 2011-10-31 2018-08-08 中外製薬株式会社 重鎖と軽鎖の会合が制御された抗原結合分子
AU2012332590B2 (en) 2011-11-01 2016-10-20 Bionomics, Inc. Anti-GPR49 antibodies
AU2012332587B2 (en) 2011-11-01 2017-02-23 Bionomics, Inc. Antibodies and methods of treating cancer
WO2013067060A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
US10598653B2 (en) 2011-11-01 2020-03-24 Bionomics Inc. Methods of blocking cancer stem cell growth
HUE056462T2 (hu) 2011-11-04 2022-02-28 Zymeworks Inc Stabil heterodimer antestest tervezés mutációkkal az FC domainben
WO2013070565A1 (en) 2011-11-07 2013-05-16 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
CN104066748A (zh) 2011-11-21 2014-09-24 霍夫曼-拉罗奇有限公司 抗c-met抗体的纯化
RU2014124530A (ru) 2011-11-23 2015-12-27 Идженика, Инк. Антитела к cd98 и способы их применения
JP6124800B2 (ja) 2011-11-30 2017-05-10 中外製薬株式会社 免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬
CN104105708B (zh) 2011-12-05 2018-04-03 X博迪生物科学公司 PDGF受体β结合多肽
TW201328706A (zh) 2011-12-05 2013-07-16 Novartis Ag 表皮生長因子受體３（ｈｅｒ３）之抗體
IN2014CN04373A (es) 2011-12-05 2015-09-04 Novartis Ag
EP2788024A1 (en) 2011-12-06 2014-10-15 F.Hoffmann-La Roche Ag Antibody formulation
WO2013101509A2 (en) 2011-12-15 2013-07-04 Alternative Innovative Technologies Llc Hsp70 fusion protein conjugates and uses thereof
RS60499B1 (sr) 2011-12-20 2020-08-31 Medimmune Llc Modifikovani polipeptidi za bispecifične skelete antitela
EP3330288A1 (en) 2011-12-21 2018-06-06 Novartis AG Compositions and methods for antibodies targeting factor p
AR089434A1 (es) 2011-12-23 2014-08-20 Genentech Inc Procedimiento para preparar formulaciones con alta concentracion de proteinas
WO2013093809A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
CA2861610A1 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual specific binding proteins directed against il-13 and/or il-17
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
CN104411717A (zh) 2012-01-09 2015-03-11 斯克利普斯研究所 具有超长cdr3s的人源化抗体
US10774132B2 (en) 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
CN111499760A (zh) 2012-01-12 2020-08-07 比奥贝拉蒂治疗公司 嵌合因子viii多肽及其用途
CA2862835A1 (en) 2012-01-13 2013-07-18 Genentech, Inc. Biological markers for identifying patients for treatment with vegf antagonists
EP2804629A1 (en) 2012-01-18 2014-11-26 Genentech, Inc. Anti-lrp5 antibodies and methods of use
KR20140119114A (ko) 2012-01-18 2014-10-08 제넨테크, 인크. Fgf19 조절제의 사용 방법
CA2848985A1 (en) 2012-02-01 2013-08-08 Compugen Ltd. C10rf32 antibodies, and uses thereof for treatment of cancer
WO2013117647A1 (en) 2012-02-07 2013-08-15 Innate Pharma Mica binding agents
EP2813568B1 (en) 2012-02-09 2025-04-23 Chugai Seiyaku Kabushiki Kaisha Modified fc region of antibody
MX366804B (es) 2012-02-11 2019-07-25 Genentech Inc Translocaciones de la r-espondina y sus metodos de uso.
ES2771208T3 (es) 2012-02-15 2020-07-06 Bioverativ Therapeutics Inc Composiciones de factor VIII y métodos de preparación y uso de las mismas
EP2814587B1 (en) 2012-02-15 2018-05-02 F.Hoffmann-La Roche Ag Fc-receptor based affinity chromatography
DK2822577T3 (en) 2012-02-15 2019-04-01 Bioverativ Therapeutics Inc RECOMBINANT FACTOR VIII PROTEINS
TWI617577B (zh) 2012-02-24 2018-03-11 中外製藥股份有限公司 經ＦｃγＲＩＩＢ促進抗原消失之抗原結合分子
EP3093294A1 (en) 2012-02-24 2016-11-16 Stemcentrx, Inc. Dll3 modulators and methods of use
JP2015514710A (ja) 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Ｈｅｒ３阻害剤に関する診断及び治療
EP3246339B1 (en) 2012-03-28 2019-10-09 Sanofi Antibodies to bradykinin b1 receptor ligands
EP2832856A4 (en) 2012-03-29 2016-01-27 Chugai Pharmaceutical Co Ltd ANTI-LAMP5 ANTIBODIES AND USE THEREOF
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
US20150056190A1 (en) 2012-03-30 2015-02-26 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
AU2013243861A1 (en) 2012-04-05 2014-10-23 Ac Immune S.A. Humanized Tau antibody
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
KR20150006000A (ko) 2012-05-01 2015-01-15 제넨테크, 인크. 항-pmel17 항체 및 면역접합체
WO2013166290A1 (en) 2012-05-04 2013-11-07 Abbvie Biotherapeutics Inc. P21 biomarker assay
MX2014013637A (es) 2012-05-07 2015-02-05 Sanofi Sa Metodos para prevencion de la formacion de biopelicula.
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
ES2682761T3 (es) 2012-05-18 2018-09-21 Genentech, Inc. Formulaciones de anticuerpos monoclonales de alta concentración
MY181743A (en) 2012-05-21 2021-01-06 Genentech Inc Methods for improving safety of blood-brain barrier transport
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
DK2852610T3 (en) 2012-05-23 2018-09-03 Glykos Finland Oy PRODUCTION OF FUCOSYLED GLYCOPROTEIN
MX2014014086A (es) 2012-05-23 2015-01-26 Genentech Inc Metodo de seleccion para agentes terapeuticos.
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
CA2874721A1 (en) 2012-05-30 2013-12-05 Tomoyuki Igawa Target tissue-specific antigen-binding molecule
ES2856272T3 (es) 2012-05-30 2021-09-27 Chugai Pharmaceutical Co Ltd Molécula de unión a antígenos para eliminar antígenos agregados
WO2013184514A1 (en) 2012-06-04 2013-12-12 Irm Llc Site-specific labeling methods and molecules produced thereby
KR20150023679A (ko) 2012-06-08 2015-03-05 그렌마크 파머수티칼스 에스. 아. 아미노산 치환을 갖는 인간화된 항-TrkA 항체
CA2875246A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
US10202595B2 (en) 2012-06-08 2019-02-12 Bioverativ Therapeutics Inc. Chimeric clotting factors
WO2013187495A1 (ja) 2012-06-14 2013-12-19 中外製薬株式会社 改変されたFc領域を含む抗原結合分子
KR20150023711A (ko) 2012-06-15 2015-03-05 제넨테크, 인크. 항-pcsk9 항체, 제제, 투여, 및 사용 방법
CA2877363A1 (en) * 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
EP3421486B1 (en) 2012-06-22 2023-09-27 The Trustees Of Dartmouth College Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
WO2014004586A1 (en) 2012-06-25 2014-01-03 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
EP3138578B1 (en) 2012-07-04 2022-01-12 F. Hoffmann-La Roche AG Anti-theophylline antibodies and methods of use
RU2684595C2 (ru) 2012-07-04 2019-04-09 Ф.Хоффманн-Ля Рош Аг Ковалентно связанные конъюгаты антиген-антитело
CA2872192A1 (en) 2012-07-04 2014-01-09 F. Hoffmann-La Roche Ag Anti-biotin antibodies and methods of use
CN110042114B (zh) 2012-07-05 2024-09-10 弗·哈夫曼-拉罗切有限公司 表达和分泌系统
EP3632462A1 (en) 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
EP2870250B2 (en) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
AU2013285355A1 (en) 2012-07-06 2015-01-29 Genmab B.V. Dimeric protein with triple mutations
US20140030280A1 (en) 2012-07-09 2014-01-30 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates
TW201408697A (zh) 2012-07-09 2014-03-01 Genentech Inc 抗ｃｄ７９ｂ抗體及免疫結合物
CN104428007B (zh) 2012-07-09 2018-03-16 基因泰克公司 包含抗cd22抗体的免疫缀合物
IN2014DN10510A (es) 2012-07-09 2015-08-21 Genentech Inc
SI2882450T1 (sl) 2012-07-11 2020-02-28 Bioverativ Therapeutics Inc. Kompleks faktorja VIII z XTEN in s proteinom von Willebrandovega faktorja in njegove uporabe
DK3495387T3 (da) 2012-07-13 2021-11-08 Roche Glycart Ag Bispecifikke anti-VEGF-/anti-ANG-2-antistoffer og deres anvendelse ved behandling af okulære vaskulære sygdomme
CN104394887A (zh) 2012-07-18 2015-03-04 葛莱高托普有限公司 采用具有低岩藻糖化的抗her2抗体的新治疗性疗法
NZ731881A (en) 2012-07-25 2022-07-29 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
EP2888279A1 (en) 2012-08-22 2015-07-01 Glaxo Group Limited Anti lrp6 antibodies
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
BR112015001955A2 (pt) 2012-08-24 2017-11-07 Chugai Pharmaceutical Co Ltd variante de região fc específica de fcgamariib
KR102036262B1 (ko) 2012-08-29 2019-10-24 에프. 호프만-라 로슈 아게 혈액 뇌 장벽 셔틀
CA2884704C (en) 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
RS57748B1 (sr) 2012-09-12 2018-12-31 Genzyme Corp Polipeptidi sa izmenjenom glikozilacijom i smanjenom efektorskom funkcijom koji sadrže fc
CA2887129A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
TW201811825A (zh) 2012-11-01 2018-04-01 美商艾伯維有限公司 抗-ｖｅｇｆ／ｄｌｌ４雙重可變區域免疫球蛋白及其用途
EP4223770A3 (en) 2012-11-05 2023-10-18 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
HK1214830A1 (zh) 2012-11-05 2016-08-05 Foundation Medicine, Inc. 新型ntrk1融合分子及其应用
CA2884431A1 (en) 2012-11-08 2014-05-15 F. Hoffmann-La Roche Ag Her3 antigen binding proteins binding to the beta-hairpin of her3
KR20150082503A (ko) 2012-11-09 2015-07-15 화이자 인코포레이티드 혈소판 유래 성장 인자 b 특이적 항체, 및 그의 조성물 및 용도
CA2890669A1 (en) 2012-11-13 2014-05-22 Genetech, Inc. Anti-hemagglutinin antibodies and methods of use
EP2733153A1 (en) 2012-11-15 2014-05-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the preparation of immunoconjugates and uses thereof
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
EP2925779A1 (en) 2012-11-30 2015-10-07 Institut Pasteur Use of anti-fcyri and/or anti-fcyriia antibodies for treating arthritis, inflammation, thrombocytopenia and allergic shock
EP3851454A1 (en) 2012-12-05 2021-07-21 Novartis AG Compositions and methods for antibodies targeting epo
SI2928923T1 (sl) 2012-12-10 2020-03-31 Biogen Ma Inc. Protitelesa proti antigenu 2 dendritičnih celic v krvi in njihova uporaba
JP2016509582A (ja) 2012-12-19 2016-03-31 アンプリミューン， インコーポレイテッド 抗ヒトｂ７−ｈ４抗体およびその使用
KR20150097688A (ko) 2012-12-21 2015-08-26 에프. 호프만-라 로슈 아게 디술피드-연결 다가 ｍｈｃ 클래스 ｉ 포함 다관능 단백질
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
US9790277B2 (en) 2012-12-21 2017-10-17 The Johns Hopkins University Anti-H7CR antibodies
EP3557260B1 (en) 2012-12-21 2022-05-18 Chugai Seiyaku Kabushiki Kaisha Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
US10766960B2 (en) 2012-12-27 2020-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
EP2938633B1 (en) 2012-12-28 2018-02-07 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
MX360155B (es) 2013-01-02 2018-10-24 Glenmark Pharmaceuticals Sa Anticuerpos que se unen al ligando 1a tipo tnf y sus usos.
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
KR20220156667A (ko) 2013-01-10 2022-11-25 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
AU2014207342C1 (en) 2013-01-18 2019-04-04 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
WO2014116749A1 (en) 2013-01-23 2014-07-31 Genentech, Inc. Anti-hcv antibodies and methods of using thereof
KR20150110659A (ko) 2013-01-24 2015-10-02 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Tnf-알파 항원-결합 단백질
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
ES2667420T3 (es) 2013-02-05 2018-05-10 Engmab Sàrl Anticuerpos biespecíficos contra cd3epsilon y bcma
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
WO2015198217A2 (en) 2013-02-08 2015-12-30 Novartis Ag Compositions and methods for long-acting antibodies targeting il-17
WO2014124258A2 (en) 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
BR112015017338B1 (pt) 2013-02-08 2022-11-29 Novartis Ag Anticorpo humano terapêutico isolado ou sua porção de ligação ao antígeno do mesmo, seu uso e seu processo de produção, composição farmacêutica, molécula de ácido nucleico isolada, vetor de clonagem ou de expressão e micro-organismo transgênico
DK2953976T3 (da) 2013-02-08 2021-06-21 Novartis Ag Specifikke modificeringssteder i antistoffer til fremstilling af immunkonjugater
WO2014126884A1 (en) 2013-02-12 2014-08-21 Bristol-Myers Squibb Company High ph protein refolding methods
WO2014126871A1 (en) 2013-02-12 2014-08-21 Bristol-Myers Squibb Company Tangential flow filtration based protein refolding methods
ES2747920T3 (es) 2013-02-14 2020-03-12 Innate Pharma Anticuerpo anti-NKP46 para diagnóstico de un linfoma de células T periféricas no cutáneo (PTCL)
WO2014127215A1 (en) 2013-02-15 2014-08-21 Biogen Idec Ma Inc. Optimized factor viii gene
ES2878749T3 (es) 2013-02-20 2021-11-19 Innate Pharma Un compuesto que se une específicamente a KIR3DL2 para el uso en el tratamiento de linfoma de células T periférico
SMT201900339T1 (it) 2013-02-22 2019-07-11 Medimmune Ltd Coniugati anticorpo anti-dll3/pbd e loro usi
JP2016509045A (ja) 2013-02-22 2016-03-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんを治療し、薬剤耐性を防止する方法
RU2015140573A (ru) 2013-02-25 2017-03-30 Дженентек, Инк. Способы и композиции для обнаружения и лечения устойчивого к лекарственным средствам мутанта акт
WO2014131715A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Anti-mcsp antibodies
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
JP2016510751A (ja) 2013-03-06 2016-04-11 ジェネンテック， インコーポレイテッド 抗がん剤耐性を治療及び予防する方法
WO2014164503A1 (en) 2013-03-11 2014-10-09 Genzyme Corporation Hyperglycosylated binding polypeptides
BR112015022587A2 (pt) 2013-03-13 2017-10-24 Eleven Biotherapeutics Inc formulações de citocina quimérica para entrega ocular
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
EP2968565A2 (en) 2013-03-14 2016-01-20 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
CN105246916A (zh) 2013-03-14 2016-01-13 诺华股份有限公司 针对notch 3的抗体
CN105189552B (zh) 2013-03-14 2019-08-02 基因泰克公司 抗b7-h4抗体和免疫缀合物
LT2968520T (lt) 2013-03-14 2021-09-27 Macrogenics, Inc. Bispecifinės molekulės, kurios yra imunoreaktyvios imuninių efektorių ląstelėms, kurios ekspresuoja aktyvuojantį receptorių
EP2968540A2 (en) 2013-03-14 2016-01-20 Genentech, Inc. Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
EP3514178A1 (en) 2013-03-15 2019-07-24 Novartis AG Antibody drug conjugates
WO2014144357A1 (en) 2013-03-15 2014-09-18 Merck Patent Gmbh Tetravalent bispecific antibodies
JP2016517441A (ja) 2013-03-15 2016-06-16 ジェネンテック， インコーポレイテッド 抗ＣＲＴｈ２抗体及び使用方法
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
BR112015023752B1 (pt) 2013-03-15 2023-11-14 Zyngenia, Inc. Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
CN105143252A (zh) 2013-03-15 2015-12-09 豪夫迈·罗氏有限公司 IL-22多肽和IL-22Fc融合蛋白及其使用方法
JP6568514B2 (ja) 2013-03-15 2019-08-28 エーシー イミューン エス．エー． 抗タウ抗体及び使用方法
ES2808654T3 (es) 2013-03-15 2021-03-01 Glaxosmithkline Ip Dev Ltd Proteínas de unión anti-LAG-3
EP2968495B1 (en) 2013-03-15 2019-07-03 Daniel J. Capon Hybrid immunoglobulin containing non-peptidyl linkage
CA2904448A1 (en) 2013-03-15 2014-09-18 Tariq Ghayur Dual specific binding proteins directed against il-1.beta. and/or il-17
WO2014151006A2 (en) 2013-03-15 2014-09-25 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
SG10201913874TA (en) 2013-03-15 2020-03-30 Biogen Ma Inc Factor ix polypeptide formulations
CN105142668B (zh) 2013-03-15 2018-04-27 达纳-法伯癌症研究院公司 治疗性肽
HK1211963A1 (en) 2013-03-15 2016-06-03 豪夫迈．罗氏有限公司 Compositions and methods for diagnosis and treatment of hepatic cancers
EP2970921B1 (en) 2013-03-15 2018-09-19 aTyr Pharma, Inc. Histidyl-trna synthetase-fc conjugates
KR20150128796A (ko) 2013-03-15 2015-11-18 바이오젠 엠에이 인코포레이티드 항-알파 v 베타 5개 항체를 이용한 급성 신장 손상의 치료 및 예방
FR3003171B1 (fr) * 2013-03-15 2015-04-10 Lab Francais Du Fractionnement Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
CN105339001A (zh) 2013-03-15 2016-02-17 基因泰克公司 治疗癌症和预防癌症耐药性的方法
AU2014241552B2 (en) 2013-03-27 2018-08-16 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
JP6598680B2 (ja) 2013-04-02 2019-10-30 中外製薬株式会社 Ｆｃ領域改変体
AU2014257650A1 (en) 2013-04-22 2015-11-12 Glycotope Gmbh Anti-cancer treatments with anti-EGFR antibodies having a low fucosylation
PE20151807A1 (es) 2013-04-29 2015-12-02 Hoffmann La Roche Anticuerpos modificados de union a fcrn humano y metodo de utilizacion
JP6618893B2 (ja) 2013-04-29 2019-12-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｆｃ受容体結合が変更された非対称抗体および使用方法
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
ES2938708T3 (es) 2013-04-29 2023-04-14 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado
HRP20240107T1 (hr) 2013-05-20 2024-04-12 F. Hoffmann - La Roche Ag Protutijela na transferinski receptor i postupci uporabe
AU2014268298B2 (en) 2013-05-24 2019-01-17 Medlmmune, Llc Anti-B7-H5 antibodies and their uses
CA2927309A1 (en) 2013-05-24 2014-11-27 Promis Neurosciences Inc. Fasr antibodies for diagnostic and therapeutic use
BR112015029788B1 (pt) 2013-05-31 2024-01-02 Zymeworks Inc HETERO-MULTÍMERO, USO E MÉTODO PARA PREPARAR DO MESMO, COMPOSIÇÃO FARMACÊUTICA E MÉTODO PARA REDUZIR FUNÇÃO EFETORA DE UM CONSTRUTO IgG FC
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
US9562101B2 (en) 2013-06-21 2017-02-07 Novartis Ag Lectin-like oxidized LDL receptor 1 antibodies and methods of use
MX2015017852A (es) 2013-06-24 2016-08-11 Chugai Pharmaceutical Co Ltd Agente terapeutico que comprende el anticuerpo anti-epirregulina humanizado con ingrediente activo contra el carcinoma de pulmon de celulas no pequeñas excluyendo el adenocarcinoma.
AU2014290361B2 (en) 2013-07-18 2019-04-18 Taurus Biosciences, Llc Humanized antibodies with ultralong complementarity determining regions
EP3022224A2 (en) 2013-07-18 2016-05-25 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
US10947269B2 (en) 2013-08-08 2021-03-16 Bioverativ Therapeutics Inc. Purification of chimeric FVIII molecules
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
JP6463359B2 (ja) 2013-08-12 2019-01-30 ジェネンテック， インコーポレイテッド 補体関連病態を治療するための組成物及び方法
SG10201710013RA (en) 2013-08-13 2018-01-30 Sanofi Sa Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
TW201722994A (zh) 2013-08-13 2017-07-01 賽諾菲公司 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
BR112016002198A2 (pt) 2013-08-14 2017-09-12 Novartis Ag métodos de tratamento de miosite por corpos de inclusão esporádica
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
CA2922529A1 (en) 2013-08-28 2015-03-05 Stemcentrx, Inc. Novel sez6 modulators and methods of use
AU2014312190A1 (en) 2013-08-28 2016-02-18 Bioasis Technologies Inc. CNS-targeted conjugates of antibodies
WO2015031698A1 (en) 2013-08-28 2015-03-05 Stem Centrx, Inc. Site-specific antibody conjugation methods and compositions
WO2015035606A1 (en) 2013-09-13 2015-03-19 Beigene, Ltd. Anti-pd1 antibodies and their use as therapeutics and diagnostics
JP2016537399A (ja) 2013-09-17 2016-12-01 ジェネンテック， インコーポレイテッド 抗ｌｇｒ５抗体を使用する方法
US10611794B2 (en) 2013-09-25 2020-04-07 Bioverativ Therapeutics Inc. On-column viral inactivation methods
EP3050896B1 (en) 2013-09-27 2021-07-07 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
EP3733244A1 (en) 2013-10-02 2020-11-04 Medlmmune, LLC Neutralizing anti-influenza a antibodies and uses thereof
RU2016115866A (ru) 2013-10-11 2017-11-16 Ф. Хоффманн-Ля Рош Аг Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
CN105814078A (zh) 2013-10-11 2016-07-27 豪夫迈·罗氏有限公司 Nsp4抑制剂及其使用方法
MX2016004802A (es) 2013-10-18 2016-07-18 Genentech Inc Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
AR098155A1 (es) 2013-10-23 2016-05-04 Genentech Inc Métodos para diagnosticar y tratar trastornos eosinofílicos
US10988745B2 (en) 2013-10-31 2021-04-27 Resolve Therapeutics, Llc Therapeutic nuclease-albumin fusions and methods
US10053511B2 (en) 2013-11-06 2018-08-21 Abbvie Stemcentrx Llc Anti-claudin antibodies and methods of use
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
CN105849125B (zh) 2013-11-07 2020-05-15 国家医疗保健研究所 神经调节蛋白变构抗her3抗体
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
CN113307873B (zh) 2013-11-11 2025-02-18 中外制药株式会社 含有改变了抗体可变区的抗原结合分子
CN113150144A (zh) 2013-11-13 2021-07-23 辉瑞大药厂 肿瘤坏死因子样配体1a特异性抗体及其组合物和用途
RU2718990C1 (ru) 2013-11-21 2020-04-15 Ф. Хоффманн-Ля Рош Аг Антитела к альфа-синуклеину и способы применения
BR112016012094A2 (pt) 2013-12-04 2017-09-26 Chugai Pharmaceutical Co Ltd moléculas de ligação a antígeno, cuja atividade de ligação a antígeno varia de acordo com a concentração de compostos e bibliotecas das ditas moléculas
MX371187B (es) 2013-12-06 2020-01-22 Dana Farber Cancer Inst Inc Péptidos terapéuticos.
AU2014363944B2 (en) 2013-12-09 2020-03-26 Allakos Inc. Anti-Siglec-8 antibodies and methods of use thereof
CN106030310B (zh) 2013-12-13 2019-01-04 通用医疗公司 可溶性高分子量(hmw)tau种类及其应用
PE20160712A1 (es) 2013-12-13 2016-07-26 Genentech Inc Anticuerpos e inmunoconjugados anti-cd33
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
JP2017501167A (ja) 2013-12-17 2017-01-12 ジェネンテック， インコーポレイテッド Ｏｘ４０結合アゴニスト及びｐｄ−１軸結合アンタゴニストを含む併用療法
CN112353943A (zh) 2013-12-17 2021-02-12 豪夫迈·罗氏有限公司 用pd-1轴结合拮抗剂和紫杉烷治疗癌症的方法
WO2015095410A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
HRP20240939T1 (hr) 2013-12-17 2024-10-25 Genentech, Inc. Anti-cd3 protutijela i metode uporabe
CA2932958A1 (en) 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Humanized anti-tau(ps422) antibodies and methods of use
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
AU2014372309C1 (en) 2013-12-24 2017-12-14 Janssen Pharmaceutica Nv Anti-VISTA antibodies and fragments
EA035324B1 (ru) 2013-12-24 2020-05-28 Ардженкс Бвба АНТАГОНИСТЫ НЕОНАТАЛЬНЫХ Fc-РЕЦЕПТОРОВ (FCRN) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2015101586A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
CA2930154A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
EP3089759B1 (en) 2014-01-03 2018-12-05 F. Hoffmann-La Roche AG Covalently linked polypeptide toxin-antibody conjugates
JP6557664B2 (ja) 2014-01-06 2019-08-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 一価の血液脳関門シャトルモジュール
NZ721544A (en) 2014-01-10 2022-10-28 Bioverativ Therapeutics Inc Factor viii chimeric proteins and uses thereof
CA2931986A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and maintained protein a-binding properties
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
AU2015209131B2 (en) 2014-01-24 2020-06-25 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
JP2017505305A (ja) 2014-01-24 2017-02-16 ジェネンテック， インコーポレイテッド 抗ｓｔｅａｐ１抗体及びイムノコンジュゲートを使用する方法
EP3102197B1 (en) 2014-02-04 2018-08-29 Genentech, Inc. Mutant smoothened and methods of using the same
ES2873248T3 (es) 2014-02-08 2021-11-03 Hoffmann La Roche Métodos para tratar la enfermedad de Alzheimer
KR20160111039A (ko) 2014-02-08 2016-09-23 제넨테크, 인크. 알츠하이머 질환을 치료하는 방법
TR201810635T4 (tr) 2014-02-12 2018-08-27 Hoffmann La Roche Anti-jagged1 antikorları ve kullanım yöntemleri.
SG11201606714TA (en) 2014-02-14 2016-09-29 Andrew S Chi Improved methods for the treatment of vascularizing cancers
KR20160124165A (ko) 2014-02-21 2016-10-26 제넨테크, 인크. 항-il-13/il-17 이중특이적 항체 및 그의 용도
DK3110446T3 (da) 2014-02-28 2022-02-28 Allakos Inc Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
US9732154B2 (en) * 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
EP3129407A2 (en) 2014-03-12 2017-02-15 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
EP4169944A1 (en) 2014-03-14 2023-04-26 Biomolecular Holdings LLC Process for preparing hybrid immunoglobulin containing non-peptidyl linkage
RU2684703C2 (ru) 2014-03-14 2019-04-11 Иннейт Фарма Гуманизированные антитела с повышенной стабильностью
CN106456728A (zh) 2014-03-14 2017-02-22 达纳－法伯癌症研究所公司 恢复对抗癌症的nkg2d通路功能的疫苗组合物和方法
EP3116999B1 (en) 2014-03-14 2021-09-15 F. Hoffmann-La Roche AG Methods and compositions for secretion of heterologous polypeptides
CN116333148A (zh) 2014-03-19 2023-06-27 建新公司 靶向模块的位点特异性糖工程化
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
EP3119812B1 (en) 2014-03-21 2020-04-29 X-Body, Inc. Bi-specific antigen-binding polypeptides
US20170107294A1 (en) 2014-03-21 2017-04-20 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
CA2943329A1 (en) 2014-03-24 2015-10-01 Genentech, Inc. Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
CA2939246A1 (en) 2014-03-27 2015-10-01 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
CN106103486B (zh) 2014-03-31 2020-04-21 豪夫迈·罗氏有限公司 抗ox40抗体和使用方法
CA2943834A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
MX2016012873A (es) 2014-04-04 2017-03-07 Bionomics Inc Anticuerpos humanizados que se unen al receptor 5 acoplado a proteina g que contiene repeticion rica en leucina (lgr5).
TWI726842B (zh) 2014-04-07 2021-05-11 日商中外製藥股份有限公司 免疫活化抗原結合分子
KR20160143808A (ko) 2014-04-11 2016-12-14 메디뮨 엘엘씨 이중특이적 her2 항체
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
MX2016014160A (es) 2014-05-01 2017-02-16 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos.
KR102409014B1 (ko) 2014-05-08 2022-06-14 추가이 세이야쿠 가부시키가이샤 Gpc3 표적 치료제 요법이 유효한 환자에게 투여되는 gpc3 표적 치료제
SG11201609370QA (en) * 2014-05-13 2016-12-29 Chugai Pharmaceutical Co Ltd T cell-redirected antigen-binding molecule for cells having immunosuppression function
RU2746738C2 (ru) 2014-05-16 2021-04-20 Аблинкс Нв Улучшенные вариабельные домены иммуноглобулина
KR20250099289A (ko) 2014-05-16 2025-07-01 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
KR20170003582A (ko) 2014-05-22 2017-01-09 제넨테크, 인크. 항-gpc3 항체 및 면역접합체
JP2017524371A (ja) 2014-05-23 2017-08-31 ジェネンテック， インコーポレイテッド Ｍｉｔバイオマーカーとその使用方法
MX377844B (es) 2014-05-28 2025-03-11 Agenus Inc Anticuerpos anti proteína relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticóides (gitr) y sus métodos de uso.
AP2016009586A0 (en) 2014-05-29 2016-11-30 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
SMT201900745T1 (it) 2014-05-30 2020-01-14 Henlix Biotech Co Ltd Anticopri anti-recettore del fattore di crescita epidermico (egfr)
PT3151921T (pt) 2014-06-06 2019-11-21 Bristol Myers Squibb Co Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
CA2949982A1 (en) 2014-06-11 2015-12-17 Genentech, Inc. Anti-lgr5 antibodies and uses thereof
MX389695B (es) 2014-06-11 2025-03-20 Kathy A Green Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
EP3164419B1 (en) 2014-06-26 2024-07-24 F. Hoffmann-La Roche AG Anti-brdu antibodies and methods of use
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
JP6702893B2 (ja) 2014-06-27 2020-06-03 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 多重特異的抗原結合タンパク質
AU2015279316B2 (en) 2014-06-27 2021-03-04 Innate Pharma Multispecific NKp46 binding proteins
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
CN106604742B (zh) 2014-07-03 2019-01-11 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
WO2016007775A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Notch pathway inhibition
RU2715038C2 (ru) 2014-07-11 2020-02-21 Дженентек, Инк. Антитела анти-pd-l1 и способы их диагностического применения
RU2711141C2 (ru) 2014-07-22 2020-01-15 СиБи ТЕРЕПЬЮТИКС, ИНК. Антитела против pd-1
WO2016022630A1 (en) 2014-08-05 2016-02-11 Jiping Zha Anti-pd-l1 antibodies
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
TW201613977A (en) 2014-08-07 2016-04-16 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EP3177642B1 (en) 2014-08-07 2021-11-24 Novartis AG Angiopoietin-like 4 antibodies and methods of use
EA201790334A1 (ru) 2014-08-12 2017-06-30 Новартис Аг Конъюгаты анти-cdh6 антитела с лекарственным средством
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
GEAP202114450A (en) 2014-08-19 2021-07-26 Merck Sharp & Dohme Corp Us Anti-tigit antibodies
WO2016030488A1 (en) 2014-08-27 2016-03-03 Innate Pharma Treatment of celiac disease
DK4074735T3 (da) 2014-08-28 2025-07-14 Bioatla Inc Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
FR3025515B1 (fr) 2014-09-05 2016-09-09 Lab Francais Du Fractionnement Procede de purification d'un anticorps monoclonal
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
CN107108724A (zh) 2014-09-12 2017-08-29 豪夫迈·罗氏有限公司 半胱氨酸改造抗体和缀合物
MX2017003126A (es) 2014-09-12 2017-08-28 Genentech Inc Anticuerpos anti-her2 e inmunoconjugados.
SG11201701627PA (en) 2014-09-12 2017-03-30 Genentech Inc Anti-cll-1 antibodies and immunoconjugates
CN113698485A (zh) 2014-09-12 2021-11-26 基因泰克公司 抗-b7-h4抗体及免疫缀合物
RU2727663C2 (ru) 2014-09-17 2020-07-22 Дженентек, Инк. Иммуноконъюгаты, содержащие антитела против her2 и пирролбензодиазепины
RS60349B8 (sr) 2014-09-23 2022-10-31 Hoffmann La Roche Postupak upotrebe anti-cd79b imunokonjugata
SG11201701803XA (en) 2014-09-26 2017-04-27 Bayer Pharma AG Stabilized adrenomedullin derivatives and use thereof
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
MX386297B (es) 2014-09-29 2025-03-18 Univ Duke Moleculas biespecificas que comprenden un brazo orientado a la envoltura vih-1.
US20160108105A1 (en) * 2014-10-06 2016-04-21 Genexine, Inc. Human igg4 fc polypeptide variant
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
AU2015330869B2 (en) 2014-10-09 2021-07-08 Genzyme Corporation Glycoengineered antibody drug conjugates
CA2964317C (en) 2014-10-14 2021-10-05 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
MA41480A (fr) 2014-10-17 2017-12-19 Glenmark Pharmaceuticals Sa Anticorps qui se lient au ccr6 et leurs utilisations
EP3209687A1 (en) 2014-10-23 2017-08-30 Innate Pharma Treatment of cancers using anti-nkg2a agents
EA037749B1 (ru) 2014-10-29 2021-05-18 Тева Фармасьютикалз Острэйлиа Пти Лтд ВАРИАНТЫ ИНТЕРФЕРОНА 2b
KR20170086540A (ko) 2014-11-03 2017-07-26 제넨테크, 인크. T 세포 면역 하위세트를 검출하기 위한 검정 및 그의 사용 방법
RU2017119231A (ru) 2014-11-03 2018-12-06 Дженентек, Инк. Способы и биомаркеры для прогнозирования эффективности и оценки лечения агонистом ох40
ES2819256T3 (es) 2014-11-05 2021-04-15 Genentech Inc Métodos para producir proteínas bicatenarias en bacterias
EP3215526A1 (en) 2014-11-05 2017-09-13 F. Hoffmann-La Roche AG Methods of producing two chain proteins in bacteria
MX2017003478A (es) 2014-11-05 2018-02-01 Genentech Inc Anticuerpos anti-fgfr2/3 y metodos para su uso.
PL3215528T3 (pl) 2014-11-06 2020-01-31 F.Hoffmann-La Roche Ag Warianty regionu Fc ze zmodyfikowanym wiązaniem FcRn i sposoby stosowania
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
RU2017119428A (ru) 2014-11-06 2018-12-06 Дженентек, Инк. Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit
BR112017006591A2 (pt) 2014-11-06 2018-01-16 Hoffmann La Roche polipeptídeo heterodimérico, formulação farmacêutica e uso de um polipeptídeo heterodimérico
US10093730B2 (en) 2014-11-10 2018-10-09 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
WO2016077369A1 (en) 2014-11-10 2016-05-19 Genentech, Inc. Animal model for nephropathy and agents for treating the same
SG11201703332SA (en) 2014-11-10 2017-05-30 Medimmune Ltd Binding molecules specific for cd73 and uses thereof
EP3789403A1 (en) 2014-11-11 2021-03-10 MedImmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
TWI831044B (zh) 2014-11-11 2024-02-01 日商中外製藥股份有限公司 抗原結合分子、包含抗原結合分子的醫藥組合物以及製造及選擇抗原結合分子之方法
JP6831783B2 (ja) 2014-11-14 2021-02-17 ノバルティス アーゲー 抗体薬物コンジュゲート
KR20170096112A (ko) 2014-11-17 2017-08-23 제넨테크, 인크. Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
RS60739B1 (sr) 2014-11-17 2020-09-30 Regeneron Pharma Postupci za lečenje tumora upotrebom cd3xcd20 bispecifičnog antitela
WO2016081643A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
CN107108745B (zh) 2014-11-19 2021-01-12 基因泰克公司 抗bace1的抗体和其用于神经疾病免疫疗法的用途
SI3221349T1 (sl) 2014-11-19 2021-02-26 Axon Neuroscience Se Humanizirano tau protitelo pri alzheimerjevi bolezni
JP6993228B2 (ja) 2014-11-19 2022-03-03 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
EP3221346B1 (en) 2014-11-21 2020-09-02 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
UY36404A (es) 2014-11-21 2016-06-01 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware ANTICUERPOS MONOCLONALES (Ab) COMO DETECTORES DE CD73 E INHIBIDORES DE SU ACTIVIDAD ENZIMÁTICA, Y COMPOSICIONES QUE LOS CONTIENEN
US9382321B2 (en) * 2014-11-26 2016-07-05 Adventis Health System/Sunbelt, Inc. Effector-deficient anti-CD32A antibodies
JP6721590B2 (ja) 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
WO2016090347A1 (en) 2014-12-05 2016-06-09 Immunext, Inc. Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
PL3227336T3 (pl) 2014-12-05 2019-11-29 Hoffmann La Roche Przeciwciała anty-CD79b i sposoby stosowania
ES2764299T3 (es) 2014-12-09 2020-06-02 Inst Nat Sante Rech Med Anticuerpos monoclonales humanos contra AXL
KR20170085595A (ko) 2014-12-10 2017-07-24 제넨테크, 인크. 혈뇌 장벽 수용체 항체 및 사용 방법
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
EP3633371A1 (en) 2014-12-18 2020-04-08 F. Hoffmann-La Roche AG Assay and method for determining cdc eliciting antibodies
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
EP4600372A3 (en) 2014-12-19 2025-11-19 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
DK3233912T3 (da) 2014-12-19 2021-08-02 Regenesance B V Antistoffer, der binder human c6, og anvendelser deraf
US10189902B2 (en) 2014-12-23 2019-01-29 Bristol-Myers Squibb Company Antibodies to TIGIT
SG11201705721WA (en) 2015-01-14 2017-08-30 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
WO2016117346A1 (en) 2015-01-22 2016-07-28 Chugai Seiyaku Kabushiki Kaisha A combination of two or more anti-c5 antibodies and methods of use
TWI688572B (zh) 2015-01-26 2020-03-21 美商宏觀基因股份有限公司 包含dr5-結合結構域的多價分子
JP2018506275A (ja) 2015-01-28 2018-03-08 ジェネンテック， インコーポレイテッド 多発性硬化症の遺伝子発現マーカー及び治療
HK1244512A1 (zh) 2015-02-04 2018-08-10 健泰科生物技术公司 突变型smoothened及其使用方法
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
AU2016219511B2 (en) 2015-02-09 2020-11-12 Research Development Foundation Engineered immunoglobulin Fc polypeptides displaying improved complement activation
HRP20221284T1 (hr) 2015-02-19 2022-12-23 Compugen Ltd. Anti-pvrig antitijela i postupci uporabe
DK3259597T3 (da) 2015-02-19 2022-05-09 Compugen Ltd Pvrig-polypeptider og fremgangsmåder til behandling
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
MX2017010336A (es) 2015-02-26 2017-12-20 Genentech Inc Antagonistas de integrina beta7 y métodos para el tratamiento de la enfermedad de crohn.
AU2016230827B2 (en) 2015-03-09 2021-10-28 argenx BV Methods of reducing serum levels of fc-containing agents using fcrn antagonists
WO2016149276A1 (en) 2015-03-16 2016-09-22 Genentech, Inc. Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
CA2981312C (en) 2015-03-30 2023-09-26 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
FR3034420A1 (fr) 2015-03-31 2016-10-07 Lab Francais Du Fractionnement Anticorps monoclonaux anti-cd303
AR104368A1 (es) 2015-04-03 2017-07-19 Lilly Co Eli Anticuerpos biespecíficos anti-cd20- / anti-baff
CA2979732A1 (en) 2015-04-03 2016-10-06 Eureka Therapeutics, Inc. Constructs targeting afp peptide/mhc complexes and uses thereof
CA2981183A1 (en) * 2015-04-07 2016-10-13 Greg Lazar Antigen binding complex having agonistic activity and methods of use
JP2018512856A (ja) 2015-04-17 2018-05-24 アルパイン イミューン サイエンシズ インコーポレイテッド 調整可能な親和性を有する免疫調節タンパク質
HRP20211159T1 (hr) 2015-04-24 2021-10-29 F. Hoffmann - La Roche Ag Postupci identifikacije bakterija koje sadrže vezujuće polipeptide
JP2018520642A (ja) 2015-05-01 2018-08-02 ジェネンテック， インコーポレイテッド マスク抗ｃｄ３抗体及びその使用方法
EA201792451A1 (ru) 2015-05-07 2018-05-31 Агенус Инк. Антитела к ox40 и способы их применения
HK1248577A1 (zh) 2015-05-11 2018-10-19 F. Hoffmann-La Roche Ag 治疗狼疮性肾炎的组合物和方法
IL295002A (en) 2015-05-12 2022-09-01 Genentech Inc Therapeutic and diagnostic methods for cancer containing a pd–l1 binding antagonist
CN107921127B (zh) 2015-05-22 2022-04-08 纪念斯隆-凯特琳癌症中心 对于prame肽具有特异性的t细胞受体样抗体
JP6770533B2 (ja) 2015-05-22 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｃａｔｈ−Ｄの触媒活性と、そのＬＲＰ１レセプターへの結合との両方を阻害するヒトモノクローナル抗体フラグメント
EP3763827A1 (en) 2015-05-29 2021-01-13 F. Hoffmann-La Roche AG Pd-l1 promoter methylation in cancer
HK1248773A1 (zh) 2015-05-29 2018-10-19 豪夫迈‧罗氏有限公司 用於癌症的治疗和诊断方法
HK1250723A1 (zh) 2015-05-29 2019-01-11 F. Hoffmann-La Roche Ag 人源化抗埃博拉病毒糖蛋白抗体和使用方法
WO2016196228A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
HRP20200640T1 (hr) 2015-05-30 2020-07-10 Molecular Templates, Inc. De-imunizirane, okosnice podjedinice shiga toksina a i molekule koje ciljaju stanice koje ih sadrže
EP3302552A1 (en) 2015-06-02 2018-04-11 H. Hoffnabb-La Roche Ag Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
CR20180013A (es) 2015-06-05 2018-12-06 Ac Immune Sa Anticuerpos anti-tau y métodos de uso.
JP2018522540A (ja) 2015-06-05 2018-08-16 ノバルティス アーゲー 骨形成タンパク質９（ｂｍｐ９）を標的とする抗体およびそれらのための方法
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
EP3303397A1 (en) 2015-06-08 2018-04-11 H. Hoffnabb-La Roche Ag Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
MX2017014740A (es) 2015-06-08 2018-08-15 Genentech Inc Métodos de tratamiento del cáncer con anticuerpos anti-ox40.
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
HK1255483A1 (zh) 2015-06-15 2019-08-16 基因泰克公司 抗体和免疫结合物
JP6871874B2 (ja) 2015-06-16 2021-05-19 ジェネンテック， インコーポレイテッド ＦｃＲＨ５に対するヒト化親和性成熟抗体及び使用方法
EP3310811B1 (en) 2015-06-16 2021-06-16 Genentech, Inc. Anti-cd3 antibodies and methods of use
US10501545B2 (en) 2015-06-16 2019-12-10 Genentech, Inc. Anti-CLL-1 antibodies and methods of use
EP3310812B1 (en) 2015-06-17 2025-07-30 F. Hoffmann-La Roche AG Anti-her2 antibodies and methods of use
HK1251493A1 (zh) 2015-06-17 2019-02-01 豪夫迈‧罗氏有限公司 使用pd-1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
US10774145B2 (en) 2015-06-17 2020-09-15 Allakos Inc. Methods and compositions for treating fibrotic diseases
WO2016207278A1 (en) 2015-06-23 2016-12-29 Innate Pharma Multispecific nk engager proteins
DK3313876T3 (da) 2015-06-23 2025-04-22 Innate Pharma Multispecifikke antigenbindende proteiner
EP3722314A1 (en) 2015-06-24 2020-10-14 Janssen Pharmaceutica NV Anti-vista antibodies and fragments
EP3744732B1 (en) 2015-06-24 2025-09-10 F. Hoffmann-La Roche AG Humanized anti-tau(ps422) antibodies and methods of use
CN120665195A (zh) 2015-06-24 2025-09-19 豪夫迈·罗氏有限公司 具有定制亲和力的抗转铁蛋白受体抗体
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
JP7114460B2 (ja) 2015-06-26 2022-08-08 サノフィ・バイオテクノロジー モノクローナル抗ＩＬ－１ＲＡｃＰ抗体
ES2878316T3 (es) 2015-06-29 2021-11-18 Ventana Med Syst Inc Materiales y procedimientos para realizar ensayos histoquímicos de pro-epirregulina y anfirregulina humanas
CN108473573A (zh) 2015-06-29 2018-08-31 豪夫迈·罗氏有限公司 Ii型抗cd20抗体用于器官移植中
ES2896055T3 (es) 2015-07-13 2022-02-23 Compugen Ltd Composiciones de HIDE1 y métodos
JP6858185B2 (ja) * 2015-07-22 2021-04-14 イナサリス 増殖性および炎症性疾患の処置における抗ＴｆＲ抗体およびその使用
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
WO2017019729A1 (en) 2015-07-27 2017-02-02 The General Hospital Corporation Antibody derivatives with conditionally enabled effector function
GEAP202215554A (en) 2015-07-30 2022-06-10 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
EP3328994A4 (en) 2015-07-31 2019-04-17 Memorial Sloan-Kettering Cancer Center CD56-Faced Antigen-Binding Proteins and Uses Thereof
CN108350072B (zh) 2015-08-03 2022-05-24 诺华股份有限公司 治疗fgf21相关病症的方法
TWI741992B (zh) 2015-08-03 2021-10-11 美商百歐維拉提夫治療公司 因子ｉｘ融合蛋白以及其製備及使用方法
RS60030B1 (sr) 2015-08-03 2020-04-30 Engmab Sarl Monoklonska antitela protiv humanog antigena sazrevanja b ćelija (bcma)
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
EP3932953A1 (en) 2015-08-28 2022-01-05 F. Hoffmann-La Roche AG Anti-hypusine antibodies and uses thereof
HK1257840A1 (zh) 2015-09-01 2019-11-01 Agenus Inc. 抗-pd-1抗体及其使用方法
CN108699145A (zh) 2015-09-02 2018-10-23 伊缪泰普有限公司 抗lag-3抗体
EP3347377B1 (en) 2015-09-09 2021-02-17 Novartis AG Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
AU2016320748B2 (en) 2015-09-09 2019-05-02 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
CA2993423C (en) 2015-09-18 2024-03-12 Chugai Seiyaku Kabushiki Kaisha Il-8-binding antibodies and uses thereof
CN108367004B (zh) 2015-09-21 2022-09-13 阿帕特夫研究和发展有限公司 Cd3结合多肽
EP3353206A1 (en) 2015-09-22 2018-08-01 Spring Bioscience Corporation Anti-ox40 antibodies and diagnostic uses thereof
RU2763916C2 (ru) 2015-09-23 2022-01-11 Дженентек, Инк. Оптимизированные варианты анти-vegf антител
JP6955487B2 (ja) 2015-09-24 2021-10-27 アブビトロ， エルエルシー Ｈｉｖ抗体組成物および使用方法
HRP20241752T1 (hr) 2015-09-25 2025-02-28 F. Hoffmann - La Roche Ag Anti-tigit protutijela i metode uporabe
AU2016332725A1 (en) 2015-09-29 2018-03-22 Celgene Corporation PD-1 binding proteins and methods of use thereof
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
ES2886569T3 (es) 2015-10-02 2021-12-20 Hoffmann La Roche Anticuerpos biespecíficos específicos para PD1 y TIM3
PE20181092A1 (es) 2015-10-02 2018-07-09 Hoffmann La Roche Anticuerpos anti-pd1 y metodos de uso
MX2018003820A (es) 2015-10-02 2018-12-10 F Hoffmann ­La Roche Ag Anticuerpos biespecificos especificos para un receptor de tnf coestimulador.
EP3150636A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Tetravalent multispecific antibodies
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
AU2016333512B2 (en) 2015-10-02 2022-11-17 F. Hoffmann-La Roche Ag Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
KR20180075537A (ko) 2015-10-06 2018-07-04 제넨테크, 인크. 다발성 경화증을 치료하기 위한 방법
RU2018116402A (ru) 2015-10-07 2019-11-07 Ф. Хоффманн-Ля Рош Аг Биспецифические антитела, четырехвалентные в отношении костимуляторного tnf-рецептора
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
WO2017066714A1 (en) 2015-10-16 2017-04-20 Compugen Ltd. Anti-vsig1 antibodies and drug conjugates
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
AU2016340989B2 (en) 2015-10-23 2023-09-14 Pfizer Inc. Anti-IL-2 antibodies and compositions and uses thereof
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
EP3184547A1 (en) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
EP3368568B1 (en) 2015-10-29 2022-04-06 F. Hoffmann-La Roche AG Anti-variant fc-region antibodies and methods of use
EP3368074A2 (en) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-factor d antibodies and conjugates
EP3368579B1 (en) 2015-10-30 2021-11-24 F. Hoffmann-La Roche AG Hinge modified antibody fragments and methods of making
WO2017075212A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-htra1 antibodies and methods of use thereof
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
JP6998869B2 (ja) 2015-11-08 2022-02-04 ジェネンテック， インコーポレイテッド 多重特異性抗体のスクリーニング方法
WO2017086419A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 液性免疫応答の増強方法
JP6931329B2 (ja) 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
US10556948B2 (en) 2015-11-30 2020-02-11 Bristol-Myers Squibb Company IP-10 antibodies and their uses
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods for using them
KR102803158B1 (ko) 2015-12-02 2025-05-08 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도
EP3383908A1 (en) 2015-12-02 2018-10-10 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
KR102213790B1 (ko) 2015-12-04 2021-02-09 노파르티스 아게 항체 시토카인 그라프트된 조성물 및 면역조절을 위한 사용 방법
MX2018007089A (es) 2015-12-14 2019-01-30 Macrogenics Inc Moleculas biespecificas que tienen inmunorreactividad con pd-1 y ctla-4, y metodos de uso de las mismas.
MX2018007406A (es) 2015-12-16 2018-08-15 Merck Sharp & Dohme Anticuerpos anti-lag3 y fragmentos de enlace al antigeno.
CR20180364A (es) 2015-12-18 2018-08-22 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y métodos de uso
CA3008102A1 (en) 2015-12-18 2017-06-22 Novartis Ag Antibodies targeting cd32b and methods of use thereof
TWI868415B (zh) 2015-12-18 2025-01-01 日商中外製藥股份有限公司 抗肌抑素抗體、含變異fc區之多肽及使用方法
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
BR112018009312A8 (pt) 2015-12-28 2019-02-26 Chugai Pharmaceutical Co Ltd método para promover eficiência de purificação de polipeptídeo contendo região de fc
EP3400246B1 (en) 2016-01-08 2020-10-21 H. Hoffnabb-La Roche Ag Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
JP7022067B2 (ja) 2016-01-14 2022-02-17 メモリアル スローン ケタリング キャンサー センター Ｆｏｘｐ３由来のペプチドに特異的なｔ細胞受容体様抗体
CA3011739A1 (en) 2016-01-20 2017-07-27 Genentech, Inc. High dose treatments for alzheimer's disease
LT3411478T (lt) 2016-02-01 2022-09-26 Bioverativ Therapeutics Inc. Optimizuoti viii faktoriaus genai
JP2019509721A (ja) 2016-02-04 2019-04-11 キュリス，インコーポレイテッド 突然変異体スムースンド及びその使用方法
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
KR20180107151A (ko) 2016-02-17 2018-10-01 노파르티스 아게 Tgf베타 2 항체
JP6821693B2 (ja) 2016-02-29 2021-01-27 ジェネンテック， インコーポレイテッド がんのための治療方法及び診断方法
CA3016187A1 (en) 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
DK3430039T3 (da) * 2016-03-14 2026-01-19 Univ I Oslo Manipulerede immunglobuliner med ændret fcrn-binding
BR112018068363A2 (pt) 2016-03-14 2019-01-15 Chugai Seiyaku Kabushiki Kaisha fármaco terapêutico indutor de dano celular para uso em terapia de câncer
EP4112641A1 (en) 2016-03-15 2023-01-04 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
BR112018068678A2 (pt) 2016-03-15 2019-01-15 Innate Pharma anticorpos anti-mica
CN108884142A (zh) 2016-03-16 2018-11-23 梅里麦克制药股份有限公司 用于癌症治疗的工程化trail
EP3433272A1 (en) 2016-03-22 2019-01-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Humanized anti-claudin-1 antibodies and uses thereof
JP2019509322A (ja) 2016-03-22 2019-04-04 バイオノミクス リミテッド 抗ｌｇｒ５モノクローナル抗体の投与
CN108700598A (zh) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 多路总抗体和抗体缀合的药物量化测定法
JP7468992B2 (ja) 2016-03-29 2024-04-16 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２及び／又は－２３抗体の増加した間隔投与による乾癬の処置
US20170319688A1 (en) 2016-04-14 2017-11-09 Genentech, Inc. Anti-rspo3 antibodies and methods of use
CA3020864A1 (en) 2016-04-15 2017-10-19 Macrogenics, Inc. Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
CN109154613A (zh) 2016-04-15 2019-01-04 豪夫迈·罗氏有限公司 用于监测和治疗癌症的方法
JP7527758B2 (ja) 2016-04-15 2024-08-05 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｄ８０バリアント免疫調節タンパク質およびその使用
WO2017181079A2 (en) 2016-04-15 2017-10-19 Genentech, Inc. Methods for monitoring and treating cancer
KR20230119259A (ko) 2016-04-15 2023-08-16 이뮤넥스트, 인크. 항-인간 vista 항체 및 이의 용도
CN109563164A (zh) 2016-04-15 2019-04-02 生物蛋白有限公司 抗axl抗体、抗体片段和它们的免疫缀合物以及其用途
CN109328069B (zh) 2016-04-15 2023-09-01 亿一生物医药开发(上海)有限公司 Il-22在治疗坏死性小肠结肠炎中的用途
KR102824067B1 (ko) 2016-04-15 2025-06-23 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
WO2017184562A1 (en) 2016-04-20 2017-10-26 Merck Sharp & Dohme Corp. Cmv neutralizing antigen binding proteins
AU2017254674A1 (en) 2016-04-21 2018-11-01 Abbvie Stemcentrx Llc Novel anti-BMPR1B antibodies and methods of use
CN109071634A (zh) 2016-04-26 2018-12-21 R.P.谢勒技术有限责任公司 抗体偶联物及其制备和使用方法
EP3448887A1 (en) 2016-04-27 2019-03-06 Novartis AG Antibodies against growth differentiation factor 15 and uses thereof
MX2018013342A (es) 2016-05-02 2019-05-09 Hoffmann La Roche Polipeptido de fusion multicircular "contorsbody" - ligante de diana de cadena sencilla.
IL321475A (en) 2016-05-06 2025-08-01 Medimmune Llc Bispecific binding proteins and their uses
MX392069B (es) 2016-05-09 2025-03-21 Bristol Myers Squibb Co Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
JP7089483B2 (ja) 2016-05-11 2022-06-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 修飾された抗テネイシン抗体及び使用方法
MX394735B (es) 2016-05-13 2025-03-24 Bioatla Llc Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
JP2019517473A (ja) 2016-05-27 2019-06-24 アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 難治性全身型重症筋無力症の処置のための方法
JP7022080B2 (ja) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド 部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
MX389710B (es) 2016-05-27 2025-03-20 Agenus Inc Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
CN109476648B (zh) 2016-06-06 2022-09-13 豪夫迈·罗氏有限公司 司维司群抗体-药物缀合物和使用方法
DK3468997T5 (da) 2016-06-08 2024-09-09 Xencor Inc Behandling af IgG4-relaterede sygdomme med anti-CD9-antistoffer med tværbinding til CD32B
US11434269B2 (en) 2016-06-15 2022-09-06 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
EP3472200B1 (en) 2016-06-17 2026-01-28 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN109563160B (zh) 2016-06-24 2023-02-28 豪夫迈·罗氏有限公司 抗聚泛素多特异性抗体
EP4410378A3 (en) 2016-07-01 2024-10-09 Resolve Therapeutics, LLC Optimized binuclease fusions and methods
EP3478717B1 (en) 2016-07-04 2022-01-05 F. Hoffmann-La Roche AG Novel antibody format
JP6993056B2 (ja) 2016-07-05 2022-02-15 ベイジーン リミテッド 癌治療のためのｐｄ－１アンタゴニスト及びｒａｆ阻害剤の組合せ
BR112019000431A2 (pt) 2016-07-14 2019-07-09 Bristol-Myers Squibb Company anticorpos contra tim3 e usos dos mesmos
WO2018014067A1 (en) 2016-07-19 2018-01-25 Teva Pharmaceuticals Australia Pty Ltd Anti-cd47 combination therapy
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
US20200148750A1 (en) 2016-07-21 2020-05-14 Emory University Ebola Virus Antibodies and Binding Agents Derived Therefrom
EP3487880A1 (en) 2016-07-25 2019-05-29 Biogen MA Inc. Anti-hspa5 (grp78) antibodies and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018022946A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
BR112019001179A2 (pt) 2016-07-29 2019-04-30 Chugai Seiyaku Kabushiki Kaisha anticorpo biespecífico que exibe atividade alternativa aumentada de função de cofator fviii
BR112019001693A2 (pt) 2016-07-29 2019-07-02 INSERM (Institut National de la Santé et de la Recherche Médicale) anticorpos direcionados a macrófagos associados a tumores e seus usos
KR102777127B1 (ko) 2016-08-02 2025-03-07 비스테라, 인크. 조작된 폴리펩티드 및 그의 용도
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
WO2018027042A1 (en) 2016-08-03 2018-02-08 Bio-Techne Corporation Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy
KR102102734B1 (ko) 2016-08-05 2020-04-22 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
CA3032437A1 (en) 2016-08-05 2018-02-08 Allakos, Inc. Anti-siglec-7 antibodies for the treatment of cancer
KR20190077306A (ko) 2016-08-05 2019-07-03 메디뮨 엘엘씨 항-o2 항체 및 이의 용도
WO2018029124A1 (en) 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
CA3033661A1 (en) * 2016-08-12 2018-02-15 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
ES2774320T3 (es) 2016-08-17 2020-07-20 Compugen Ltd Anticuerpos anti-TIGIT, anticuerpos anti-PVRIG y combinaciones de los mismos
US11701357B2 (en) 2016-08-19 2023-07-18 Beigene Switzerland Gmbh Treatment of B cell cancers using a combination comprising Btk inhibitors
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
WO2018045379A1 (en) 2016-09-02 2018-03-08 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
US20190270821A1 (en) 2016-09-13 2019-09-05 Humanigen, Inc. Epha3 antibodies for the treatment of pulmonary fibrosis
MY199683A (en) 2016-09-16 2023-11-16 Shanghai Henlius Biotech Inc Anti-pd-1 antibodies
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JP2019534859A (ja) 2016-09-19 2019-12-05 セルジーン コーポレイション Ｐｄ−１結合タンパク質を使用して白斑を治療する方法
SG11201901950TA (en) 2016-09-19 2019-04-29 Celgene Corp Methods of treating immune disorders using pd-1 binding proteins
EP3515932B1 (en) 2016-09-19 2023-11-22 F. Hoffmann-La Roche AG Complement factor based affinity chromatography
EP4360714A3 (en) 2016-09-21 2024-07-24 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof
CN110035769A (zh) 2016-09-21 2019-07-19 奈斯科尔公司 针对siglec-15的抗体及其使用方法
RS64550B1 (sr) 2016-09-23 2023-09-29 Hoffmann La Roche Upotreba il-13 antagonista za lečenje atopičnog dermatitisa
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
WO2018064436A1 (en) 2016-09-30 2018-04-05 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il23 specific antibody
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
CA3038712A1 (en) 2016-10-06 2018-04-12 Genentech, Inc. Therapeutic and diagnostic methods for cancer
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
JP7160484B2 (ja) 2016-10-19 2022-10-25 メディミューン，エルエルシー 抗ｏ１抗体およびその使用
KR102423086B1 (ko) 2016-10-20 2022-07-20 아이-맵 바이오파마 유에스 리미티드 새로운 cd47 단일클론 항체 및 그 용도
TW202300515A (zh) 2016-10-20 2023-01-01 法商賽諾菲公司 抗ｃｈｉｋｖ抗體及其用途
WO2018073363A1 (en) 2016-10-21 2018-04-26 Innate Pharma Treatment with anti-kir3dl2 agents
EP3532091A2 (en) 2016-10-29 2019-09-04 H. Hoffnabb-La Roche Ag Anti-mic antibidies and methods of use
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
EP4295918A3 (en) 2016-11-02 2024-03-20 Bristol-Myers Squibb Company Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
US11370794B2 (en) 2016-11-11 2022-06-28 Dynavax Technologies Corporation Toll-like receptor antagonist compounds and methods of use
JP2020500020A (ja) 2016-11-14 2020-01-09 ノバルティス アーゲー 融合誘導性タンパク質ｍｉｎｉｏｎに関連する組成物、方法、および治療上の使用
CN109923128A (zh) 2016-11-15 2019-06-21 基因泰克公司 用于用抗cd20/抗cd3双特异性抗体进行治疗的给药
IL323048A (en) 2016-11-16 2025-10-01 Janssen Biotech Inc Method for treating psoriasis with a specific anti-IL-23 antibody
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
JP7313684B2 (ja) 2016-11-21 2023-07-25 キュレアブ ゲーエムベーハー 抗ｇｐ７３抗体及びイムノコンジュゲート
US20230192896A1 (en) 2016-11-23 2023-06-22 Bioverativ Therapeutics Inc. Bispecific antibodies binding to coagulation factor ix and coagulation factor x
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
CN110520149A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 诱导对凝血因子的免疫耐受性的方法
WO2018104893A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
TWI789371B (zh) 2016-12-07 2023-01-11 美商建南德克公司 抗-ｔａｕ抗體及使用方法
CA3046082A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Antibodies and methods of use thereof
KR102504605B1 (ko) 2016-12-07 2023-03-02 아게누스 인코포레이티드 항-ctla-4 항체 및 이의 사용 방법
IL266911B2 (en) 2016-12-07 2024-10-01 Genentech Inc Anti-tau antibodies and uses thereof in treating tauopathy, retaining or increasing cognitive memory capacity or slowing memory loss
JP2020511408A (ja) 2016-12-12 2020-04-16 ジェネンテック， インコーポレイテッド 抗ｐｄ−ｌ１抗体及び抗アンドロゲン薬を使用してがんを治療する方法
WO2018115960A1 (en) 2016-12-19 2018-06-28 Mosaic Biomedicals, S.L. Antibodies against lif and uses thereof
US11390670B2 (en) 2016-12-19 2022-07-19 Medimmune Limited Antibodies against LIF and uses thereof
EP3559034B1 (en) 2016-12-20 2020-12-02 H. Hoffnabb-La Roche Ag Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
IL267113B2 (en) 2016-12-21 2024-09-01 Cephalon Llc Antibodies that bind specifically to human IL-15 and their uses
WO2018115262A1 (en) 2016-12-23 2018-06-28 Innate Pharma Heterodimeric antigen binding proteins
CN110325550B (zh) 2016-12-23 2024-03-08 诺华股份有限公司 因子xi抗体和使用方法
JOP20190134A1 (ar) 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
MX2019007795A (es) 2017-01-03 2019-08-16 Hoffmann La Roche Moleculas de union a antigeno biespecificas que comprenden el clon 20h4.9 anti-4-1bb.
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
EP3565586B1 (en) 2017-01-06 2025-10-08 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
WO2018129332A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
US11274157B2 (en) 2017-01-12 2022-03-15 Eureka Therapeutics, Inc. Constructs targeting histone H3 peptide/MHC complexes and uses thereof
TWI774726B (zh) 2017-01-25 2022-08-21 英屬開曼群島商百濟神州有限公司 (S)-7-(1-(丁-2-炔醯基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氫吡唑并[1,5-a]嘧啶-3-甲醯胺的晶型、及其製備和用途
US20190367599A1 (en) 2017-01-31 2019-12-05 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
TWI786087B (zh) 2017-02-08 2022-12-11 瑞士商諾華公司 Fgf21模擬抗體及其用途
IL268593B2 (en) * 2017-02-10 2025-05-01 Genmab Bv Polypeptides and antibodies having increased cdc and/or agonistic activity and their uses in medicine
EP3580240A1 (en) 2017-02-10 2019-12-18 H. Hoffnabb-La Roche Ag Anti-tryptase antibodies, compositions thereof, and uses thereof
EA201991720A1 (ru) 2017-02-17 2020-01-20 Бристол-Маерс Сквибб Компани Антитела к альфа-синуклеину и их применения
NZ756763A (en) 2017-02-17 2023-04-28 Denali Therapeutics Inc Engineered transferrin receptor binding polypeptides
MX2019010028A (es) 2017-02-28 2019-10-14 Seattle Genetics Inc Anticuerpos con cisteina mutada por conjugacion.
CN116440257A (zh) 2017-02-28 2023-07-18 百时美施贵宝公司 具有增强的adcc的抗ctla-4抗体增强对疫苗的免疫应答的用途
EP3589754B1 (en) 2017-03-01 2023-06-28 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for cancer
WO2018158398A1 (en) 2017-03-02 2018-09-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
MX2019010887A (es) 2017-03-16 2019-10-15 Alpine Immune Sciences Inc Proteinas inmunomoduladoras de cb80 variante y usos de estas.
US11732022B2 (en) 2017-03-16 2023-08-22 Alpine Immune Sciences, Inc. PD-L2 variant immunomodulatory proteins and uses thereof
CA3053804C (en) 2017-03-16 2025-09-23 Alpine Immune Sciences, Inc. Immunomodulatory Proteins of PD-L1 Variants and Associated Uses
MX2019011141A (es) 2017-03-22 2019-11-05 Genentech Inc Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares.
IL269083B2 (en) 2017-03-24 2024-12-01 Novartis Ag Methods for preventing and treating heart disease
CN110494446A (zh) 2017-03-28 2019-11-22 基因泰克公司 治疗神经退行性疾病的方法
WO2018178055A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
CN110382542B (zh) 2017-03-29 2023-06-09 豪夫迈·罗氏有限公司 针对共刺激性tnf受体的双特异性抗原结合分子
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
CA3053358A1 (en) 2017-04-04 2018-10-11 F. Hoffmann-La Roche Ag Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
PE20210256A1 (es) 2017-04-05 2021-02-10 Hoffmann La Roche Anticuerpos anti-lag3
TWI690538B (zh) 2017-04-05 2020-04-11 瑞士商赫孚孟拉羅股份公司 特異性結合至pd1至lag3的雙特異性抗體
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
AU2018253176B2 (en) 2017-04-13 2023-02-02 Agenus Inc. Anti-CD137 antibodies and methods of use thereof
WO2018191660A1 (en) 2017-04-14 2018-10-18 Genentech, Inc. Diagnostic and therapeutic methods for cancer
CA3058282A1 (en) 2017-04-14 2018-10-18 Gamamabs Pharma Amhrii-binding compounds for preventing or treating cancers
KR20250017758A (ko) 2017-04-14 2025-02-04 엑셀리시스, 인코포레이티드 폐암을 예방 또는 치료하기 위한 amhrii-결합 화합물
US11767520B2 (en) 2017-04-20 2023-09-26 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
TW201841656A (zh) 2017-04-21 2018-12-01 美商建南德克公司 Ｋｌｋ５拮抗劑用於治療疾病之用途
CA3059820A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
EP3615572A1 (en) 2017-04-27 2020-03-04 Tesaro Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
TW202402800A (zh) 2017-05-01 2024-01-16 美商艾吉納斯公司 抗ｔｉｇｉｔ抗體類和使用彼等之方法
EP3618868A4 (en) 2017-05-05 2021-02-24 Allakos Inc. METHODS AND COMPOSITIONS FOR TREATING ALLERGIC EYE DISEASES
TW201904578A (zh) 2017-05-10 2019-02-01 美商艾歐凡斯生物治療公司 源自液體腫瘤之腫瘤浸潤性淋巴細胞的擴增和該經擴增腫瘤浸潤性淋巴細胞之治療用途
EP3625251A1 (en) 2017-05-15 2020-03-25 University Of Rochester Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
CN110662762A (zh) 2017-05-24 2020-01-07 诺华股份有限公司 抗体细胞因子移植蛋白和用于治疗癌症的方法
US20200362058A1 (en) 2017-05-24 2020-11-19 Novartis Ag Antibody-cytokine engrafted proteins and methods of use
WO2018218056A1 (en) 2017-05-25 2018-11-29 Birstol-Myers Squibb Company Antibodies comprising modified heavy constant regions
JP7369038B2 (ja) 2017-05-31 2023-10-25 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子並びにその治療的使用
JP7768666B2 (ja) 2017-05-31 2025-11-12 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子を用いて癌を治療する方法
JP7348072B2 (ja) 2017-06-01 2023-09-20 コンピュジェン リミテッド 三重併用抗体療法
CN121248782A (zh) 2017-06-06 2026-01-02 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2018229706A1 (en) 2017-06-16 2018-12-20 Novartis Ag Combination therapy for the treatment of cancer
EP3642239A1 (en) 2017-06-20 2020-04-29 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
CN111587124B (zh) 2017-06-23 2024-01-12 维洛斯生物股份有限公司 Ror1抗体免疫缀合物
TWI877099B (zh) 2017-06-26 2025-03-21 英屬開曼群島商百濟神州有限公司 抗ｐｄ－１抗體或其抗原結合片段在製備治療用於患有肝細胞癌（ｈｃｃ）之藥物的用途
WO2019003104A1 (en) 2017-06-28 2019-01-03 Novartis Ag METHOD FOR PREVENTING AND TREATING URINARY INCONTINENCE
TWI823859B (zh) 2017-07-21 2023-12-01 美商建南德克公司 癌症之治療及診斷方法
SG11202000658PA (en) 2017-07-26 2020-02-27 Forty Seven Inc Anti-sirp-alpha antibodies and related methods
CN107748258A (zh) * 2017-07-26 2018-03-02 东曜药业有限公司 一种FcγRII受体的ELISA检测方法
CN107748253A (zh) * 2017-07-26 2018-03-02 东曜药业有限公司 一种FcγRI受体的ELISA检测方法
CN107748259A (zh) * 2017-07-26 2018-03-02 东曜药业有限公司 一种FcRn受体的ELISA检测方法
CN107748262A (zh) * 2017-07-26 2018-03-02 东曜药业有限公司 一种FcγRIIIA受体的ELISA检测方法
FI3658184T3 (fi) 2017-07-27 2023-11-30 Alexion Pharma Inc Korkean pitoisuuden omaavia anti-c5-vasta-aineformulaatioita
IL322212A (en) 2017-08-09 2025-09-01 Bioverativ Therapeutics Inc Nucleic acid molecules and their uses
EP3665197A2 (en) 2017-08-11 2020-06-17 H. Hoffnabb-La Roche Ag Anti-cd8 antibodies and uses thereof
MX2020002070A (es) 2017-08-22 2020-03-24 Sanabio Llc Receptores solubles de interferon y usos de los mismos.
CA3070774A1 (en) 2017-08-25 2019-02-28 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
ES2873650T3 (es) 2017-09-19 2021-11-03 Tillotts Pharma Ag Variantes de anticuerpos
ES2978167T3 (es) 2017-09-19 2024-09-06 Tillotts Pharma Ag Variantes de anticuerpos
EP3684413A1 (en) 2017-09-20 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
UA128389C2 (uk) 2017-09-29 2024-07-03 Чугаі Сейяку Кабусікі Кайся Мультиспецифічна антигензв'язувальна молекула, яка має активність заміщувати кофакторну функцію фактора коагуляції крові viii (fviii), та фармацевтичний склад, який містить згадану молекулу як активний інгредієнт
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
KR20250020681A (ko) 2017-10-10 2025-02-11 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
CA3185107A1 (en) 2017-10-12 2019-04-18 Immunowake Inc. Vegfr-antibody light chain fusion protein
SG11202002384VA (en) 2017-10-14 2020-04-29 Cytomx Therapeutics Inc Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
TWI899046B (zh) 2017-10-18 2025-10-01 美商艾爾潘免疫科學有限公司 變異型icos 配位體免疫調節蛋白及相關組合物及方法
MX2020003497A (es) 2017-10-20 2020-07-22 Hoffmann La Roche Metodo para generar anticuerpos multiespecificos a partir de anticuerpos monoespecificos.
EP3700933A1 (en) 2017-10-25 2020-09-02 Novartis AG Antibodies targeting cd32b and methods of use thereof
KR20240162603A (ko) 2017-10-26 2024-11-15 알렉시온 파마슈티칼스, 인코포레이티드 발작성 야간 혈색소뇨 (pnh) 및 비정형 용혈성 요독 증후군 (ahus)의 치료를 위한 항-c5 항체의 투여량 및 투여
AU2018358883B2 (en) 2017-10-30 2025-09-25 F. Hoffmann-La Roche Ag Method for in vivo generation of multispecific antibodies from monospecific antibodies
JP2021502349A (ja) 2017-11-06 2021-01-28 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で乾癬性関節炎を治療する安全かつ有効な方法
PL3707510T3 (pl) 2017-11-06 2024-09-30 F. Hoffmann-La Roche Ag Sposoby diagnostyczne i terapeutyczne w chorobach nowotworowych
WO2019093342A1 (ja) 2017-11-08 2019-05-16 協和発酵キリン株式会社 ＣＤ４０とＥｐＣＡＭに結合するバイスペシフィック抗体
JP7731196B2 (ja) 2017-11-14 2025-08-29 中外製薬株式会社 抗Ｃ１ｓ抗体および使用方法
US20200325232A1 (en) 2017-11-21 2020-10-15 Innate Pharma Multispecific antigen binding proteins
EP3714041A1 (en) 2017-11-22 2020-09-30 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
CN111902427A (zh) 2017-11-22 2020-11-06 诺华股份有限公司 抗因子XI/XIa抗体的逆转结合剂及其用途
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
WO2019106578A2 (en) 2017-12-01 2019-06-06 Novartis Ag Polyomavirus neutralizing antibodies
US11952422B2 (en) 2017-12-05 2024-04-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137
EP3720877A1 (en) 2017-12-08 2020-10-14 Argenx BVBA Use of fcrn antagonists for treatment of generalized myasthenia gravis
EP3724885A2 (en) 2017-12-15 2020-10-21 Iovance Biotherapeutics, Inc. Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
WO2019126133A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-cd200 antibodies
WO2019126536A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Humanized anti-cd200 antibodies and uses thereof
EP3502140A1 (en) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
EP3728321A1 (en) 2017-12-22 2020-10-28 F. Hoffmann-La Roche AG Use of pilra binding agents for treatment of a disease
EP3732195A4 (en) 2017-12-28 2022-02-09 Chugai Seiyaku Kabushiki Kaisha CYTOTOXICITY-INDUCING THERAPEUTIC
CN111542543B (zh) 2017-12-28 2023-12-22 南京传奇生物科技有限公司 针对pd-l1的抗体及其变体
SG11202004158QA (en) 2017-12-28 2020-06-29 Nanjing Legend Biotech Co Ltd Single-domain antibodies and variants thereof against tigit
EP3731865A1 (en) 2017-12-29 2020-11-04 F. Hoffmann-La Roche AG Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
FR3076294B1 (fr) 2017-12-29 2022-01-28 Lab Francais Du Fractionnement Procede de purification d'anticorps a partir de lait brut
SG11202006148UA (en) 2018-01-03 2020-07-29 Alpine Immune Sciences Inc Multi-domain immunomodulatory proteins and methods of use thereof
US20220153871A1 (en) 2018-01-04 2022-05-19 Iconic Therapeutics, Inc. Anti-Tissue Factor Antibodies, Antibody-Drug Conjugates, and Related Methods
AU2019205090A1 (en) 2018-01-05 2020-08-06 Ac Immune Sa Misfolded TDP-43 binding molecules
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
CN111886255B (zh) 2018-01-12 2025-04-04 百时美施贵宝公司 抗tim3抗体及其用途
CA3084518A1 (en) 2018-01-15 2019-07-18 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against pd-1
CA3088649A1 (en) 2018-01-16 2019-07-25 Lakepharma, Inc. Bispecific antibody that binds cd3 and another target
EP3743437A1 (en) 2018-01-26 2020-12-02 F. Hoffmann-La Roche AG Il-22 fc fusion proteins and methods of use
SI3743088T1 (sl) 2018-01-26 2023-01-31 F. Hoffmann - La Roche Ag Farmacevtski sestavki IL-22 Fc in načini njihove uporabe
CN111788221B (zh) * 2018-01-26 2026-02-13 建新公司 具有与FcRn增强的结合及延长的半衰期的Fc变体
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
MX2020008152A (es) 2018-02-01 2020-11-24 Bioverativ Therapeutics Inc Uso de vectores lentivirales que expresan el factor viii.
WO2019148410A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
CN111868082A (zh) 2018-02-02 2020-10-30 博奥泰克尼公司 调节vista和vsig3的相互作用的化合物及其制备和使用方法
EP3749361A1 (en) 2018-02-08 2020-12-16 F. Hoffmann-La Roche AG Bispecific antigen-binding molecules and methods of use
BR112020016172A2 (pt) 2018-02-09 2020-12-15 Genentech, Inc. Métodos de tratamento, métodos para determinar, métodos para selecionar uma terapia, métodos para avaliar uma resposta e monitorar a resposta, kits para identificar um paciente, agentes selecionados, agentes para uso, uso de um agente selecionado e uso de um antagonista
MA51875A (fr) 2018-02-13 2020-12-23 Iovance Biotherapeutics Inc Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
CN111757894B (zh) 2018-02-14 2025-02-25 Abba疗法股份公司 抗人类pd-l2抗体
SG11202007821WA (en) 2018-02-21 2020-09-29 Five Prime Therapeutics Inc B7-h4 antibody formulations
CN111757751A (zh) 2018-02-21 2020-10-09 豪夫迈·罗氏有限公司 用于使用IL-22 Fc融合蛋白的治疗的剂量方案
CA3092108A1 (en) 2018-02-26 2019-08-29 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
US20210002373A1 (en) 2018-03-01 2021-01-07 Nextcure, Inc. KLRG1 Binding Compositions and Methods of Use Thereof
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
KR20200144094A (ko) 2018-03-02 2020-12-28 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 및 이의 사용 방법
CA3092551A1 (en) 2018-03-05 2019-09-12 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
CA3092002A1 (en) 2018-03-13 2019-09-19 F. Hoffmann-La Roche Ag Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
EP3765522A4 (en) 2018-03-14 2022-05-18 Beijing Xuanyi Pharmasciences Co., Ltd. ANTI-CLAUDIN 18.2 ANTIBODIES
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
US11891432B2 (en) 2018-03-15 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use
TW201945393A (zh) 2018-03-21 2019-12-01 美商戊瑞治療有限公司 在酸性pH結合至VISTA之抗體
US20210070860A1 (en) * 2018-03-21 2021-03-11 Dana-Farber Cancer Institute, Inc. Fc variant compositions and methods of use thereof
CA3093407A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
PE20210313A1 (es) 2018-03-28 2021-02-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
SG11202009542PA (en) 2018-03-29 2020-10-29 Genentech Inc Modulating lactogenic activity in mammalian cells
KR102876940B1 (ko) 2018-03-30 2025-10-24 난징 레전드 바이오테크 씨오., 엘티디. Lag-3에 대한 단일-도메인 항체 및 이의 용도
WO2019195126A1 (en) 2018-04-02 2019-10-10 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
TW202011029A (zh) 2018-04-04 2020-03-16 美商建南德克公司 偵測及定量fgf21之方法
EP3552631A1 (en) 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer
AU2019251289B2 (en) 2018-04-12 2024-01-18 Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats Combination of LIF inhibitors and PD-1 axis inhibitors for use in treating cancer
CR20250325A (es) 2018-04-13 2025-08-29 Genentech Inc Formulaciones inmunoconjugadas anti-cd79b estables (divisional expediente 2020-0550)
AR115052A1 (es) 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
EP3787678A1 (en) 2018-05-03 2021-03-10 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof
EP3790587A4 (en) 2018-05-11 2022-01-26 Janssen Biotech, Inc. Methods of treating depression using il-23 antibodies
CN110464842B (zh) 2018-05-11 2022-10-14 信达生物制药(苏州)有限公司 包含抗pcsk9抗体的制剂及其用途
EP3794031A2 (en) 2018-05-14 2021-03-24 MedImmune Limited Antibodies against lif and dosage forms thereof
ES2991497T3 (es) 2018-05-16 2024-12-03 Csl Ltd Variantes del receptor soluble del complemento de tipo 1 y usos de las mismas
MA52630B1 (fr) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Procédés de traitement de l'hémophilie a
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
EP3797123A4 (en) 2018-05-23 2022-03-02 BeiGene, Ltd. ANTI-OX40 ANTIBODIES AND METHODS OF USE
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
ES2996257T3 (en) 2018-05-31 2025-02-12 Alexion Pharma Inc Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
JP7490574B2 (ja) 2018-05-31 2024-05-27 ノバルティス アーゲー Ｂ型肝炎抗体
BR112020024351A2 (pt) 2018-06-01 2021-02-23 Novartis Ag moléculas de ligação contra bcma e usos das mesmas
CN113039202A (zh) 2018-06-01 2021-06-25 康姆普根有限公司 抗pvrig/抗tigit双特异性抗体和使用方法
US12460012B2 (en) 2018-06-04 2025-11-04 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) in pediatric patients
JP7372237B2 (ja) 2018-06-04 2023-10-31 中外製薬株式会社 細胞質内での半減期が変化した抗原結合分子
US12037398B2 (en) 2018-06-04 2024-07-16 Biogen Ma Inc. Anti-VLA-4 antibodies having reduced effector function
MA52783A (fr) 2018-06-05 2021-04-14 Amgen Inc Modulation de la phagocytose cellulaire dépendant de l'anticorps
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
AU2019283673B2 (en) 2018-06-08 2023-12-07 argenx BV Compositions and methods for treating immune thrombocytopenia
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
CA3103936A1 (en) 2018-06-18 2019-12-26 Eureka Therapeutics, Inc. Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
SG11202012576QA (en) 2018-06-18 2021-01-28 Medimmune Ltd Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer
JP7637415B2 (ja) 2018-06-22 2025-02-28 キュージーン インコーポレイテッド インターロイキン－２バリアントおよびその使用方法
MY205645A (en) 2018-06-23 2024-11-02 Genentech Inc Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
EP3814373A1 (en) 2018-06-28 2021-05-05 Alexion Pharmaceuticals, Inc. Methods of producing anti-c5 antibodies
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
CN112601517A (zh) 2018-07-03 2021-04-02 百时美施贵宝公司 Fgf-21配制品
TW202035447A (zh) 2018-07-04 2020-10-01 瑞士商赫孚孟拉羅股份公司 新穎雙特異性促效性4-1bb抗原結合分子
SG11202100096XA (en) 2018-07-09 2021-02-25 Five Prime Therapeutics Inc Antibodies binding to ilt4
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN121203021A (zh) 2018-07-11 2025-12-26 戊瑞治疗有限公司 在酸性pH下结合至VISTA的抗体
AU2019305637A1 (en) 2018-07-18 2021-03-11 Genentech, Inc. Methods of treating lung cancer with a PD-1 axis binding antagonist, an antimetabolite, and a platinum agent
US20200025776A1 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody
WO2020023918A1 (en) 2018-07-26 2020-01-30 Atyr Pharma, Inc. Compositions and methods for treating nrp2-associated diseases
SMT202400271T1 (it) 2018-08-01 2024-07-09 Chugai Pharmaceutical Co Ltd Composizione farmaceutica per l’uso nel trattamento o nella prevenzione di una patologia correlata a c5
CN113286824A (zh) 2018-08-03 2021-08-20 中外制药株式会社 包含两个彼此连接的抗原结合结构域的抗原结合分子
EP3608674A1 (en) 2018-08-09 2020-02-12 Regeneron Pharmaceuticals, Inc. Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor
CN113227385B (zh) 2018-08-09 2024-12-24 比奥维拉迪维治疗股份有限公司 核酸分子及其用于非病毒基因疗法的用途
CN112839960B (zh) 2018-08-10 2024-09-06 中外制药株式会社 抗cd137抗原结合分子及其应用
US12259395B2 (en) 2018-08-17 2025-03-25 Ab Studio Inc. Catabodies and methods of use thereof
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
PL3844189T3 (pl) 2018-08-31 2025-03-31 Regeneron Pharmaceuticals, Inc. Strategia dawkowania, która łagodzi zespół uwalniania cytokin, dla przeciwciał dwuswoistych cd3/cd20
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
WO2020053742A2 (en) 2018-09-10 2020-03-19 Novartis Ag Anti-hla-hbv peptide antibodies
WO2020052542A1 (en) 2018-09-10 2020-03-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against cll1 and constructs thereof
MA53603A (fr) 2018-09-11 2021-07-21 Amgen Inc Procédés de modulation de la cytotoxicité à médiation cellulaire dépendante des anticorps
CA3109366A1 (en) 2018-09-13 2020-03-19 The Board Of Regents Of The University Of Texas System Novel lilrb4 antibodies and uses thereof
JP2022502076A (ja) 2018-09-18 2022-01-11 メリマック ファーマシューティカルズ インコーポレーティッド 抗ｔｎｆｒ２抗体およびその使用
EP3853247A2 (en) 2018-09-19 2021-07-28 Alpine Immune Sciences, Inc. Methods and uses of variant cd80 fusion proteins and related constructs
AU2019342099A1 (en) 2018-09-19 2021-04-08 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
JP7475336B2 (ja) 2018-09-21 2024-04-26 ジェネンテック， インコーポレイテッド トリプルネガティブ乳癌のための診断方法
FI3883606T3 (fi) 2018-09-24 2023-09-07 Janssen Biotech Inc Turvallinen ja tehokas menetelmä haavaisen paksusuolitulehduksen hoitamiseksi anti-il12/il23-vasta-aineella
EP3856764A4 (en) 2018-09-27 2022-11-02 Xilio Development, Inc. MASKED CYTOKINE POLYPEPTIDES
PE20211491A1 (es) 2018-09-27 2021-08-11 Celgene Corp PROTEINAS DE FIJACION A SIRPa Y METODOS DE USO DE ESTAS
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
AU2019347408A1 (en) 2018-09-28 2021-04-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region
CA3114154A1 (en) 2018-09-28 2020-04-02 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneously
EP3861025A1 (en) 2018-10-01 2021-08-11 F. Hoffmann-La Roche AG Bispecific antigen binding molecules with trivalent binding to cd40
MX2021003548A (es) 2018-10-01 2021-05-27 Hoffmann La Roche Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap.
WO2020076969A2 (en) 2018-10-10 2020-04-16 Tilos Therapeutics, Inc. Anti-lap antibody variants and uses thereof
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
KR20210079311A (ko) 2018-10-18 2021-06-29 제넨테크, 인크. 육종성 신장암에 대한 진단과 치료 방법
MA54052A (fr) 2018-10-29 2022-02-09 Hoffmann La Roche Formulation d'anticorps
CA3118282A1 (en) 2018-10-30 2020-05-07 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
EP3873532A1 (en) 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody drug conjugates
WO2020089437A1 (en) 2018-10-31 2020-05-07 Engmab Sàrl Combination therapy
EP4219550A1 (en) 2018-11-02 2023-08-02 Oklahoma Medical Research Foundation Monoclonal antibodies to eltd1 and uses thereof
SG11202104104VA (en) 2018-11-05 2021-05-28 Genentech Inc Methods of producing two chain proteins in prokaryotic host cells
SG11202104663PA (en) 2018-11-05 2021-06-29 Iovance Biotherapeutics Inc Treatment of nsclc patients refractory for anti-pd-1 antibody
MX2021005751A (es) 2018-11-16 2021-10-01 Memorial Sloan Kettering Cancer Center Anticuerpos contra mucina 16 y métodos de uso de los mismos.
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
CA3120237A1 (en) 2018-11-20 2020-05-28 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il-23 specific antibody
US20220364171A1 (en) 2018-11-23 2022-11-17 Katholieke Universiteit Leuven Predicting a treatment response in inflammatory bowel disease
CA3120729A1 (en) 2018-11-27 2020-06-04 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof
CA3101670C (en) 2018-11-27 2024-02-06 Innovent Biologics (Suzhou) Co., Ltd. Anti-il-23p19 antibody and use thereof
CN113348177A (zh) 2018-11-28 2021-09-03 百时美施贵宝公司 包含经修饰的重链恒定区的抗体
KR20210135987A (ko) 2018-11-30 2021-11-16 알파인 이뮨 사이언시즈, 인코포레이티드 Cd86 변이체 면역조절 단백질 및 그의 용도
WO2020116560A1 (ja) 2018-12-05 2020-06-11 株式会社バイカ・セラピュティクス 抗体のＦｃ領域改変体
JP7671248B2 (ja) 2018-12-05 2025-05-01 ジェネンテック， インコーポレイテッド がんの免疫療法のための診断方法及び診断用組成物
JP2022513708A (ja) 2018-12-05 2022-02-09 モルフォシス・アーゲー 多重特異性抗原結合分子
KR20210100668A (ko) 2018-12-06 2021-08-17 제넨테크, 인크. 항-CD79b 면역접합체, 알킬화제 및 항-CD20 항체를 포함하는 미만성 큰 B-세포 림프종의 조합 요법
WO2020118011A1 (en) 2018-12-06 2020-06-11 Alexion Pharmaceuticals, Inc. Anti-alk2 antibodies and uses thereof
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
US20220010003A1 (en) 2018-12-14 2022-01-13 Boehringer Ingelheim Io Canada Inc. Anti-periostin antibodies and uses thereof
EP3897722A4 (en) 2018-12-18 2022-09-14 Janssen Biotech, Inc. SAFE AND EFFECTIVE METHOD OF TREATMENT OF LUPUS WITH ANTI-IL12/IL23 ANTIBODIES
PH12021551285A1 (en) 2018-12-18 2022-05-02 Boehringer Ingelheim Io Canada Inc Flt3 agonist antibodies and uses thereof
EP3898688A1 (en) 2018-12-18 2021-10-27 Catapult Therapeutics B.V. The use of anti-ccr7 mabs for the prevention or treatment of graft-versus-host disease (gvhd)
WO2020128863A1 (en) 2018-12-19 2020-06-25 Novartis Ag Anti-tnf-alpha antibodies
TW202035442A (zh) 2018-12-20 2020-10-01 美商建南德克公司 經修飾之抗體Fc及其使用方法
CN113195531B (zh) 2018-12-21 2025-03-04 豪夫迈·罗氏有限公司 与VEGF和IL-1β结合的抗体及其使用方法
KR102910209B1 (ko) 2018-12-21 2026-01-09 제넨테크, 인크. 세포사멸에 내성인 세포주를 사용한 폴리펩티드 생산 방법
CN113490687A (zh) 2018-12-26 2021-10-08 西利欧发展公司 抗ctla4抗体和其使用方法
JP7506607B2 (ja) 2018-12-28 2024-06-26 協和キリン株式会社 ＴｆＲに結合するバイスペシフィック抗体
US11447551B2 (en) 2018-12-28 2022-09-20 Sparx Bioscience Limited Binding molecules specific for claudin 18.2, compositions and methods thereof, for the treatment of cancer and other diseases
WO2020141145A1 (en) 2018-12-30 2020-07-09 F. Hoffmann-La Roche Ag Anti-rabbit cd19 antibodies and methods of use
EP3906062A1 (en) 2019-01-04 2021-11-10 Resolve Therapeutics, LLC Treatment of sjogren's disease with nuclease fusion proteins
MX2021008434A (es) 2019-01-14 2021-09-23 Genentech Inc Metodos para tratar el cancer con un antagonista de union al eje de pd-1 y una vacuna de arn.
WO2020148207A1 (en) 2019-01-14 2020-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies binding to hla-a2
AU2020210710A1 (en) 2019-01-22 2021-07-29 Innate Pharma Treatment of T cell lymphoma
CN113329763A (zh) 2019-01-22 2021-08-31 豪夫迈·罗氏有限公司 免疫球蛋白a抗体以及制备和使用方法
CN118894938A (zh) 2019-01-22 2024-11-05 百时美施贵宝公司 抗IL-7Rα亚基的抗体及其用途
KR20210119448A (ko) 2019-01-23 2021-10-05 앙세파 Cd31 경쟁인자(competitor) 및 이의 용도
AU2020211407A1 (en) 2019-01-23 2021-08-12 Millennium Pharmaceuticals, Inc. Anti-CD38 antibodies
CA3124515A1 (en) 2019-01-23 2020-07-30 Genentech, Inc. Methods of producing multimeric proteins in eukaryotic host cells
JPWO2020153467A1 (ja) 2019-01-24 2021-12-02 中外製薬株式会社 新規がん抗原及びそれらの抗原に対する抗体
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
SG11202109061YA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to t cell related cancer cells and uses thereof
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
KR20210133237A (ko) 2019-02-27 2021-11-05 제넨테크, 인크. 항-tigit 및 항-cd20 또는 항-cd38 항체로 치료를 위한 투약
CN113874051A (zh) 2019-02-27 2021-12-31 安吉克公司 包含抗tm4sf1抗体的抗体-药物缀合物及其使用方法
CN113874083A (zh) 2019-03-01 2021-12-31 梅里麦克制药股份有限公司 抗-tnfr2抗体及其用途
WO2020180733A1 (en) 2019-03-01 2020-09-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
KR102866290B1 (ko) 2019-03-08 2025-10-01 제넨테크, 인크. 세포외 소포 상에서 막 관련 단백질을 검출하고 정량하기 위한 방법
JP7730761B2 (ja) 2019-03-14 2025-08-28 ジェネンテック， インコーポレイテッド 抗ＨＥＲ２ ＭＡＢと組み合わせたＨＥＲ２ｘＣＤ３二重特異性抗体によるがんの処置
WO2020183418A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
MA55383A (fr) 2019-03-18 2022-01-26 Janssen Biotech Inc Méthode de traitement du psoriasis chez des sujets pédiatriques avec un anticorps anti-il12/il23
JP7601758B2 (ja) 2019-03-19 2024-12-17 中外製薬株式会社 Ｍｔａ依存的に抗原に対する結合活性が変化する抗原結合ドメインを含む抗原結合分子及び当該抗原結合ドメイン取得用ライブラリ
WO2020193520A1 (en) 2019-03-25 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species
WO2020206063A1 (en) 2019-04-03 2020-10-08 Genzyme Corporation Anti-alpha beta tcr binding polypeptides with reduced fragmentation
MX2021012160A (es) 2019-04-08 2022-01-06 Biogen Ma Inc Anticuerpos antiintegrina y usos de los mismos.
GB2589049C (en) 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
WO2020214606A1 (en) * 2019-04-15 2020-10-22 The Medical College Of Wisconsin, Inc. Recombinant pd-l1 peptides and methods of use
KR20220035032A (ko) 2019-04-17 2022-03-21 알파인 이뮨 사이언시즈, 인코포레이티드 변이체 icos 리간드(icosl) 융합 단백질의 방법 및 용도
EP3955960B1 (en) 2019-04-18 2025-01-15 Bristol-Myers Squibb Company Ipilimumab variants with enhanced specificity for binding at low ph
MX2021012608A (es) 2019-04-18 2021-11-12 Ac Immune Sa Nuevas moleculas para terapia y diagnostico.
AU2020257748A1 (en) 2019-04-19 2021-11-18 Chugai Seiyaku Kabushiki Kaisha Chimeric receptor recognizing modification site of antibody
TW202043291A (zh) 2019-04-19 2020-12-01 美商建南德克公司 抗mertk抗體及使用方法
TWI879768B (zh) 2019-05-03 2025-04-11 美商建南德克公司 用抗pd-l1抗體治療癌症之方法
AU2020275415B2 (en) 2019-05-14 2026-01-15 Genentech, Inc. Methods of using anti-CD79B immunoconjugates to treat follicular lymphoma
CN119798452A (zh) 2019-05-15 2025-04-11 中外制药株式会社 抗原结合分子、药物组合物和方法
JPWO2020230899A1 (es) 2019-05-15 2020-11-19
TWI875760B (zh) 2019-05-15 2025-03-11 日商協和麒麟股份有限公司 與cd40及gpc3結合之雙專一性抗體
CN119613486A (zh) 2019-05-20 2025-03-14 诺华股份有限公司 具有包含亲水性基团的接头的抗体药物缀合物
CN113874398B (zh) 2019-05-21 2025-08-01 诺华股份有限公司 Cd19结合分子及其用途
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
KR20220010743A (ko) 2019-05-21 2022-01-26 노파르티스 아게 Bcma에 대한 삼중특이적 결합 분자 및 이의 용도
KR20220012270A (ko) 2019-05-23 2022-02-03 에이씨 이뮨 에스.에이. 항-tdp-43 결합 분자 및 이의 용도
WO2020245766A1 (en) 2019-06-04 2020-12-10 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
KR20220017430A (ko) 2019-06-05 2022-02-11 추가이 세이야쿠 가부시키가이샤 항체 절단 부위 결합 분자
MA56102A (fr) 2019-06-07 2022-04-13 Argenx Bvba Formulations pharmaceutique d'inhibiteurs de fcrn appropriées pour une administration par voie sous-cutanée
US20220348658A1 (en) 2019-06-10 2022-11-03 Chugai Seiyaku Kabushiki Kaisha Anti-t cell antigen-binding molecule to be used in combination with cytokine inhibitor
US20220298230A1 (en) * 2019-06-11 2022-09-22 The Rockefeller University Antibodies and methods for treatment of viral infections
WO2020260326A1 (en) 2019-06-27 2020-12-30 F. Hoffmann-La Roche Ag Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
CA3145139A1 (en) 2019-07-09 2021-01-14 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing pseudomonas pcrv and uses thereof
MX2022000111A (es) 2019-07-10 2022-02-10 Chugai Pharmaceutical Co Ltd Moleculas de union a claudina-6 y usos de las mismas.
WO2021005232A1 (en) 2019-07-11 2021-01-14 Umc Utrecht Holding B.V. Intranasal administration of neutralising antiviral antibodies
JPWO2021010326A1 (es) 2019-07-12 2021-01-21
US20220372139A1 (en) 2019-07-15 2022-11-24 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
WO2021011681A1 (en) 2019-07-15 2021-01-21 Bristol-Myers Squibb Company Antibodies against human trem-1 and uses thereof
CN114258401B (zh) 2019-07-16 2025-08-12 Inserm(法国国家健康医学研究院) 对cd38具有特异性的抗体及其用途
EP4004044A1 (en) 2019-07-24 2022-06-01 H. Lundbeck A/S Anti-mglur5 antibodies and uses thereof
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
WO2021021605A1 (en) 2019-07-26 2021-02-04 Vanderbilt University Human monoclonal antibodies to enterovirus d68
MX2022001146A (es) 2019-07-29 2022-03-17 Compugen Ltd Formulaciones de anticuerpos anti-pvrig y sus usos.
CN114466660A (zh) 2019-07-31 2022-05-10 豪夫迈·罗氏有限公司 通过使用抗c5抗体可伐利单抗来治疗或预防c5相关疾病的剂量和施用方案
WO2021019036A1 (en) 2019-07-31 2021-02-04 F. Hoffmann-La Roche Ag Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab
CA3146471A1 (en) 2019-08-06 2021-02-11 James K. Kranz Compositions comprising anti-bcma antigen binding proteins for treating bcma-mediated diseases or disorders
CN114641490B (zh) 2019-08-06 2023-06-06 新旭生技股份有限公司 结合至病理性tau种类的抗体及其用途
MX2022001882A (es) 2019-08-12 2022-05-30 Aptevo Res & Development Llc Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
WO2021030633A1 (en) 2019-08-13 2021-02-18 Elpis Biopharmaceuticals Engineered interleukin-2 receptor beta agonists
WO2021042019A1 (en) 2019-08-30 2021-03-04 Agenus Inc. Anti-cd96 antibodies and methods of use thereof
EP4438057A3 (en) 2019-09-12 2025-01-01 F. Hoffmann-La Roche AG Compositions and methods of treating lupus nephritis
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
EP4031579A2 (en) 2019-09-18 2022-07-27 F. Hoffmann-La Roche AG Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
AU2020350689A1 (en) 2019-09-19 2022-03-31 Bristol-Myers Squibb Company Antibodies binding to VISTA at acidic pH
MX2022003266A (es) 2019-09-20 2022-04-11 Genentech Inc Dosis para anticuerpos anti-triptasa.
KR20220088428A (ko) 2019-09-26 2022-06-27 주식회사 에스티큐브앤컴퍼니 글리코실화된 ctla-4에 대해 특이적인 항체 및 이의 사용 방법
WO2021058729A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
AU2020351734A1 (en) 2019-09-27 2022-04-14 Genentech, Inc. Dosing for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies
EP4034160A1 (en) 2019-09-27 2022-08-03 Janssen Biotech, Inc. Anti-ceacam antibodies and uses thereof
CN114450304B (zh) 2019-09-27 2023-12-12 国家医疗保健研究所 抗苗勒管抑制物质抗体及其用途
TW202126284A (zh) 2019-09-30 2021-07-16 美商百歐維拉提夫治療公司 慢病毒載體配製物
KR20220082007A (ko) 2019-10-08 2022-06-16 넥틴 테라퓨틱스 리미티드 폴리오바이러스 수용체(pvr)에 대한 항체 및 이의 용도
CN114829404B (zh) 2019-10-09 2025-09-09 斯特库比公司 对糖基化的lag3特异的抗体及其使用方法
CA3153880A1 (en) 2019-10-18 2020-06-09 Juana Elva HERNANDEZ MONTALVO Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
US20220378742A1 (en) 2019-11-04 2022-12-01 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
JP2022553803A (ja) 2019-11-06 2022-12-26 ジェネンテック， インコーポレイテッド 血液がんの処置のための診断方法及び治療方法
WO2021096888A1 (en) 2019-11-12 2021-05-20 Foundation Medicine, Inc. Methods of detecting a fusion gene encoding a neoantigen
WO2021110995A1 (en) 2019-12-04 2021-06-10 Ac Immune Sa Novel molecules for therapy and diagnosis
CN114929741A (zh) 2019-12-04 2022-08-19 免疫医疗有限公司 针对lif的抗体及其用途
US20230057899A1 (en) 2019-12-05 2023-02-23 Compugen Ltd. Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
US20230040928A1 (en) 2019-12-09 2023-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to her4 and uses thereof
KR20220113790A (ko) 2019-12-13 2022-08-16 제넨테크, 인크. 항-ly6g6d 항체 및 사용 방법
WO2021119429A1 (en) 2019-12-13 2021-06-17 Cugene Inc. Novel interleukin-15 (il-15) fusion proteins and uses thereof
KR20240035914A (ko) 2019-12-27 2024-03-18 추가이 세이야쿠 가부시키가이샤 항ctla-4 항체 및 그의 사용
CN113045655A (zh) 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 抗ox40抗体及其用途
EP4084823A4 (en) 2020-01-03 2024-05-15 Marengo Therapeutics, Inc. ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
US11859000B2 (en) 2020-01-06 2024-01-02 Vaccinex Inc. Anti-CCR8 antibodies and uses thereof
FI4087875T3 (fi) 2020-01-08 2024-10-25 argenx BV Vastasyntyneen ihmisen Fc-reseptorin (FcRn) antagonisteja pemfigus-häiriöiden hoitoon
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
CN116650628A (zh) 2020-01-31 2023-08-29 基因泰克公司 用pd-1轴结合拮抗剂和rna疫苗诱导新表位特异性t细胞的方法
KR20220139915A (ko) 2020-02-06 2022-10-17 브리스톨-마이어스 스큅 컴퍼니 Il-10 및 그의 용도
KR20220140568A (ko) 2020-02-11 2022-10-18 벤더르빌트 유니버시티 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 인간 단일클론 항체
TWI895351B (zh) 2020-02-12 2025-09-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
TWI888487B (zh) 2020-02-14 2025-07-01 日商協和麒麟股份有限公司 與ｃｄ３結合之雙特異性抗體
EP4106794A4 (en) 2020-02-19 2024-03-20 Evive Biotechnology (Shanghai) Ltd METHOD FOR TREATING TRANSPLANT AND HOST DISEASE
WO2021173844A1 (en) 2020-02-26 2021-09-02 Biograph 55, Inc. C19 c38 bispecific antibodies
BR112022016491A2 (pt) 2020-02-28 2022-10-11 Shanghai Henlius Biotech Inc Construto anti-cd137 e usos do mesmo
WO2021170071A1 (en) 2020-02-28 2021-09-02 Shanghai Henlius Biotech, Inc. Anti-cd137 constructs, multispecific antibody and uses thereof
KR20220148235A (ko) 2020-02-28 2022-11-04 젠자임 코포레이션 최적화된 약물 접합을 위한 변형된 결합 폴리펩티드
KR20220151195A (ko) 2020-03-06 2022-11-14 오엔에이 테라퓨틱스 에스.엘. 항-cd36 항체 및 암을 치료하기 위한 이의 용도
US20230340114A1 (en) 2020-03-12 2023-10-26 Immune-Onc Therapeutics, Inc. Novel anti-lilrb4 antibodies and derivative products
JP7767298B2 (ja) 2020-03-13 2025-11-11 ジェネンテック， インコーポレイテッド 抗インターロイキン－３３抗体及びその使用
JP7705873B2 (ja) 2020-03-13 2025-07-10 江蘇恒瑞医薬股▲ふん▼有限公司 Ｐｖｒｉｇ結合タンパク質及びその医薬用途
KR102811560B1 (ko) 2020-03-19 2025-05-22 제넨테크, 인크. 동종형 선택적 항-tgf-베타 항체 및 이용 방법
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
WO2021194860A1 (en) 2020-03-23 2021-09-30 Genentech, Inc. Tocilizumab and remdesivir combination therapy for covid-19 pneumonia
WO2021194861A1 (en) 2020-03-23 2021-09-30 Genentech, Inc. Biomarkers for predicting response to il-6 antagonist in covid-19 pneumonia
EP4107184A1 (en) 2020-03-23 2022-12-28 Genentech, Inc. Method for treating pneumonia, including covid-19 pneumonia, with an il6 antagonist
MX2022011752A (es) 2020-03-24 2022-10-18 Genentech Inc Agentes de fijacion a tie2 y metodos de uso.
WO2021195385A1 (en) 2020-03-26 2021-09-30 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
UY39135A (es) 2020-03-26 2021-10-29 Univ Vanderbilt ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRAEL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
EP4127153A2 (en) 2020-03-26 2023-02-08 Genentech, Inc. Modified mammalian cells having reduced host cell proteins
JP2023520773A (ja) 2020-03-27 2023-05-19 ノバルティス アーゲー 増殖性疾患及び自己免疫疾患を治療するための二重特異性組合せ治療
EP4126940A1 (en) 2020-03-30 2023-02-08 F. Hoffmann-La Roche AG Antibody that binds to vegf and pdgf-b and methods of use
WO2021200898A1 (en) 2020-03-31 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Dll3-targeting multispecific antigen-binding molecules and uses thereof
AU2021250381A1 (en) 2020-03-31 2022-10-06 Chugai Seiyaku Kabushiki Kaisha Method for producing multispecific antigen-binding molecules
CA3170570A1 (en) 2020-04-01 2021-10-07 James J. KOBIE Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
CN115698717A (zh) 2020-04-03 2023-02-03 基因泰克公司 癌症的治疗和诊断方法
EP4132971A1 (en) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinity matured anti-lap antibodies and uses thereof
TW202204622A (zh) 2020-04-09 2022-02-01 大陸商蘇州艾博生物科技有限公司 針對冠狀病毒之核酸疫苗
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
KR20230015328A (ko) 2020-04-17 2023-01-31 허치슨 메디파르마 리미티드 항-ox40 항체 및 이의 용도
JP2023522417A (ja) 2020-04-24 2023-05-30 エフ． ホフマン－ラ ロシュ アーゲー スルフヒドリル化合物およびその誘導体を用いた酵素および経路調節
BR112022021441A2 (pt) 2020-04-24 2022-12-13 Genentech Inc Métodos para tratar linfoma folicular e linfoma difuso de grandes células b e kits
CA3172880A1 (en) 2020-04-27 2021-11-04 Sotirios Tsimikas Isoform-independent antibodies to lipoprotein(a)
EP3921034A2 (en) 2020-04-28 2021-12-15 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies and methods of use thereof
WO2021222167A1 (en) 2020-04-28 2021-11-04 Genentech, Inc. Methods and compositions for non-small cell lung cancer immunotherapy
IL297830A (en) 2020-05-03 2023-01-01 Levena Suzhou Biopharma Co Ltd Antibody-drug conjugates (adcs) comprising an anti-trop-2 antibody, compositions comprising such adcs, as well as methods of making and using the same
BR112022022378A2 (pt) 2020-05-05 2022-12-13 Janssen Biotech Inc Métodos para tratamento da doença de crohn com anticorpo específico anti-il23
CA3178882A1 (en) 2020-05-08 2021-11-11 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins and methods of use thereof
WO2021228956A1 (en) 2020-05-12 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
JP2023528235A (ja) 2020-05-17 2023-07-04 アストラゼネカ・ユーケイ・リミテッド ＳＡＲＳ－ＣｏＶ－２抗体、並びにこれを選択及び使用する方法
GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
EP4139002A2 (en) 2020-05-22 2023-03-01 Formycon AG Ace2-fc fusion proteins and uses thereof
US20230220057A1 (en) 2020-05-27 2023-07-13 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing nerve growth factor and uses thereof
US20230235075A1 (en) 2020-06-02 2023-07-27 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
JP2023527918A (ja) 2020-06-08 2023-06-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｈｂｖ抗体及び使用方法
CN115702169A (zh) 2020-06-10 2023-02-14 株式会社梅花治疗 包含促红细胞生成素多肽的融合蛋白
WO2021252977A1 (en) 2020-06-12 2021-12-16 Genentech, Inc. Methods and compositions for cancer immunotherapy
MX2022015877A (es) 2020-06-16 2023-01-24 Genentech Inc Metodos y composiciones para tratar cancer de mama triple negativo.
MX2022015881A (es) 2020-06-18 2023-01-24 Genentech Inc Tratamiento con anticuerpos anti-tigit y antagonistas de union al eje de pd-1.
CN115768478A (zh) 2020-06-19 2023-03-07 中外制药株式会社 用于和血管新生抑制剂组合使用的抗t细胞抗原结合分子
AU2021297856A1 (en) 2020-06-22 2023-02-02 Innovent Biologics (Suzhou) Co., Ltd. Anti-CD73 antibody and use thereof
CA3183557A1 (en) 2020-06-24 2021-12-30 Bioverativ Therapeutics Inc. Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
JP2023533217A (ja) 2020-06-24 2023-08-02 ジェネンテック， インコーポレイテッド アポトーシス耐性細胞株
IL299292A (en) 2020-06-25 2023-02-01 Merck Sharp & Dohme Llc High-affinity antibodies to tau phosphorylated at serine 413
US20230265211A1 (en) 2020-06-29 2023-08-24 Inserm (Institut National De La Santé Et De Ls Recherche Médicale) Anti-protein s single-domain antibodies and polypeptides comprising thereof
WO2022006153A1 (en) 2020-06-29 2022-01-06 Resolve Therapeutics, Llc Treatment of sjogren's syndrome with nuclease fusion proteins
CA3189402A1 (en) 2020-07-13 2022-01-20 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
CN116406377A (zh) 2020-07-17 2023-07-07 基因泰克公司 抗notch2抗体及其使用方法
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
EP4188550A1 (en) 2020-07-29 2023-06-07 Dynamicure Biotechnology LLC Anti-cd93 constructs and uses thereof
US20220073603A1 (en) 2020-07-30 2022-03-10 Janssen Biotech, Inc. Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody
AU2021317974A1 (en) 2020-07-31 2023-03-16 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical Composition comprising Cell Expressing Chimeric Receptor
EP4189121A1 (en) 2020-08-03 2023-06-07 Genentech, Inc. Diagnostic and therapeutic methods for lymphoma
KR20230044312A (ko) 2020-08-06 2023-04-03 바이오버라티브 유에스에이 인코포레이티드 보체 매개된 질환을 갖는 대상체의 염증성 시토카인 및 피로
AU2021325339A1 (en) 2020-08-10 2023-04-06 Astrazeneca Uk Limited SARS-CoV-2 antibodies for treatment and prevention of COVID-19
JP2023537761A (ja) 2020-08-14 2023-09-05 エイシー イミューン ソシエテ アノニム ヒト化抗ｔｄｐ－４３結合分子およびその使用
SI4200018T1 (sl) 2020-08-18 2025-07-31 Cephalon Llc Protitelesa proti-PAR-2 in postopki njihove uporabe
WO2022038411A1 (en) * 2020-08-19 2022-02-24 Astellas Pharma, Inc. Human non-naturally occurring modified fc region of igg specifically binding to non-naturally occurring modified fc receptor
WO2022040470A1 (en) * 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions and methods for treating ceacam positive cancers
CN116724052A (zh) * 2020-08-20 2023-09-08 A2生物治疗股份有限公司 用于治疗ceacam阳性癌症的组合物和方法
KR20250140123A (ko) 2020-08-20 2025-09-24 에이투 바이오쎄라퓨틱스, 인크. 메소텔린 양성 암을 치료하기 위한 조성물 및 방법
EP4204448A2 (en) 2020-08-27 2023-07-05 cureab GmbH Anti-golph2 antibodies for macrophage and dendritic cell differentiation
US20230303665A1 (en) 2020-08-28 2023-09-28 Sana Biotechnology, Inc. Modified anti-viral binding agents
JP7731359B2 (ja) * 2020-08-28 2025-08-29 中外製薬株式会社 ヘテロ二量体Ｆｃポリペプチド
JP2023539201A (ja) 2020-08-28 2023-09-13 ジェネンテック， インコーポレイテッド 宿主細胞タンパク質のＣＲＩＳＰＲ／Ｃａｓ９マルチプレックスノックアウト
EP4208201A1 (en) 2020-09-04 2023-07-12 F. Hoffmann-La Roche AG Antibody that binds to vegf-a and ang2 and methods of use
EP4213877A1 (en) 2020-09-17 2023-07-26 Genentech, Inc. Results of empacta: a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tocilizumab in hospitalized patients with covid-19 pneumonia
EP4217389A4 (en) 2020-09-28 2025-03-19 Angitia Incorporated Limited ANTI-SCLEROSTIN CONSTRUCTS AND USES THEREOF
US20230365680A1 (en) 2020-09-30 2023-11-16 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
TWI836278B (zh) 2020-10-05 2024-03-21 美商建南德克公司 用抗fcrh5/抗cd3雙特異性抗體進行治療之給藥
EP4225330A1 (en) 2020-10-06 2023-08-16 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
EP4229082A1 (en) 2020-10-16 2023-08-23 AC Immune SA Antibodies binding to alpha-synuclein for therapy and diagnosis
CA3192306A1 (en) 2020-10-20 2022-04-28 Burkhard Ludewig Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
AU2021363766A1 (en) 2020-10-22 2023-06-15 Janssen Biotech, Inc. Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses
WO2022090801A2 (en) 2020-10-26 2022-05-05 Compugen Ltd. Pvrl2 and/or pvrig as biomarkers for treatment
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
AU2021367988A1 (en) 2020-10-29 2023-05-11 Formycon Ag Ace2 fusion proteins and uses thereof
EP4240492A2 (en) 2020-11-04 2023-09-13 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
CA3196076A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
US11919945B2 (en) 2020-11-04 2024-03-05 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies
IL302217A (en) 2020-11-04 2023-06-01 Genentech Inc Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies and anti-CD79B drug antibody conjugates
JP2023548529A (ja) 2020-11-06 2023-11-17 ノバルティス アーゲー Ｃｄ１９結合分子及びその使用
CN116390933A (zh) 2020-11-06 2023-07-04 诺华股份有限公司 治疗b细胞恶性肿瘤的抗cd19剂和b细胞靶向剂组合疗法
KR20230113581A (ko) 2020-11-25 2023-07-31 실리오 디벨럽먼트, 인크. 종양 특이적 절단성 링커
IL303328A (en) 2020-12-01 2023-07-01 Aptevo Res & Development Llc Heterodimeric psma and cd3-binding bispecific antibodies
AU2021391054A1 (en) 2020-12-02 2023-06-22 Shanghai Henlius Biotech, Inc. ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
EP4255451A4 (en) 2020-12-03 2025-01-01 The Board Of Regents Of The University Of Texas System Methods for identifying lilrb-blocking antibodies
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
US20240131064A1 (en) 2020-12-11 2024-04-25 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
EP4259661A1 (en) 2020-12-14 2023-10-18 Novartis AG Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
WO2022133140A1 (en) 2020-12-17 2022-06-23 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
US20240123067A1 (en) 2020-12-17 2024-04-18 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocyte therapies
CR20230263A (es) 2020-12-17 2023-08-21 Hoffmann La Roche Anticuerpos anti-hla-g y uso de estos
CA3203257A1 (en) 2020-12-23 2022-06-30 Li Li Anti-b7-h3 antibody and uses thereof
WO2022140797A1 (en) 2020-12-23 2022-06-30 Immunowake Inc. Immunocytokines and uses thereof
JP2024501845A (ja) 2020-12-31 2024-01-16 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の自動化された産生のためのデバイス及びプロセス
CA3202832A1 (en) 2020-12-31 2022-07-07 Romesh R. Subramanian Muscle targeting complexes and uses thereof for treating myotonic dystrophy
AU2022206061A1 (en) 2021-01-06 2023-07-06 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
EP4277926A1 (en) 2021-01-15 2023-11-22 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
CA3205670A1 (en) 2021-01-22 2022-07-28 Kehao Zhao Anti-pd-l1 monoclonal antibodies and fusion proteins with interleukin-15 (il-15), interleukin-15 receptor 15 alpha or interleukin-2
WO2022162203A1 (en) 2021-01-28 2022-08-04 Vaccinvent Gmbh Method and means for modulating b-cell mediated immune responses
US20240082397A1 (en) 2021-01-28 2024-03-14 Compugen Ltd. Anti-pvrig antibodies formulations and uses thereof
EP4284422A1 (en) 2021-01-28 2023-12-06 Vaccinvent GmbH Method and means for modulating b-cell mediated immune responses
WO2022165275A2 (en) 2021-01-28 2022-08-04 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations and anti-pd-1-antibodies
CN117120084A (zh) 2021-01-28 2023-11-24 维肯芬特有限责任公司 用于调节b细胞介导的免疫应答的方法和手段
TW202241508A (zh) 2021-01-29 2022-11-01 美商艾歐凡斯生物治療公司 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
EP4288458A1 (en) 2021-02-03 2023-12-13 Genentech, Inc. Multispecific binding protein degrader platform and methods of use
MX2023009497A (es) 2021-02-15 2023-08-23 Takeda Pharmaceuticals Co Composiciones y metodos de terapia celular para modular la se?alizacion del factor de crecimiento transformador-beta (tgf-beta).
JP7559257B2 (ja) 2021-02-17 2024-10-01 プロメテウス バイオサイエンシーズ，インク． 抗ｃｄ３０ｌ抗体およびその使用
EP4301467A1 (en) 2021-03-01 2024-01-10 Xilio Development, Inc. Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
US20220340662A1 (en) 2021-03-01 2022-10-27 Xilio Development, Inc. Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
EP4301418A1 (en) 2021-03-03 2024-01-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates comprising an anti-bcma antibody
EP4301333A2 (en) 2021-03-03 2024-01-10 Formycon AG Formulations of ace2 fc fusion proteins
CN117279506A (zh) 2021-03-05 2023-12-22 艾欧凡斯生物治疗公司 肿瘤储存及细胞培养组合物
WO2022187863A1 (en) 2021-03-05 2022-09-09 Dynamicure Biotechnology Llc Anti-vista constructs and uses thereof
US20240392004A1 (en) 2021-03-10 2024-11-28 Immunowake Inc. Immunomodulatory molecules and uses thereof
CA3212729A1 (en) 2021-03-12 2022-09-15 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
AU2022232007A1 (en) 2021-03-12 2023-10-26 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
JP2024512377A (ja) 2021-03-12 2024-03-19 ジェネンテック， インコーポレイテッド 抗ｋｌｋ７抗体、抗ｋｌｋ５抗体、多重特異性抗ｋｌｋ５／ｋｌｋ７抗体、及び使用方法
WO2022198192A1 (en) 2021-03-15 2022-09-22 Genentech, Inc. Compositions and methods of treating lupus nephritis
WO2022197877A1 (en) 2021-03-19 2022-09-22 Genentech, Inc. Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
US20240191191A1 (en) 2021-03-19 2024-06-13 Iovance Biotherapeutics, Inc. Methods for infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
WO2022204155A1 (en) 2021-03-23 2022-09-29 Iovance Biotherapeutics, Inc. Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
CN117616041A (zh) 2021-03-25 2024-02-27 当康生物技术有限责任公司 抗-igfbp7构建体及其用途
CA3213163A1 (en) 2021-03-25 2022-09-29 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
EP4314059A1 (en) 2021-03-26 2024-02-07 Janssen Biotech, Inc. Humanized antibodies against paired helical filament tau and uses thereof
CA3207652A1 (en) 2021-03-26 2022-09-29 Stephanie Cornen Cytokine anchors for nkp46-binding nk cell engager proteins
EP4313296A1 (en) 2021-03-31 2024-02-07 Bioverativ USA Inc. Reducing surgery-associated hemolysis in cold agglutinin disease patients
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
AU2022263418A1 (en) 2021-04-19 2023-10-26 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
EP4326855A1 (en) 2021-04-19 2024-02-28 Genentech, Inc. Modified mammalian cells
EP4334343A2 (en) 2021-05-06 2024-03-13 The Rockefeller University Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
EP4333869A1 (en) 2021-05-07 2024-03-13 Alpine Immune Sciences, Inc. Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
KR20240007184A (ko) 2021-05-12 2024-01-16 제넨테크, 인크. 미만성 거대 b세포 림프종을 치료하기 위해 항-cd79b 면역접합체를 사용하는 방법
AU2022273541A1 (en) 2021-05-14 2023-11-30 Genentech, Inc. Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
JP2024518545A (ja) 2021-05-14 2024-05-01 ジェネンテック， インコーポレイテッド Ｔｒｅｍ２のアゴニスト
US20230115257A1 (en) 2021-05-17 2023-04-13 Curia Ip Holdings, Llc Sars-cov-2 spike protein antibodies
US20240239875A1 (en) 2021-05-17 2024-07-18 Curia Ip Holdings, Llc Sars-cov-2 spike protein antibodies
US20240269180A1 (en) 2021-05-17 2024-08-15 Iovance Biotherapeutics, Inc. Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2022243261A1 (en) 2021-05-19 2022-11-24 F. Hoffmann-La Roche Ag Agonistic cd40 antigen binding molecules targeting cea
WO2022246259A1 (en) 2021-05-21 2022-11-24 Genentech, Inc. Modified cells for the production of a recombinant product of interest
WO2022248870A1 (en) 2021-05-28 2022-12-01 Glaxosmithkline Intellectual Property Development Limited Combination therapies for treating cancer
EP4347647A1 (en) 2021-06-01 2024-04-10 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of b cell depleting agents for the treatment of rheumatic heart disease
TW202306994A (zh) 2021-06-04 2023-02-16 日商中外製藥股份有限公司 抗ddr2抗體及其用途
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
JP2024521405A (ja) 2021-06-09 2024-05-31 イナート・ファルマ・ソシエテ・アノニム Ｎｋｐ４６、サイトカイン受容体、腫瘍抗原およびｃｄ１６ａに結合する多特異性タンパク質
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
CN117529504A (zh) 2021-06-09 2024-02-06 先天制药公司 结合至cd20、nkp46、cd16并缀合至il-2的多特异性抗体
BR112023025863A2 (pt) 2021-06-11 2024-03-05 Genentech Inc Métodos para tratar doença pulmonar obstrutiva crônica (dpoc), para reduzir a frequência de exacerbações moderadas a graves em um paciente com dpoc, para tratar ou prevenir dpoc, para manter e/ou melhorar a função pulmonar, para melhorar a contagem de linha de base de eosinófilos no sangue, kit, antagonistas de st2 e anticorpo anti-st2
WO2022263357A1 (en) 2021-06-14 2022-12-22 Argenx Iip Bv Anti-il-9 antibodies and methods of use thereof
WO2022266660A1 (en) 2021-06-17 2022-12-22 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
KR20240023123A (ko) 2021-06-22 2024-02-20 노파르티스 아게 화농성 한선염의 치료에 사용하기 위한 이중특이적 항체
US12448451B2 (en) 2021-06-25 2025-10-21 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
MX2023014453A (es) 2021-06-25 2024-01-31 Chugai Pharmaceutical Co Ltd Uso de anticuerpos anti-antigeno 4 del linfocito t citotoxico (anti-ctla-4).
CA3221833A1 (en) 2021-06-25 2022-12-29 Chugai Seiyaku Kabushiki Kaisha Anti-ctla-4 antibody
EP4363450A1 (en) 2021-07-01 2024-05-08 Compugen Ltd. Anti-tigit and anti-pvrig in monotherapy and combination treatments
EP4363449A2 (en) 2021-07-02 2024-05-08 Genentech, Inc. Methods and compositions for treating cancer
US20250011448A1 (en) 2021-07-08 2025-01-09 Staidson Biopharma Inc. Antibodies specifically recognizing tnfr2 and uses thereof
EP4367138A1 (en) 2021-07-09 2024-05-15 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
JP2024530402A (ja) 2021-07-12 2024-08-21 ジェネンテック， インコーポレイテッド 抗体－リパーゼ結合を減少させるための構造
EP4370553A1 (en) 2021-07-14 2024-05-22 Genentech, Inc. Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
KR20240058075A (ko) 2021-07-14 2024-05-03 스테이드슨 (베이징) 바이오팔마슈티칼스 캄퍼니 리미티드 Cd40을 특이적으로 식별하는 항체 및 이의 응용
EP4373270A2 (en) 2021-07-22 2024-05-29 Iovance Biotherapeutics, Inc. Method for cryopreservation of solid tumor fragments
WO2023001884A1 (en) 2021-07-22 2023-01-26 F. Hoffmann-La Roche Ag Heterodimeric fc domain antibodies
JP2024526880A (ja) 2021-07-22 2024-07-19 ジェネンテック， インコーポレイテッド 脳標的化組成物及びその使用方法
EP4377338A2 (en) 2021-07-27 2024-06-05 Novab, Inc. Engineered vlrb antibodies with immune effector functions
JP2024529451A (ja) 2021-07-28 2024-08-06 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんを治療するための方法及び組成物
WO2023009716A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
KR20240042476A (ko) 2021-07-30 2024-04-02 오엔에이 테라퓨틱스 에스.엘. 항-cd36 항체 및 암을 치료하기 위한 이의 용도
WO2023011338A1 (zh) 2021-08-02 2023-02-09 信达生物制药(苏州)有限公司 抗CD79b×CD3双特异性抗体及其用途
JP2024528217A (ja) 2021-08-03 2024-07-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗体および使用方法
EP4380981A2 (en) 2021-08-03 2024-06-12 GlaxoSmithKline Intellectual Property Development Limited Biopharmaceutical compositions and stable isotope labeling peptide mapping method
US20240336697A1 (en) 2021-08-07 2024-10-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
JP2024534004A (ja) 2021-08-13 2024-09-18 ジェネンテック， インコーポレイテッド 抗トリプターゼ抗体のための投与量
WO2023021055A1 (en) 2021-08-19 2023-02-23 F. Hoffmann-La Roche Ag Multivalent anti-variant fc-region antibodies and methods of use
AU2022332728A1 (en) 2021-08-26 2024-03-14 Kyowa Kirin Co., Ltd. Bispecific antibody that binds to cd116 and cd131
IL310382A (en) 2021-08-27 2024-03-01 Genentech Inc Methods for treating tau pathologies
JP2024532620A (ja) 2021-08-30 2024-09-05 ラッセン・セラピューティクス１・インコーポレイテッド 抗ＩＬ－１１Ｒα抗体
WO2023034750A1 (en) 2021-08-30 2023-03-09 Genentech, Inc. Anti-polyubiquitin multispecific antibodies
CA3231018A1 (en) 2021-09-09 2023-03-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1 talen knockdown
KR102908049B1 (ko) * 2021-09-17 2026-01-07 고려대학교 산학협력단 FcγRⅢa 선택적 결합력 향상 당화 Fc 변이체들
WO2023043124A1 (ko) * 2021-09-17 2023-03-23 고려대학교 산학협력단 Fcγrⅲa 결합력이 향상된 당화 fc 변이체들
CA3232700A1 (en) 2021-09-24 2023-03-30 Rafael CUBAS Expansion processes and agents for tumor infiltrating lymphocytes
CN118541392A (zh) 2021-09-28 2024-08-23 准星生物医药有限公司 多种形式的分子复合物
WO2023053282A1 (ja) 2021-09-29 2023-04-06 中外製薬株式会社 がんの治療に用いるための細胞傷害誘導治療剤
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
AU2022358522A1 (en) 2021-09-30 2024-03-28 Seagen Inc. B7-h4 antibody-drug conjugates for the treatment of cancer
CN118159294A (zh) 2021-10-05 2024-06-07 葛兰素史密斯克莱知识产权发展有限公司 用于治疗癌症的联合疗法
CN116064598B (zh) 2021-10-08 2024-03-12 苏州艾博生物科技有限公司 冠状病毒的核酸疫苗
AR127269A1 (es) 2021-10-08 2024-01-03 Chugai Pharmaceutical Co Ltd Formulación de anticuerpo anti-hla-dq2.5
US20250339522A1 (en) 2021-10-15 2025-11-06 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
CA3235824A1 (en) 2021-10-27 2023-05-04 Frederick G. Vogt Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
CA3236779A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
TW202342095A (zh) 2021-11-05 2023-11-01 英商阿斯特捷利康英國股份有限公司 用於治療和預防ｃｏｖｉｄ—１９之組成物
EP4426748A4 (en) 2021-11-05 2025-11-26 Mab Biotec Inc Monoclonal antibodies against carcinomebryonal antigens and their uses
EP4430072A1 (en) 2021-11-10 2024-09-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
CA3237410A1 (en) 2021-11-10 2023-05-19 Friedrich Graf Finck VON FINCKENSTEIN Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
CA3238377A1 (en) 2021-11-15 2023-05-19 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
CA3235206A1 (en) 2021-11-16 2023-05-25 Davide BASCO Novel molecules for therapy and diagnosis
TW202337494A (zh) 2021-11-16 2023-10-01 美商建南德克公司 用莫蘇妥珠單抗治療全身性紅斑狼瘡（ｓｌｅ）之方法及組成物
AU2022394462A1 (en) 2021-11-17 2024-05-02 AbbVie Deutschland GmbH & Co. KG Methods for treating anemia of kidney disease
US20230159633A1 (en) 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
US20250027067A1 (en) 2021-11-24 2025-01-23 Formycon Ag Improved ace2 fusion proteins
WO2023094571A1 (en) 2021-11-25 2023-06-01 Formycon Ag Stabilization of ace2 fusion proteins
EP4445911A4 (en) 2021-12-06 2025-10-22 Beijing Solobio Genetechnology Co Ltd BISPECIFIC ANTIBODY THAT BINDS SPECIFICALLY TO KLEBSIELLA PNEUMONIAE O1 AND O2 ANTIGENS AND COMPOSITION
CA3237618A1 (en) 2021-12-15 2023-06-22 Genentech, Inc. Stabilized il-18 polypeptides and uses thereof
WO2023109901A1 (en) 2021-12-17 2023-06-22 Shanghai Henlius Biotech, Inc. Anti-ox40 antibodies and methods of use
EP4448578A4 (en) 2021-12-17 2026-02-18 Shanghai Henlius Biotech Inc ANTI-OX40 ANTIBODIES, MULTI-SPECIFIC ANTIBODIES AND METHODS OF USE
IL313306A (en) 2021-12-17 2024-08-01 Viiv Healthcare Co Combined treatments for HIV infections and their uses
CR20240246A (es) 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
UY40097A (es) 2022-01-07 2023-07-14 Johnson & Johnson Entpr Innovation Inc Materiales y métodos de proteínas de unión a il-1b
EP4466070A1 (en) 2022-01-18 2024-11-27 argenx BV Galectin-10 antibodies
WO2023141445A1 (en) 2022-01-19 2023-07-27 Genentech, Inc. Anti-notch2 antibodies and conjugates and methods of use
EP4469159A1 (en) 2022-01-27 2024-12-04 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
JP2025503987A (ja) 2022-01-28 2025-02-06 アイオバンス バイオセラピューティクス，インコーポレイテッド ペイロードを発現するように操作された腫瘍浸潤リンパ球
JP2025504908A (ja) 2022-01-28 2025-02-19 アイオバンス バイオセラピューティクス，インコーポレイテッド サイトカイン関連腫瘍浸潤リンパ球組成物及び方法
IL315043A (en) 2022-02-16 2024-10-01 Ac Immune Sa Humanized anti-tdp-43 binding molecules and uses thereof
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體
AR128689A1 (es) 2022-03-03 2024-06-05 Univ Yale Anticuerpos 3e10 humanizados, variantes y fragmentos de unión al antígeno de los mismos
US20250243260A1 (en) 2022-03-07 2025-07-31 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies and related methods and uses
CA3245693A1 (en) 2022-03-10 2023-09-14 Vivasor, Inc. ANTIBODY-DRUG CONJUGATIONS AND THEIR USES
WO2023170291A1 (en) 2022-03-11 2023-09-14 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof
IL315544A (en) 2022-03-11 2024-11-01 Janssen Pharmaceutica Nv Multispecific antibodies and their uses
CA3254615A1 (en) 2022-03-11 2023-09-14 Janssen Pharmaceutica Nv MULTISPECIFIC ANTIBODIES AND THEIR USES
IL314346A (en) 2022-03-15 2024-09-01 Compugen Ltd Antibodies antagonistic to IL-18BP and their use in monotherapy and combination therapy in cancer treatment
US20240103010A1 (en) 2022-03-18 2024-03-28 Compugen Ltd. Pvrl2 and/or pvrig as biomarkers for treatment
CN119562970A (zh) 2022-03-18 2025-03-04 进化免疫治疗公司 双特异性抗体融合分子及其使用方法
JP2025514610A (ja) 2022-03-25 2025-05-09 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド 抗ｍｓｌｎ抗体及び使用方法
JP2025511000A (ja) 2022-03-28 2025-04-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト インターフェロンガンマバリアントおよびこれを含む抗原結合分子
US20230312703A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of Treating Psoriasis with IL-23 Specific Antibody
TW202405009A (zh) 2022-03-30 2024-02-01 瑞士商諾華公司 使用抗利尿鈉肽受體１（ｎｐｒ１）抗體治療障礙之方法
WO2023191816A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
GB202204813D0 (en) 2022-04-01 2022-05-18 Bradcode Ltd Human monoclonal antibodies and methods of use thereof
EP4504220A1 (en) 2022-04-06 2025-02-12 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
EP4504775A1 (en) 2022-04-08 2025-02-12 AC Immune SA Anti-tdp-43 binding molecules
JP2025512342A (ja) 2022-04-13 2025-04-17 ジェネンテック， インコーポレイテッド 治療用タンパク質の医薬組成物および使用方法
CA3248034A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT
EP4511395A1 (en) 2022-04-20 2025-02-26 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
CR20240528A (es) 2022-04-29 2025-04-04 Astrazeneca Uk Ltd Anticuerpos contra el sars-cov-2 y métodos para utilizarlos
EP4514383A1 (en) 2022-04-29 2025-03-05 23Andme, Inc. Antigen binding proteins
CN119137157A (zh) 2022-05-03 2024-12-13 基因泰克公司 抗Ly6E抗体、免疫缀合物及其用途
EP4524158A4 (en) 2022-05-09 2025-12-17 Staidson Beijing Biopharmaceuticals Co Ltd Antibody that specifically recognizes gdf15 and use thereof
CA3251533A1 (en) 2022-05-10 2023-11-16 Iovance Biotherapeutics, Inc. TREATMENT OF CANCER PATIENTS WITH TUMOR-INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH AN IL-15R AGONIST
CN119731199A (zh) 2022-05-10 2025-03-28 艾佩斯瑞生物制药公司 工程化的白细胞介素-2受体β降低结合的激动剂
AR129268A1 (es) 2022-05-11 2024-08-07 Hoffmann La Roche Anticuerpo que se une a vegf-a e il6 y métodos de uso
WO2023219613A1 (en) 2022-05-11 2023-11-16 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
US20230374122A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
US20250376533A1 (en) 2022-05-31 2025-12-11 Futuregen Biopharmaceutical (Beijing) Co., Ltd. Anti-cd40 antibody, anti-pd-l1×cd40 bispecific antibody, and use thereof
CN119856056A (zh) 2022-06-07 2025-04-18 基因泰克公司 用于确定包括抗pd-l1拮抗剂和抗tight拮抗剂抗体的肺癌治疗的疗效的方法
WO2023237706A2 (en) 2022-06-08 2023-12-14 Institute For Research In Biomedicine (Irb) Cross-specific antibodies, uses and methods for discovery thereof
WO2023239803A1 (en) 2022-06-08 2023-12-14 Angiex, Inc. Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
IL317545A (en) 2022-06-10 2025-02-01 Horizon Therapeutics Ireland Dac Antibodies against IGF1R
AU2023291783A1 (en) 2022-06-15 2024-12-12 argenx BV Fcrn binding molecules and methods of use
TW202417039A (zh) 2022-06-15 2024-05-01 美商百歐維拉提夫美國公司 抗補體ｃ１ｓ抗體調配物
US20240025978A1 (en) 2022-06-24 2024-01-25 Bioverativ Usa Inc. Methods for treating complement-mediated diseases
EP4551681A1 (en) 2022-07-06 2025-05-14 Iovance Biotherapeutics, Inc. Devices and processes for automated production of tumor infiltrating lymphocytes
CA3261147A1 (en) 2022-07-13 2024-01-18 Genentech, Inc. DOSAGE FOR TREATMENT WITH BISOPECIFIC ANTI-FCRH5/ANTI-CD3 ANTIBODIES
CN119604530A (zh) 2022-07-19 2025-03-11 基因泰克公司 用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
US20260035464A1 (en) 2022-07-19 2026-02-05 Staidson Biopharma Inc. Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
EP4558528A1 (en) 2022-07-22 2025-05-28 Genentech, Inc. Anti-steap1 antigen-binding molecules and uses thereof
AU2023312054A1 (en) 2022-07-22 2025-01-23 Bristol-Myers Squibb Company Antibodies binding to human pad4 and uses thereof
MA71620A (fr) 2022-07-27 2025-05-30 Cephalon Llc Formulations d'anticorps anti-tl1a
EP4562040A1 (en) 2022-07-27 2025-06-04 Cephalon LLC Anti-tl1a antibodies for the treatment of ulcerative colitis and crohn's disease
US20260035460A1 (en) 2022-07-28 2026-02-05 Adeboye Henry ADEWOYE, MD Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
EP4565683A1 (en) 2022-08-01 2025-06-11 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
CA3263779A1 (en) 2022-08-05 2024-02-08 Janssen Biotech, Inc. CD98 LINKAGE CONSTRUCTIONS FOR THE TREATMENT OF BRAIN TUMORS
CN120077064A (zh) 2022-08-05 2025-05-30 詹森生物科技公司 用于治疗脑肿瘤的转铁蛋白受体结合蛋白
IL318702A (en) 2022-08-19 2025-03-01 Evive Biotechnology Shanghai Ltd Compositions containing G-CSF and their uses
TW202423979A (zh) 2022-08-22 2024-06-16 美商雅博得樂醫療公司 Dll3結合分子及其用途
US20250296995A1 (en) 2022-08-25 2025-09-25 Glaxosmithkline Intellectual Property Development Limited Antigen binding protein and uses thereof
WO2024044675A1 (en) 2022-08-25 2024-02-29 Beigene, Ltd. Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies
KR20250054799A (ko) 2022-08-29 2025-04-23 다이이찌 산쿄 가부시키가이샤 변이 Fc 영역을 포함하는 항체 약물 콘쥬게이트
JP2025529210A (ja) 2022-09-01 2025-09-04 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド アポリポタンパク質ｌ１を導いて哺乳動物の細胞死を誘導するための組成物及び方法
CN120153254A (zh) 2022-09-01 2025-06-13 基因泰克公司 膀胱癌的治疗和诊断方法
CN120077071A (zh) 2022-09-07 2025-05-30 当康生物技术有限责任公司 抗vista构建体及其用途
JP2025531832A (ja) 2022-09-08 2025-09-25 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ＬＴＢＰ２（潜在的形質転換増殖因子β結合タンパク質２）に対する特異性を有する抗体及びその使用
CN120225559A (zh) 2022-09-12 2025-06-27 国家健康与医学研究院 新型抗itgb8抗体及其用途
US12054552B2 (en) 2022-09-21 2024-08-06 Sanofi Biotechnology Humanized anti-IL-1R3 antibody and methods of use
WO2024061930A1 (en) 2022-09-22 2024-03-28 Institut National de la Santé et de la Recherche Médicale New method to treat and diagnose peripheral t-cell lymphoma (ptcl)
WO2024067344A1 (zh) 2022-09-27 2024-04-04 舒泰神（北京）生物制药股份有限公司 特异性识别light的抗体及其应用
CN120344256A (zh) 2022-10-04 2025-07-18 高山免疫科学股份有限公司 突变的taci-fc融合蛋白用于在治疗自身抗体介导的疾病中的用途
IL319943A (en) 2022-10-07 2025-05-01 Genentech Inc Methods for treating cancer with anti-C motif chemokine receptor 8 (CCR8) antibodies
EP4606886A1 (en) 2022-10-20 2025-08-27 Beijing SoloBio Genetechnology Company Ltd. Antibody combination specifically binding to trail or fasl, and bispecific antibody
EP4608859A1 (en) 2022-10-25 2025-09-03 Ablynx N.V. Glycoengineered fc variant polypeptides with enhanced effector function
EP4608512A2 (en) 2022-10-25 2025-09-03 Ablexis, LLC Anti-cd3 antibodies
TW202426505A (zh) 2022-10-25 2024-07-01 美商建南德克公司 癌症之治療及診斷方法
WO2024094741A1 (en) 2022-11-03 2024-05-10 F. Hoffmann-La Roche Ag Combination therapy with anti-cd19/anti-cd28 bispecific antibody
JP2025537155A (ja) 2022-11-04 2025-11-14 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｃｄ３９／ｃｄ１０３選択に関連した腫瘍浸潤リンパ球（ｔｉｌ）拡張のための方法
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
AU2023375342A1 (en) 2022-11-08 2025-04-24 F. Hoffmann-La Roche Ag Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
WO2024107731A2 (en) 2022-11-14 2024-05-23 Ablexis, Llc Anti-pd-l1 antibodies
WO2024107752A2 (en) 2022-11-15 2024-05-23 Onestone Therapeutics Llc Compositions and methods for immunomodulatory bifunctional fusion molecules
KR20250106304A (ko) 2022-11-17 2025-07-09 사노피 Ceacam5 항체-약물 접합체 및 이의 사용 방법
JP2025539712A (ja) 2022-11-21 2025-12-09 アイオバンス バイオセラピューティクス，インコーポレイテッド 遺伝子編集されたｔ細胞の増殖能を評価するための方法
KR20250122544A (ko) 2022-11-21 2025-08-13 이오반스 바이오테라퓨틱스, 인크. 종양 침윤 림프구의 확장을 위한 2차원 공정 및 이를 통한 요법
WO2024110898A1 (en) 2022-11-22 2024-05-30 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
TW202434306A (zh) 2022-11-24 2024-09-01 瑞士商百濟神州瑞士有限責任公司 抗ｃｅａ抗體藥物軛合物及使用方法
IL320881A (en) 2022-11-25 2025-07-01 Chugai Pharmaceutical Co Ltd Method for producing protein
EP4382120A1 (en) 2022-12-05 2024-06-12 Institut Regional du Cancer de Montpellier Anti-slc1a4 monoclonal antibodies and uses thereof
WO2024120516A1 (zh) 2022-12-08 2024-06-13 南京诺唯赞生物科技股份有限公司 特异性结合rsv的抗体
EP4386084A1 (en) 2022-12-14 2024-06-19 Formycon AG Improved ace2 fusion proteins
CN120476149A (zh) 2022-12-23 2025-08-12 成都恩沐生物科技有限公司 靶向gprc5d的多特异性多肽复合物
JP2025542327A (ja) 2022-12-23 2025-12-25 チマゲン・バイオサイエンシズ，リミテッド 新規抗ｇｐｒｃ５ｄ抗体
WO2024145398A1 (en) 2022-12-27 2024-07-04 Yale University Antibody drug conjugates
CN120858108A (zh) 2023-01-06 2025-10-28 拉森医疗公司 抗il-18bp抗体
JP2026503273A (ja) 2023-01-06 2026-01-28 ラッセン・セラピューティクス・インコーポレイテッド 抗ｉｌ－１８ｂｐ抗体
EP4646441A1 (en) 2023-01-06 2025-11-12 Lassen Therapeutics, Inc. Anti-il-11r alpha antibodies for treating thyroid eye disease
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
WO2024150074A2 (en) 2023-01-13 2024-07-18 Takeda Pharmaceutical Company Limited Coronavirus antibodies and therapeutic uses thereof
TW202432607A (zh) 2023-01-18 2024-08-16 美商建南德克公司 多特異性抗體及其用途
KR20250135302A (ko) 2023-01-19 2025-09-12 비원 메디슨즈 아이 게엠베하 항-cmet 항체 및 사용 방법
EP4655007A1 (en) 2023-01-23 2025-12-03 Yale University Antibody oligonucleotide conjugates
WO2024163494A1 (en) 2023-01-31 2024-08-08 F. Hoffmann-La Roche Ag Methods and compositions for treating non-small cell lung cancer and triple-negative breast cancer
WO2024163009A1 (en) 2023-01-31 2024-08-08 Genentech, Inc. Methods and compositions for treating urothelial bladder cancer
EP4665392A2 (en) 2023-02-14 2025-12-24 Evolveimmune Therapeutics, Inc. Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment
WO2024170543A1 (en) 2023-02-14 2024-08-22 Institut National de la Santé et de la Recherche Médicale Anti-cd44 antibodies and uses thereof
WO2024182443A2 (en) 2023-02-27 2024-09-06 Compugen Ltd. Triple combination therapy with anti-pvrig antibodies, anti-tigit antibodies, and pembrolizumab
KR20250158054A (ko) 2023-03-02 2025-11-05 알로이 테라퓨틱스, 인크. 항-cd22 항체 및 이의 용도
EP4676956A2 (en) 2023-03-03 2026-01-14 Celldex Therapeutics, Inc. Anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs
AU2024231640A1 (en) 2023-03-03 2025-10-16 Beone Medicines I Gmbh Muc1 and cd16a antibodies and methods of use
AR132043A1 (es) 2023-03-03 2025-05-21 Beigene Switzerland Gmbh Anticuerpos muc1 y métodos de uso
WO2024183636A1 (en) 2023-03-03 2024-09-12 Beigene Switzerland Gmbh Cd16a antibodies and methods of use
AR132064A1 (es) 2023-03-06 2025-05-21 Beigene Switzerland Gmbh Anticuerpos anti-cldn6 y métodos de uso
WO2024184810A1 (en) 2023-03-06 2024-09-12 Beigene Switzerland Gmbh Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
WO2024184811A1 (en) 2023-03-06 2024-09-12 Beigene Switzerland Gmbh Anti-cd3 multispecific antibodies and methods of use
EP4676596A1 (en) 2023-03-08 2026-01-14 AC Immune SA Anti-tdp-43 binding molecules and uses thereof
WO2024191785A1 (en) 2023-03-10 2024-09-19 Genentech, Inc. Fusions with proteases and uses thereof
WO2024188965A1 (en) 2023-03-13 2024-09-19 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
CN121399155A (zh) 2023-03-17 2026-01-23 奥西托普制药有限公司 抗磷酸胆碱抗体及其使用方法
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
TW202440636A (zh) 2023-03-21 2024-10-16 美商傳記５５有限公司 Ｃｄ１９／ｃｄ３８多特異性抗體
WO2024197302A1 (en) 2023-03-23 2024-09-26 Yale University Compositions and methods for delivering antibody oligonucleotide conjugates for exon skipping
KR20250173521A (ko) 2023-03-30 2025-12-10 272바이오 리미티드 GnRH-결합 폴리펩티드 및 그의 용도
TW202446789A (zh) 2023-03-31 2024-12-01 美商建南德克公司 抗αｖβ８整合素抗體及使用方法
WO2024206738A1 (en) 2023-03-31 2024-10-03 Immunai Inc. Humanized anti-trem2 antibodies
EP4687997A2 (en) 2023-04-05 2026-02-11 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
EP4687996A1 (en) 2023-04-05 2026-02-11 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
EP4687995A1 (en) 2023-04-05 2026-02-11 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024212827A1 (en) 2023-04-12 2024-10-17 Shanghai Kangabio Co., Limited Multifunctional molecules comprising masked interleukin 12 and methods of use
CN121263210A (zh) 2023-04-17 2026-01-02 沛科生物公司 抗体和抗体-药物偶联物以及使用方法和合成工艺及中间体
WO2024226829A2 (en) 2023-04-26 2024-10-31 Yale University Enpp3-binding molecules, compositions formed therefrom, and methods of use thereof for the treatment of cancer
AU2024270495A1 (en) 2023-05-05 2025-10-09 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
AU2024269754A1 (en) 2023-05-08 2025-10-23 F. Hoffmann-La Roche Ag Targeted interferon alpha fusion proteins and methods of use
KR20260008790A (ko) 2023-05-10 2026-01-16 제넨테크, 인크. 암 치료 방법 및 조성물
TW202509065A (zh) 2023-05-16 2025-03-01 瑞士商赫孚孟拉羅股份公司 經ｐｄ－１調節之ｉｌ－２免疫結合物及其用途
WO2024236156A1 (en) 2023-05-17 2024-11-21 Institut National de la Santé et de la Recherche Médicale Anti-cathepsin-d antibodies
CN121285742A (zh) 2023-06-08 2026-01-06 基因泰克公司 用于淋巴瘤的诊断和治疗方法的巨噬细胞特征
WO2024251199A1 (zh) 2023-06-09 2024-12-12 舒泰神（北京）生物制药股份有限公司 特异性结合masp3的抗体以及特异性结合masp3和masp2的多特异性抗体
WO2024251884A1 (en) 2023-06-09 2024-12-12 Innate Pharma Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl
EP4477236A1 (en) 2023-06-14 2024-12-18 Inatherys Combination therapy for treating a tumor using adc comprising anti-cd71 antibodies and bh3 mimetics
WO2024255794A1 (zh) 2023-06-16 2024-12-19 舒泰神（北京）生物制药股份有限公司 特异性识别因子XIIa的抗体及其应用
CN121443309A (zh) 2023-06-22 2026-01-30 基因泰克公司 多发性骨髓瘤的治疗
WO2024263761A1 (en) 2023-06-22 2024-12-26 Genentech, Inc. Antibodies and uses thereof
WO2024263195A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2024263904A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
AU2024309736A1 (en) 2023-06-30 2026-01-15 Evive Biotechnology (Shanghai) Ltd G-csf dimer for use in the treatment or prevention of chemotherapy or radiotherapy induced neutropenia
AU2024296516A1 (en) 2023-07-13 2026-01-22 Iovance Biotherapeutics, Inc. Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
WO2025012417A1 (en) 2023-07-13 2025-01-16 Institut National de la Santé et de la Recherche Médicale Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
AU2024292473A1 (en) 2023-07-19 2026-01-29 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc
WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
WO2025021790A2 (en) 2023-07-24 2025-01-30 F. Hoffmann-La Roche Ag Multispecific antibodies
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
WO2025032071A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032069A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032070A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Anti-a-beta protein antibodies, methods and uses thereof
WO2025041077A1 (en) 2023-08-23 2025-02-27 Sanofi Ctla-4-based lysosomal degraders and uses thereof
WO2025049905A1 (en) 2023-09-01 2025-03-06 Gennao Bio, Inc. Dnase co-expression in host cells
WO2025046298A2 (en) 2023-09-01 2025-03-06 iTeos Belgium SA Anti-trem2 antibodies and methods of use
WO2025045250A1 (en) 2023-09-03 2025-03-06 Kira Pharmaceuticals (Us) Llc Anti-human factor d antibody constructs and uses thereof
WO2025059037A1 (en) 2023-09-11 2025-03-20 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof
WO2025064890A1 (en) 2023-09-20 2025-03-27 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof
WO2025064885A1 (en) 2023-09-20 2025-03-27 Evolveimmune Therapeutics, Inc. Multispecific antibodies that bind cd3 and cd2 and methods of use thereof
AR133909A1 (es) 2023-09-25 2025-11-12 Hoffmann La Roche ANTICUERPO QUE SE UNE A C3bBb
US20250109187A1 (en) 2023-09-28 2025-04-03 Novavax, Inc. ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19
WO2025068957A1 (en) 2023-09-29 2025-04-03 Novartis Ag Bispecific antibodies for use in lowering the risk of cardiovascular disease events in subjects known to be a carrier of clonal expansion of hematopoietic cell lines with somatic mutations
US20250109209A1 (en) 2023-10-03 2025-04-03 Absci Corporation Tl1a associated antibody compositions and methods of use
WO2025076389A1 (en) 2023-10-06 2025-04-10 Seagen Inc. Methods of treating advanced solid tumors with b7-h4 antibody-drug conjugates
WO2025085489A1 (en) 2023-10-17 2025-04-24 Bristol-Myers Squibb Company Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
WO2025099120A1 (en) 2023-11-09 2025-05-15 F. Hoffmann-La Roche Ag Multispecific antibodies with conditional activity
WO2025106474A1 (en) 2023-11-14 2025-05-22 Genentech, Inc. Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
AR134489A1 (es) 2023-11-27 2026-01-21 Glaxosmithkline Ip Dev Ltd Proteinas de unión a antígeno
WO2025120015A1 (en) 2023-12-06 2025-06-12 Institut National de la Santé et de la Recherche Médicale Cd5 targeting antibodies with depleting and t or b-cell activation effects
WO2025122885A1 (en) 2023-12-08 2025-06-12 Absci Corporation Anti-her2 associated antibody compositions designed by artificial intelligence and methods of use
WO2025128839A1 (en) 2023-12-13 2025-06-19 Horizon Therapeutics Ireland Dac Methods for the treatment of thyroid eye disease with anti igf-1r antagonistic antibodies
WO2025133707A1 (en) 2023-12-19 2025-06-26 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
WO2025133694A1 (en) 2023-12-20 2025-06-26 argenx BV Fcrn/hsa-binding molecules and methods of use
GB202319605D0 (en) 2023-12-20 2024-01-31 argenx BV Monovalent binding molecules and methods of use
WO2025132503A1 (en) 2023-12-20 2025-06-26 F. Hoffmann-La Roche Ag Antibodies binding to ceacam5
WO2025133042A2 (en) 2023-12-22 2025-06-26 F. Hoffmann-La Roche Ag Activatable fusion proteins and methods of use
WO2025146131A1 (en) 2024-01-05 2025-07-10 Beigene, Ltd. ANTI-FGFR2b ANTIBODIES, CONJUGATES AND METHODS OF USE
WO2025147696A1 (en) 2024-01-05 2025-07-10 Resolve Therapeutics, Llc Treatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents
WO2025149633A1 (en) 2024-01-12 2025-07-17 Laigo Bio B.V. Bispecific antigen binding proteins
WO2025149947A1 (en) 2024-01-12 2025-07-17 Seagen Inc. Antibody-drug conjugates
WO2025155877A2 (en) 2024-01-18 2025-07-24 The Regents Of The University Of California Antibodies binding to pad4 and uses thereof
US12319742B1 (en) 2024-01-24 2025-06-03 Shattuck Labs, Inc. Antibodies that bind TNFRSF25
US20250313644A1 (en) 2024-01-26 2025-10-09 Futuregen Biopharmaceutical (Beijing) Co., Ltd. Antibodies capable of specifically binding tl1a and use thereof
WO2025171182A1 (en) 2024-02-08 2025-08-14 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
WO2025174974A1 (en) 2024-02-14 2025-08-21 Bristol-Myers Squibb Company Anti-cd33 antibodies and uses thereof
WO2025172924A1 (en) 2024-02-15 2025-08-21 Janssen Biotech, Inc. Anti-transferrin receptor compositions and methods thereof
WO2025184211A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibody drug conjugates
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2025186332A1 (en) 2024-03-05 2025-09-12 Ac Immune Sa Vectorized anti-tdp-43 antibodies
CA3249015A1 (en) 2024-03-20 2025-10-31 Janssen Biotech, Inc. Methods of treating crohn’s disease with anti-il23 specific antibody
US20250295801A1 (en) 2024-03-21 2025-09-25 Seagen Inc. Cd25 antibodies, antibody drug conjugates, and uses thereof
WO2025215060A1 (en) 2024-04-11 2025-10-16 F. Hoffmann-La Roche Ag Antibodies that specifically bind modified oligonucleotides
WO2025226603A1 (en) 2024-04-22 2025-10-30 Surface Oncology, LLC Methods for treating cancer using anti-ccr8 antibodies
WO2025226808A1 (en) 2024-04-24 2025-10-30 Genentech, Inc. Compositions and methods of treating lupus nephritis
WO2025224297A1 (en) 2024-04-26 2025-10-30 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to tgfbi and uses thereof
EP4644413A1 (en) 2024-05-03 2025-11-05 Genmab B.V. Binding agents having altered fc-mediated effector functions
WO2025242732A1 (en) 2024-05-21 2025-11-27 Institut National de la Santé et de la Recherche Médicale Pan antibodies against sars-cov-2 spike protein and uses thereof for therapeutical purposes
WO2025245176A1 (en) 2024-05-22 2025-11-27 Bristol-Myers Squibb Company Multispecific antibody constructs
WO2025250969A1 (en) 2024-05-31 2025-12-04 Vertex Pharmaceuticals Incorporated Anti-cd74 antibodies, conjugates and uses thereof
WO2025254987A1 (en) 2024-06-03 2025-12-11 Alector Llc Siglec-9 ecd fusion molecule variants and methods of use thereof
WO2025255405A1 (en) 2024-06-06 2025-12-11 Bristol-Myers Squibb Company Anti-fap antibodies and uses thereof
US20250376536A1 (en) 2024-06-06 2025-12-11 Bristol-Myers Squibb Company Multispecific anti-cd40 / anti-fap antibodies and uses thereof
WO2025257181A1 (en) 2024-06-11 2025-12-18 Institut National de la Santé et de la Recherche Médicale Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
WO2025262604A1 (en) 2024-06-17 2025-12-26 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
WO2025262216A1 (en) 2024-06-21 2025-12-26 Glaxosmithkline Intellectual Property Development Limited Multispecific antigen binding proteins binding to il23 and il18
WO2026006495A1 (en) 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anti-wt1/hla-a2 antibody and uses thereof
WO2026006492A2 (en) 2024-06-25 2026-01-02 Ypsilon Therapeutics, Inc. Anti-prame/hla-a2 antibodies and uses thereof
WO2026006494A1 (en) 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anti-cd3 antibodies and uses thereof
WO2026003761A1 (en) 2024-06-27 2026-01-02 Janssen Biotech, Inc. Methods of treating ulcerative colits with anti-il23 specific antibody
WO2026006784A1 (en) 2024-06-28 2026-01-02 Iovance Biotherapeutics, Inc. Methods of making tumor reactive peripheral blood lymphocytes (trpbl)
WO2026013218A1 (en) 2024-07-10 2026-01-15 Ac Immune Sa Anti-tdp-43 vectors, binding molecules and uses thereof
WO2026021476A1 (en) 2024-07-24 2026-01-29 Beone Guangzhou Biologics Manufacturing Co., Ltd. Anti-cmet and anti-egfr multispecific antibody drug conjugates
WO2026030464A1 (en) 2024-07-30 2026-02-05 Genentech, Inc. Dosage regimen for reducing cytokine release syndrome (crs) with anti-fcrh5/anti-cd3 bispecific antibodies in multiple myeloma therapy
CN119552212B (zh) * 2025-01-26 2025-04-25 杭州康源食品科技有限公司 一种具有降尿酸活性的三肽lfp及其应用

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4490473A (en) * 1983-03-28 1984-12-25 Panab Labeled antibodies and methods
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4752601A (en) * 1983-08-12 1988-06-21 Immunetech Pharmaceuticals Method of blocking immune complex binding to immunoglobulin FC receptors
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5985599A (en) * 1986-05-29 1999-11-16 The Austin Research Institute FC receptor for immunoglobulin
EP0307434B2 (en) * 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5576184A (en) * 1988-09-06 1996-11-19 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DK0479909T3 (da) 1989-06-29 1997-04-07 Medarex Inc Bispecifikke reagenser til AIDS-behandling
GB8916400D0 (en) * 1989-07-18 1989-09-06 Dynal As Modified igg3
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5364930A (en) * 1990-10-16 1994-11-15 Northwestern University Synthetic C1q peptide fragments
US5419904A (en) * 1990-11-05 1995-05-30 The Regents Of The University Of California Human B-lymphoblastoid cell line secreting anti-ganglioside antibody
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9206422D0 (en) * 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6491916B1 (en) * 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5730977A (en) * 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DE19721700C1 (de) 1997-05-23 1998-11-19 Deutsches Krebsforsch Mutierter OKT3-Antikörper
JP2002506353A (ja) * 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
EP1060194A1 (en) 1998-02-25 2000-12-20 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) * 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1068241T3 (da) * 1998-04-02 2008-02-04 Genentech Inc Antistofvarianter og fragmenter deraf
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
MX353234B (es) 1999-01-15 2018-01-08 Genentech Inc Variantes de polipeptidos con función efectora alterada.
US7183387B1 (en) * 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6676927B1 (en) * 1999-01-20 2004-01-13 The Rockefeller University Animal model and methods for its use in the selection of cytotoxic antibodies
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
JP2003531149A (ja) * 2000-04-13 2003-10-21 ザ・ロツクフエラー・ユニバーシテイ 抗体由来の免疫応答の増強
DE60143544D1 (de) * 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US20040002587A1 (en) * 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003249014B2 (en) 2002-07-09 2009-07-02 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
ATE541857T1 (de) 2002-09-27 2012-02-15 Xencor Inc Optimierte fc-varianten und herstellungsverfahren dafür
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DK1562972T3 (da) 2002-10-15 2010-12-06 Facet Biotech Corp Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
US7608260B2 (en) * 2003-01-06 2009-10-27 Medimmune, Llc Stabilized immunoglobulins
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP2007531707A (ja) 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
US20060067930A1 (en) * 2004-08-19 2006-03-30 Genentech, Inc. Polypeptide variants with altered effector function
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)

Also Published As

Publication number Publication date
AU2850500A (en) 2000-08-01
US7785791B2 (en) 2010-08-31
US7371826B2 (en) 2008-05-13
JP6312092B2 (ja) 2018-04-18
MXPA01007170A (es) 2002-07-30
AU2008229968A1 (en) 2008-11-06
KR20100045527A (ko) 2010-05-03
KR101155191B1 (ko) 2012-06-13
EP2366713A2 (en) 2011-09-21
JP2016136951A (ja) 2016-08-04
KR100887482B1 (ko) 2009-03-10
US7790858B2 (en) 2010-09-07
AU2008229968B2 (en) 2012-08-09
KR20090078369A (ko) 2009-07-17
IL222149B (en) 2018-11-29
US20060194291A1 (en) 2006-08-31
EP2366713A3 (en) 2012-06-27
IL223047A0 (en) 2012-12-31
CA2359067A1 (en) 2000-07-20
PL349770A1 (en) 2002-09-09
BR0008758A (pt) 2001-12-04
CN1763097B (zh) 2011-04-13
NZ539776A (en) 2006-12-22
KR20060067983A (ko) 2006-06-20
HUP1500355A2 (en) 2002-04-29
EP1141024A2 (en) 2001-10-10
EP2386574A2 (en) 2011-11-16
KR20010102976A (ko) 2001-11-17
HK1090066A1 (en) 2006-12-15
IL223048A0 (en) 2012-12-31
KR100940380B1 (ko) 2010-02-02
ES2694002T3 (es) 2018-12-17
HU230769B1 (hu) 2018-03-28
US20080274506A1 (en) 2008-11-06
KR20080090572A (ko) 2008-10-08
EP1141024B1 (en) 2018-08-08
JP6230257B2 (ja) 2017-11-15
KR101077001B1 (ko) 2011-10-26
CN1763097A (zh) 2006-04-26
ZA200105484B (en) 2002-07-29
HUP0104865A3 (en) 2004-07-28
US20060194290A1 (en) 2006-08-31
IL223048A (en) 2016-09-29
WO2000042072A3 (en) 2000-11-30
US20080274105A1 (en) 2008-11-06
PL209392B1 (pl) 2011-08-31
CA2359067C (en) 2017-03-14
JP2013166770A (ja) 2013-08-29
WO2000042072A2 (en) 2000-07-20
EP2386574A3 (en) 2012-06-27
CN1343221A (zh) 2002-04-03
JP2010227116A (ja) 2010-10-14
IL223047A (en) 2016-10-31
PL220113B1 (pl) 2015-08-31
AU778683B2 (en) 2004-12-16
EP2364997A2 (en) 2011-09-14
IL144056A (en) 2014-04-30
CN1237076C (zh) 2006-01-18
HUP0104865A2 (hu) 2002-04-29
PL394232A1 (pl) 2011-07-04
PL209786B1 (pl) 2011-10-31
EP2364997A3 (en) 2012-07-04
JP5335735B2 (ja) 2013-11-06
JP2003512019A (ja) 2003-04-02
IL144056A0 (en) 2002-04-21

Similar Documents

Publication Publication Date Title
MX353234B (es) Variantes de polipeptidos con función efectora alterada.
AU2001260085A1 (en) Cutinase variants
WO2003054152A3 (en) Novel nucleic acids and polypeptides
WO2003025148A3 (en) Novel nucleic acids and polypeptides
WO2002070539A3 (en) Novel nucleic acids and polypeptides
WO2003023013A3 (en) Novel nucleic acids and polypeptides
WO2002081731A3 (en) Novel nucleic acids and polypeptides
WO2001075067A3 (en) Novel nucleic acids and polypeptides
WO2002022660A3 (en) Novel nucleic acids and polypeptides
WO2002031111A3 (en) Novel nucleic acids and polypeptides
ZA9810679B (en) Antimicrobial peptides.
ATE286740T1 (de) Zyklische peptide mit breitspektrum antimikrobieller aktivität
WO2002059260A3 (en) Nucleic acids and polypeptides
WO2004080148A3 (en) Novel nucleic acids and polypeptides
WO2003029271A3 (en) Novel nucleic acids and polypeptides
AU2002365646A1 (en) Novel proteins with il-6 inhibiting activity
AU2002345804A1 (en) Antimicrobially active peptide
WO2002044340A3 (en) Novel nucleic acids and polypeptides
WO2002077180A3 (en) Novel nucleic acids and polypeptides
WO2001075093A8 (en) Novel nucleic acids and polypeptides
AU8952701A (en) A novel polypeptide, a enzymatic activation protein ras gtp 9.57 and the polynucleotide encoding the polypeptide
EP1591448A3 (en) Novel nucleic acids and polypeptides
AU8949001A (en) A novel polypeptide, a human ccr4 relative protein 9.5 and the polynucleotide encoding the polypeptide
AU8948301A (en) A novel polypeptide, a human splicing protein 10.56 and the polynucleotide encoding the polypeptide
AU2998101A (en) A novel polypeptide, a leucine multirepeating sequence 71 and the polynucleotideencoding the polypeptide